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Anaesthetised cats and dogs were used to show:-
1. The angiotensin converting enzyme inhibitor, captopril, inhibited
the basal output of catecholamines from the adrenal medulla and the
reflex release induced by a lowering of carotid perfusion pressure
(baroreceptor test).
2. Plasma renin activity did not increase during the ten minute
baroreceptor tests.
3. A non-pressor level of angiotensin II (All) reversed the inhibitory
effects of captopril. These results suggest that a minimum circulating
level of All is required for the adrenal gland to respond to the
reflex stimuli, and All exerts a direct facilitatory effect on the
adrenal gland.
4. Captopril reduced resting systemic blood pressure and the reflex
pressor response to baroreceptor tests.
Anaesthetised dogs were used to show:-
5. Captopril increased adrenal blood flow, an effect probably
partially related to a reduction in haematocrit.
6. Coadministration of captopril and cycloheximide, which inhibits
corticosteroid secretion in response to adrenocorticotrophic hormone
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(ACTH), severely inhibited resting adrenal catecholamine release and
abolished the reflex release in response to baroreceptor tests, and
this effect was not overcome by administration of All. ACTH reversed
the inhibitory effects of captopril on adrenal catecholamine release,
and did not increase the ratio of adrenaline : noradrenaline in
adrenal venous blood.
7. Captopril reduced adrenocorticosteroid concentration in adrenal
venous blood. Adrenocorticosteroids have previously been shown to
facilitate adrenal catecholamine release. The results suggest that All
may facilitate adrenal catecholamine release partially by an indirect
facilitatory effect on adrenocorticosteroid secretion.
8. Captopril inhibited, and a non-pressor level of All restored, the
adrenal release of catecholamines evoked by splanchnic nerve
stimulation, from the decentraiised adrenal gland. This suggests that All
may facilitate splanchnic nerve activity and that the facilitatory
effect of All is at the level of the adrenal gland and not at the
level of the central nervous system. The All antagonist, saralasin,
also inhibited the adrenal release of catecholamines in response to
splanchnic nerve stimulation, from the denervated adrenal gland.
Introductory experiments were performed on anaesthetised dogs to show
the following
9. The opiate antagonist, naloxone, increased resting adrenal
catecholamine release and both reflex release from the innervated
gland and splanchnic nerve stimulation-induced release from the
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denervated gland. This suggests that opioid peptides, stored in the
adrenal medullae and splanchnic nerves, inhibit adrenal catecholamine
release. Captopril inhibits the breakdown of opioid peptides and this
may contribute to its inhibitory effect on adrenal catecholamine
release.
10. The cyclo-oxygenase inhibitor, indomethacin, inhibited both reflex
catecholamine release from the innervated adrenal gland and splanchnic
nerve stimulation-induced release from the denervated gland, and thus
potentiates the inhibitory effects of captopril. This suggests that
prostaglandins facilitate adrenal catecholamine release. Captopril has
been shown to stimulate prostaglandin synthesis, but indomethacin did
not blunt the hypotensive effect of captopril.
11. Indomethacin reduced adrenal blood flow and induced a
vasoconstriction in the adrenal vascular bed. This suggests that
prostaglandins may play a role in the maintainance of adrenal blood
flow through a tonic vasodilation.
12. The hypotensive effect of captopril and its inhibitory effects on
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General outline of research
I shall outline here the reasons for doing this research project
and the main incentives behind the progress of the research. For a
detailed review of literature and outline of each step taken, I refer
the reader to the "Introduction and literature review" of Parts 1-5 of
this thesis. I shall refer to the relevent sections during this
general outline.
In 1977, Feuerstein, Boonyaviroj and Gutman reported that, in the
anaesthetised cat, haemorrhage induced a reflex release of
catecholamines from the adrenal medulla. They observed that blockade
of the renin-angiotensin (All) system either by bilateral nephrectomy
or by administration of the All antagonist saralasin (see "An
introduction to the renin-AII system and angiotensin- converting
enzyme inhibitors") inhibited this reflex release of catecholamines.
They also observed an increase of circulating plasma renin activity
(PRA) following haemorrhage. They concluded that the reflex release of
catecholamines was due to an increase in circulating All synthesis,
initiated by haemhorrhage, acting centrally to increase sympathetic
drive. Such an increase in sympathetic drive would stimulate
catecholamine release from the adrenal medulla,, mediated by splanchnic
nerve stimulation.
Injury, dehydration, exertion and other stresses to the
cardiovascular system are also known to induce a release of
catecholamines from the adrenal medulla. Drugs which inhibit the renin-
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All system are now widely used in the treatment of hypertension (see
"Part 1 - Introduction and literature review"). We considered it
important to understand the extent to which such drugs, in particular
the angiotensin- converting enzyme inhibitor (ACEI) captopril, impair
this protective physiological response to cardiovascular stress. Such
an understanding would assist in the clinical prediction and
management of the impaired responses to cardiovascular stress in
patients receiving drugs that inhibit the renin-AII system.
All is known to stimulate release of catecholamines from the
adrenal medulla directly, (see "Part 1") and we thought it possible
that the results of Feuerstein etal could be reinterpretated to
suggest that All was acting directly on the adrenal medulla, and not
via the central nervous system as they suggested. We thought it
possible that a minimum level of circulating All was required for the
adrenal medulla to respond to such stimuli.
Our initial experiments were on anaesthetised cats in order to
compare our results with those of Feuerstein etal (1977). Subsequent
experiments were carried out on anaesthetised dogs due to the greater
reproducibility and success of our experiments in the dog.
Haemorrhage would induce a lowering of carotid perfusion
pressure. Instead of inducing haemorrhage, we chose to induce a direct
lowering of carotid perfusion pressure (I shall refer to this as
"baroreceptor stimulation or baroreceptor test" (see "The arterial
baroreceptor")), in order to stimulate a reflex release of
catecholamines from the adrenal medulla. This afforded us a greater
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control over experimental conditions.
We discovered that captopril did indeed inhibit the release of
catecholamines in response to baroreceptor stimulation, but within the
time course of our ten minute baroreceptor tests there was no evidence
of an increase of circulating PRA. This did suggest that a minimum
circulating level of All was required for the adrenal gland to respond
to such reflex stimuli and when this was removed by captopril, the
adrenal medullary response was inhibited. The resting release of
catecholamines, prior to baroreceptor stimulation was also inhibited
by captopril, and both the resting release and reflex release of
catecholamines could be restored by an exogenous infusion of a non-
pressor level of All.
Adrenocorticosteroids can regulate the response of the adrenal
medulla to hypotension, and All can stimulate adrenocorticosteroid
secretion from the adrenal cortex. We thought it possible that part
of the facilitatory effect of All on catecholamine release could be
due to an effect on adrenocorticosteroid secretion which may
facilitate the release of both adrenaline and noradrenaline from the
adrenal medulla (see "Part 2").
We investigated this possibility and discovered that
cycloheximide, a drug known to inhibit adrenocorticosteroid secretion
in response to adrenocorticotrophic hormone (ACTH), inhibited both
resting and reflex adrenomedullary catecholamine release, and
prevented restoration of the adrenal response by All. ACTH restored
the release of catecholamines previously inhibited by captopril. We
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also determined the effect of captopril on Cortisol and corticosterone
output from the adrenal gland, and discovered that captopril reduced
the adrenal venous concentration of both adrenocorticosteroids. This
evidence supported our theory that All may affect catecholamine
release indirectly through facilitating adrenocorticosteroid
secretion.
Although our results did suggest that All was exerting a direct
facilitatory effect on catecholamine release from the adrenal medulla,
we still could not exclude the possibility that the effect was due to
central stimulation of sympathetic drive. We therefore investigated
whether captopril could inhibit the release of catecholamines from the
denervated adrenal gland. We also wanted to investigate whether All
potentiated catecholamine release in response to splanchnic nerve
stimulation. This seemed possible as there is much evidence to suggest
a facilitatory role for All on stimulation-evoked release of
noradrenaline from most sympathetic nerves and also on stimulation-
evoked acetylcholine release from both sympathetic and parasympathetic
ganglia (see Part 3)•
We discovered that captopril inhibited both the resting release
of catecholamines from the denervated adrenal gland and the release
evoked by splanchnic nerve stimulation. These releases could be
restored by an infusion of a non-pressor level of All. These results
supported a direct facilitatory effect of All on catecholamine release
from the adrenal medulla. They also supported a facilitatory effect
effect of All on splanchnic nerve stimulation-induced catecholamine
release.
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We had answered the main questions that this research had set out
to investigate at this point. Due to having only a limited ammount of
research funding remaining, I had to choose between investigating one
more area of interest in detail, or carrying out some introductory
experiments in two areas. I chose the latter option, as the two areas
were of equal interest to me. As the numbers of dogs available was
limited, the experiments described in parts 4 and 5 should be
considered as introductory, and additional to the main core of this
research project.
The first area of interest arose due to available evidence which
suggested that captopril inhibits the carboxypeptidase enzyme
responsible for the breakdown of endogenous opioid peptides. Opioid
peptides are abundant in both the adrenal medulla and the splanchnic
nerve. There was evidence to suggest that opioid peptides may inhibit
release of catecholamines from the adrenal medulla. It was possible
that the prevention of opioid peptide degradation by captopril could
contribute to its inhibitory effect on catecholamine release from the
adrenal medulla. I investigated this possibility (see "Part 4").
During this series of experiments I also investigated the effect of
dietary sodium on the resposes of the adrenal medulla to captopril, in
order to investigate whether PRA was related to the effectiveness of
captopril in the anaesthetised dog.
The second arose due to available evidence which suggested that
captopril increases secretion of prostaglandins from many sites. I
investigated the possibility of an interaction between captopril and
prostaglandin production on the release of catecholamines from the
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adrenal medulla (see "Part 5").
While emphasis has been placed on catecholamine release from the
adrenal medulla , it was also possible to determine the effects of
captopril, saralasin, All, adrenocorticosteroids, cycloheximide,
naloxone and indomethacin on other physiological aspects such as
blood pressure and adrenal blood flow.
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An introduction to the renin-angiotensin system and angiotensin-
converting enzyme inhibition.
Renin is predominantly synthesised within the juxtaglomerular
apparatus, lining the arterioles of the kidney. It is a proteolytic
enzyme which cleaves angiotensinogen, a plasma globulin synthesized in
the liver, to produce the decapeptide angiotensin I. Angiotensinogen
is always present in the blood and it is the rate of secretion of
renin in the kidney which is the rate- limiting step in angiotensin
synthesis. Renal sympathetic nerves and circulating adrenaline are
two primary stimulants for renin release. A reduction in body sodium
levels and extracellular volume, detected by the chemoreceptors and
baroreceptors, trigger a reflex increase in sympathetic tone to the
kidneys, promoting renin release.
Angiotensin I is converted to the octapeptide Angiotensin II
(All) by the angiotensin-converting enzyme (ACE), located primarily
within the pulmonary circulation. All stimulates vascular smooth
muscle and is a potent vasoconstrictor. It also stimulates
catecholamine secretion by the adrenal medulla and is the primary
input into the adrenal cortex, promoting synthesis and secretion of
aldosterone and therfore sodium retention. Both vasoconstriction and
sodium retention can increase blood pressure and much attention has
been directed towards developing drugs which prevent the actions of
All, for the treatment of renin-dependant hypertension.
There are three major ways by which drugs could inhibit the renin-






















The synthetic pathway for angiotensin II
indicating the three sites of action for
inhibitors of the renin-angiotensin system
Figure M1
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1. Inhibition of the renin-angiotensinogen reaction.
2. Blockade of the All receptor.
3. Inhibition of ACE.
1. Renin antibodies have been raised against the catalytic site
of the enzyme and have been used to investigate the role of renin in
the control of homeostasis and experimental models of hypertension
(Haber, Dzau, Kopelman, Slater and Berger, 1980). Monoclonal,
antihuman renin-specific antibodies have been isolated using cell
fusion techniques and could become useful drugs for the treatment of
malignant hypertension (Dzau, Devine, Mudgett-Hunter, Kopelman, Berger
and Haber, 1983)•
Renin normally cleaves a leucine-leucine bond in the
angiotensinogen molecule. Burton, Cody, Herd and Haber (1980) reported
that if phenylalanine is substituted for leucine , the resulting
peptide serves as a poor substrate for renin. It is a competitive
inhibitor for the reaction of renin with angiotensinogen. In addition,
if a proline residue was added at the amino terminus and a lysine
residue added at the carboxy terminus of this molecule, the resulting
peptide inhibited the action of renin in vivo.
Such inhibitory peptides are unlikely to become clinically useful
as they have many other actions besides inhibiting peripheral renin
activity. In particular, evidence indicates that they produce
parasympathetic stimulation resulting in sinus bradycardia, venous
dilation and a fall in cardiac output (Zusman, 198*0.
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2. The substitution of sarcosine and alanine for the naturally
occuring amino acids at positions one and eight in the All molecule
yields the highly competitive All receptor antagonist, saralasin
(Khosla, Smeby and Bumpers, 1972*). This has a hypotensive effect in
patients with high-renin related hypertension and in experimental
models of renovascular hypertension. In low-renin states, however, it
exerts All agonistic activity and increases blood pressure (Pals,
Masucci, Sipos and Dennings, 1971). This, and the need for saralasin
to be administered parenterally, limit its clinical usefulness.
3. In 1968 Bakhle reported that a mixture of polypeptides
isolated from the venom of the snake "Boyhrops jajaraca" inhibited the
conversion of angiotensin I to All, and also potentiated the effects
of bradykinin. Ferreira etal purified individual peptides from the
snake venom and demonstrated that these inhibited ACE and bradykinase
in pulmonary homogenate (Ferreira, Greene, Alabaster, Bakhle and Vane,
1970; Ferreira, Bartelt and Greene, 1970).
The first ACE inhibitor studied in man was SQ 20881,or teprotide,
a synthetic nonapeptide. This reduced blood pressure in patients with
high plasma renin activity, but because of its short duration of
action and the need for parenteral administration, its clinical
usefulness was limited (Antonaccio, 1982).
ACE was discovered to be a zinc-containing metalloprotein similar
to pancreatic carboxypeptidase A (Cushman, Cheung, Sabo and Ondetti,
1978). Cushman, Cheung, Sabo and Ondetti (1977) sequentially analysed
compounds known to inhibit carboxypeptidase A and discovered that an
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analogue of proline, D-3- mercapto-2- methyl-propanoyl-1-proline, was
a highly specific inhibitor of ACE in vitro. The alpha-methyl group
and the carboxyl groups on proline were later shown to interact with
the hydrophobic sites of ACE. The mercapto substitution on the beta-
carbon promoted a specific interaction with the zinc atom in ACE and
this accounts for the potent competitive inhibitory properties of the
molecule (Cushman and Ondetti, 1980). This molecule was SQ 14225 or
captopril and is an orally active potent inhibitor of ACE activity. It
is now extensively used for the treatment of hypertension.
Other ACE inhibitors have since been developed, (eg: Enalapril
(Bauer, 1984)) with similar pharmacological profiles to captopril
(Schiffrin, Gutkowska, Thibault and Genest, 1983).
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The adrenal gland
I shall give a very brief description of the anatomy, blood
supply and innervation of the adrenal gland, covering those points I
consider relevant to this research and experimental procedures. For a
detailed review of the adrenal gland, I refer the reader to "Handbook
of Physiology", Endocrinology VI, 1975, Chapters 22-31."
1 . Anatomy.
The mammalian adrenal gland derives its name from its position on
the anterior surface of the kidney and in all but the primate, they
lie seperate from the kidney. The left adrenal gland lies between the
medial border of the superior half of the left kidney and the aorta,
while the right adrenal gland lies between the liver and the vena
cava. Both lie on the dorsal abdominal wall. The left adrenal gland
is more accessible for dissection and cannulation and is therefore the
one chosen by us for study in the anaesthetised cat and dog.
The adrenal gland is composed of an outer cortex and an inner
medulla, bound by a thin capsule.
The cortex is developed from the cells of the coelomic
mesothelium and is composed of three functionally separate zones. The
outermost region of the mammalian adrenal (just below the gland
capsule) is called the zona glomerulosa and is the site for synthesis
of mineralocorticoids, desoxycorticosterone and aldosterone. Below the
zona glomerulosa is the zona fasciculata which is usually the largest
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part of the adrenal cortex and is the principle site for synthesis and
secretion of glucocorticoids. The innermost zone, closest to the
adrenal medulla, is the zona reticularis and it secretes
glucocorticoids and sex steroids. The secretions of the zonae
fasciculata and reticularis are closely controlled by
adrenocorticotrophic hormone, produced by the pituitary, which in turn
is controlled by corticotrophin releasing factor, produced by the
hypothalamus.
The medulla is developed from ectodermal cells derived from the
neural crest and is considered to be an enlarged, highly specialized
sympathetic ganglion. It is composed of large polygonal cells
separated by numerous sinusoidal vessels. Adrenal medullary cells
stain brown with fixatives containing chromium salts and are often
referred to as chromaffin cells or phaeochromocytes. These chromaffin
cells are granular, the granules evenly distributed in the cytoplasm.
They synthesise, store and release adrenaline and noradrenaline.
2. Blood supply
Numerous arteries approach the adrenal gland, derived from the
aorta, phrenic, renal, adrenolumbar, coeliac and superior mesenteric
arteries. They form a capsular plexus in the adrenal gland. The
majority of arterial branches that penetrate the capsule divide into
capillaries that pass between and around the cells of the zona
glomerulosa, between the cells of the zona fasciculata and anastamose
with each other. Two types of small arteries have also been
identified, one terminating in the adrenal cortex and one passing
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straight to the adrenal medulla where they terminate in the adrenal
medullary capillary plexus. The capillary plexus of the cortex forms
cortical venous sinuses with the medullary plexus. Blood passing
through these sinuses comes into intimate contact with chromaffin
cells. Two to four veins leave each adrenal medulla to the
adrenolumbar vein and small venous channels connect on the venous side
of the capsular plexus to the veins which accompany the adrenal
arteries and return to the renal, phrenic and adrenolumbar veins. In
the dog and cat the adrenolumbar vein fuses with either the vena cava
or the renal vein a short distance from the adrenal gland. It is this
short vessel between the adrenal gland and vena cava that I refer to
as the adrenal vein in subsequent sections of this thesis.
3. Innervation of the adrenal medulla
As previously mentioned the adrenal medulla is recognised as a
specialised sympathetic ganglion. As such, the main innervation to the
adrenal gland is cholinergic and is from the greater splanchnic
nerve, which normally leaves the sympathetic trunk at the 12th
thoracic sympathetic ganglion. The lesser splanchnic nerves (normally
two) usually leave at the 1st lumbar and 13th thoracic sympathetic
ganglia and provide a minor contribution to the innervation of the
adrenal medulla. All splanchnic nerve fibres fan out into many
branches as they approach the dorsum of the adrenal gland.




I shall briefly describe the location and function of the
arterial baroreceptors, covering those points relevant to our
experimental procedures.
Arterial baroreceptors are located at the carotid sinus
bifurcations, aortic arch, thyrocarotid junction and cardiopulmonary
area. The baroreceptors are specialised stretch receptors responding
to expansion of the vessel wall. In the "Methods" section I shall
describe the proceedure used for stimulation of the baroreceptors
located at the carotid sinus in detail. Stimulation of the arterial
baroreceptor by a decrease in carotid perfusion pressure reduces a
tonic inhibitory influence which normally presides on sympathetic
drive to the heart, blood vessels and adrenal medulla. This results in
an increase in sympathetic discharge and is the means by which we
stimulate a reflex release of adrenomedullary catecholamines in our





An introduction to catecholamine assay
Several methods have been described to determine the content of
adrenaline and noradrenaline in plasma, urine, cerebrospinal fluid and
tissues. The main techniniques available are-:
1. Biological assay - dependant on the pharmacological activity
of adrenaline and noradrenaline (see Gaddum, 1959; Callingham, 1967
for reviews).
2. Chemical techniques - discussed later (see Udenfriend, 1962;
Callingham, 1967 for reviews).
3. Radioenzymatic proceedures and double isotope derivative
analysis - The radioenzymatic proceedures employ the specific
radiolabelling of the catechol moiety with 5-adenosylmethionine and
catechol-O-methyl transferase (Ben-Jonathon and Porter, 1976). They
require multiple sample handling steps, labelled compounds and enzyme
preparations. This makes them too time consuming and expensive for
routine catecholamine analysis. Double isotope derivative analysis
(Engelman, Portnoy and Lovenberg, 1968) has similar disadvantages.
4. Gas Chromatography - This requires that catecholamines are
treated with halogenated anhydrides which gives volatile derivatives
which possess electron-capturing properties (Gelpi, Peralta and
Segura, 197*0. Sensitivity is often reduced due to the sample background
arising from derivatization reagents and contaminants from the sample
matrix and solvents. This, together with the high cost instrumentation
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required makes this method unsuitable for routine catecholamine
analysis.
5. Radioimmunoassay - This employs standard radioimmunoassay
proceedures (Johnson, Kupiecki and Baker, 1980). It is extremely
sensitive but too expensive for routine analysis.
6. High Performance Liquid Chromatography (HPLC) - discussed
later (see Davis, Schoemaker, Chen and Yamamura, 1982; Krstulovic,
1982; Hjemdahl, 1984).
The two techniques I chose to use were the chemical technique
dependant on the formation of fluorescent derivatives of the catecholamines,
using spectrofluorimetric estimation and, subsequently, HPLC with
electrochemical detection.
Chemical spectrofluorimetric catecholamine assay (CSCA) was
initially the method of choice as it fulfilled the criteria required
of an assay system for catecholamine content in adrenal venous blood.
Adrenal venous blood contains very high concentrations of
catecholamines and therefore a very high sensitivity (as obtained by
radioimmunoassay) was not required. A simple extraction and assay
procedure which yielded consistent results was required. CSCA provided
a technique which was simpler than biological assay and isotope
derivative techniques. It provided consistent results and was
relatively inexpensive to run in comparison with radioimmunoassay.
CSCA also allowed an adequate differentiation between adrenaline and
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noradrenaline and allowed a high throughput of samples, which was
necessary as many adrenal blood samples were collected during each
experiment.
My reasons for changing to HPLC for determination of
catecholamines are discussed later.
Chemical specrofluorimetric catecholamine assay
Introduction
Chemical specrofluorimetric catecholamine assay (CSCA) depends on
the observation that adrenaline, noradrenaline and their oxidation
products fluoresce. This was first observed by Vulpian in 1856 and in
1918 Loew observed that in strong alkali solution adrenaline produces
a yellow- green fluorescence. Gaddum and Schild (1934) first attempted
to develop an assay for catecholamines (CAs) based on this chemical
reaction. They also demonstrated that the reaction required the
presence of oxygen. Their assay was unsuccessful due to the
fluorescence being transient. Noradrenaline also gave a much weaker
fluorescence than adrenaline. In 1948, Ehrlen overcame the problem of
stability by discovering that ascorbic acid stabilised the adrenaline
fluorophor. The first successful fluorimetric assay was subsequently
developed by Lund in 1950.
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The critical reaction is illustrated below-
Adrenaline Adrenochrome Adrenolutine
Adrenaline and noradrenaline are oxidised to the cyclised
coloured adrenochrome and noradrenochrome respectively (Richter and
Blaschko, 1937). Addition of alkali isomerically transforms these
"chrome" derivatives to form "lutines" (Lund, 1950). The fluorescent
derivative of adrenaline was identified as 1- methyl-3,5,6-
trihydroxyindole (adrenolutine), and the reaction became known as the
"trihydroxyindole" (THI) reaction.
The oxidation rates of adrenaline and noradrenaline are pH
dependant and it was this observation that Lund (1950) used to develop
a differential assay for the two catecholamines. This technique was
later improved by Price and Price in 1957. Instead of using oxidation
at two pH levels they used light at two wavelengths to differentiate
between adrenolutine and noradrenolutine. They also introduced
potassium ferricyanide as the oxidising agent. Previously, manganese
dioxide and iodine had been used. Potassium ferricyanide yields a
greater fluorescence and reduces interferance from dopamine, Dopa
(Valori, Brunori, Renzini and Corea, 1970) and laboratory lighting.
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They also increased the stability and intensity of the fluorescence by
reacidifying the reaction products from the alkaline reaction to pH
5.0.
Many variations of the CSCA have developed, differing primarily
in the choice of oxidising and stabilising reagent. (For reviews see
Udenfriend, 1962; Haggendal, 1966; Callingham, 1967).
The observation by Vendsalu in 1960 that ascorbic acid itself
gives rise to fluorescent oxidation products when in alkaline solution
induced the introduction of sulphur containing compounds as
stabilising reagents. These include British Anti-Lewisite
(BAL)/formaldehyde mixture (Valori etal, 1970), BAL/sodium sulphite
mixture (Haggendal, 1966), sodium sulphite (Laverty and Taylor, 1968),
cysteine hydrochloride (Klensch, 1966) and thioglycolic acid
(Merrills, 1963).
The actual method I have employed is a modification of the
techniques described by Haggendal in 1966 and Valori etal in 1970.
Extraction of catecholamines from plasma, and proceedures for CSCA
Blood plasma must be purified before CSCA can be applied, to
minimise the occurrance of contaminants which could affect the
detection of fluorescence.
The method I initially chose was cation exchange chromatography
as it lent itself well to CSCA, in particular the system developed in
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this laboratory. I later changed to alumina adsorption when I changed
my method of catecholamine detection to HPLC. I shall discuss this
later in "HPLC with electrochemical detection for the assay of
catecholamines".
The extraction of catecholamines using cation exchange
chromatography depends on the catecholamines being positively charged
around a neutral pH. This results in them being retained by
negatively charged groups on either sulphonic acid or carboxylic acid
resins. The catecholamines are then readily eluted off the resin by
an acidic solution.
1. Collection of adrenal venous blood
Venous blood from the left adrenal gland was collected in cooled,
graduated centrifuge tubes (see "Methods"-Whole animal experiments ).
2. Separation and storage of plasma
Blood samples were centrifuged at 3,000 r.p.m., 4°C for ten
minutes. The total blood volume, red blood cell volume and plasma
volume were recorded and the plasma removed to fresh storage tubes,
using a pasteur pipette. A solution of 2mgml-'' sodium metabisulphite
was prepared and a volume equal to that of the plasma added, ensuring
2mgml-1 plasma was added to each sample. (Sodium metabisulphate is an
antioxidant used to minimise oxidation of the catecholamines during
storage, defrosting etc..) The samples were frozen overnight at -20°C.
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3. Extraction of catecholamines
The plasma samples were allowed to thaw. Any fibrin present was
removed by rotating a fine glass rod slowly around each sample. The
fibrin attached to the rod and was removed.
Duplicate aliquots of each plasma sample were then loaded onto
Amberlite CG50 (mesh size 100-200) resin columns of 5cms length and
0.25 cm internal diameter. (See section on "Preparation of Amberlite
CG50 columns" later, for details of CG50 resin and the preparation of
the columns used).
The columns used consisted of a 20ml reservoir leading down to
the 0.25 cm internal diameter glass column. The samples were held by
the reservoir until they were induced to pass down the column, by a
fine glass rod.
To each plasma sample 0.1N phosphate buffer pH 7.^, (447mg
monopotassium dihydrogen orthophosphate, 2.383g disodium hydrogen
orthophoshate in 250ml distilled water) and 3% EDTA was added in the
ratio 1:3:0.5, plasma:buffer:EDTA respectively. The samples were then
induced to run through the column using a fine glass rod.
The columns were then rinsed with 5mls of distilled water.
The catecholamines were eluted from the columns with 1ml of 2/3M
boric acid, into test-tubes selected to fit both the AC60 autoanalyser
and the spectrophotofluorimeter.
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A volume of 1ml 2/3M boric acid completely elutes the
catecholamines and is the ideal volume required for the CSCA. 2/3M
boric acid is used, as boric acid is insoluble at room temperature at
higher concentrations. Adrenaline and noradrenaline form complexes
with boric acid (Trautner and Messer, 1952) which promotes elution.
These complexes are stable at pH 6.5, enabling the eluates to be
stored for up to three hours.










Column standards - 0.1 ml of Ijjgml-1 standard solutions of
adrenaline and noradrenaline were loaded onto the columns in 3ml 0.1N
phosphate buffer (pH 7.H) and 0.05 ml of 3% EDTA.
Non-column blanks - these were 1ml aliquots of 0.4N phosphate
buffer, pH6.5.
Non-column standards - these were 0.1ml of l^igml standard
solutions of adrenaline and noradrenaline and 0.9ml of 0.4N phosphate
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buffer, pH 6.5 (6.805g monopotassium dihydrogen orthophosphate and
2.363g disodium hydrogen orthophosphate in 1L distilled water).
4. Spectrophotofluorimetric assay
4.1 .Preparation of fluorophors
The maximum number of samples assayed at any time was 12, assayed
in duplicate, due to availability of the columns.
The tubes were then placed into the conveyor belt of a unicam
AC60 autoanalyser in the following order-:
1+2 Non-column adrenaline standard
3+4 Non-column noradrenaline standard
5+6 Non-column blank
7+8 Column adrenaline standard
9+10 Column noradrenaline standard
11+12 Column blank
13~24 Samples 1-6 in duplicate
25-36 As 1-12
37-48 Samples 7-12 in duplicate
The THI reaction was then induced in each sample. The following




0 0.5 Potassium ferricyanide (0.05$)
containing cupric chloride (0.00025$)
3 0.5 Sodium sulphite (10$) containing B.A.L
(0.4$)
3.5 0.5 Sodium hydroxide (8N)
6.5 0.35 Glacial acetic acid (conc.)
The final pH of each sample was 5.0. The samples were then removed from
the autoanalyser, the outside of each tube carefully wiped, and each allowed
to stabalise for 30 minutes before being transferred to the Aminco-Bowman
spectrophotofluorimeter.
4.2. Reading of fluorescence
The excitation spectrum scanned over the range 300-500mp and the
emission wavelength was set at 510 mp. The Aminco-Bowman
Photomultiplier Microphotometer displayed the intensity of the
fluorescence in each sample. The intensity was also displayed on a
"servoscribe" flat-bed recorder, the chart drive of which was
synchronised to the scanning motor switch on the spectrofluorimeter
and operated only when the excitation spectrum was scanned. The chart
and wavelength scanning motor speeds were fixed and the wavelength at
any point on the trace was found by its distance from the start of
each scan. For each sample a maximum fluorescence peak was obtained




The "index of discrimination" (I.O.D.) was calculated for each
sample, ie-:
I.O.D. = F.I. adrenaline/F.1. noradrenaline (at higher wavelength)
F.I. adrenaline/F.1. noradrenaline (at lower wavelength)
F.1.=Fluorescence intensity
510mji is the emission wavelength at which the I.O.D. is high and
the fluorescence of adrenaline and noradrenaline relatively equivalent
(Ellis, 1983).
The excitation wavelengths that gave the highest I.O.D. were
calculated for each assay. An I.O.D. of greater than 9 was considered
acceptable. Figure M2 shows a typical chromatogram of 100ng
adrenaline and noradrenaline, indicating the excitation wavelength
used for calculation of I.O.D. and catecholamine values. The
excitation wavelengths used usually fell between 350 to 370 (lower),
and 450 to 470 (higher).
The mean values of each sample and blank duplicate were used, and
the value of the blanks at the lower and higher wavelengths subracted
from those of the catecholamines before calculating their values.
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FigureM2
Reducedphotocopyofaty icalfluorescencespectra100 qr nalin andnoradrenaline._.Emissionwavelength=510mu I.0,D=13-6[calculateda365 and£60mjj,indicatedbyrrows] Noradrenaline
4.3. Calculation of adrenaline and noradrenaline
The relationship between the fluorescence intensity and the
concentration of catecholamine is assumed to be linear. The
fluorescence of adrenaline and noradrenaline are also assumed to be
additive.
So, for any given point on the specrum-:
F = yN + xA
Where F = Fluorescence intensity, A and N are the fluorescence
intensities per nanogram of adrenaline and noradrenaline and y and x
are the unknown amounts of noradrenaline and adrenaline in the
sample.
If the fluorescence readings are teken at two wavelengths, one
high (H) and one low (L), then a pair of simultaneous equations can be
written (Bertler, Carlsson and Rosengren, 1958)-:
F(L) = yN(L) + xA(L) and F(H) = yN(H) + xA(H)
Solving these equations gives
y = F(L) x (A(H)/A(L )) - F(H) and x = F(H) - yN(H)
N (L ) x (A (H )/A (L)) - N (H) A (H)
A computer program was used to calculate the unknown amounts of
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noradrenaline and adrenaline for each sample. After calculation, the
percentage recovery for each batch of samples was calculated. The
maximum fluorescence (MFI) intensity of adrenaline and noradrenaline
column standards was taken as a percentage of the MFI of adrenaline
and noradrenaline non-column standards. Each calculated value was
adjusted accordingly. The percentage recoveries for ten assays was 95
± 2.1$.
In order to satisfy myself that these procedures gave accurate
values to unknown adrenaline and adrenaline mixtures, I extracted and
assayed a series of known mixtures, calculated their values and
compared the calculated value to the actual value in the mixture. The
results are shown below.
Amount added (ng) Amount calculated (ng)
Adrenaline Noradrenaline Adrenaline Noradrenaline
100 100 98.4 97.3
100 100 98.1 98.5
80 20 80.9 20.1
80 20 79.2 19.5
60 40 61 .3 37.2
60 40 60.8 37.7
50 50 49.8 50.0
50 50 49.6 49.2
I repeated this series of determinations at fortnightly intervals
to ensure the assay was giving accurate results.
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Preparation of Amberlite CG50 columns
Introduction
Amberlite CG50 was the resin of choice, as a 5cm column was found
to give recoveries consistently over 90%. In addition, with the
stronger sulphonic acid resins such as CG120, up to 4ml of 1N HC1 is
required to elute the catecholamines and it is necessary to neutralise
each eluate to pH 6.5 before the THI reaction can be induced. The
catecholamines can be eluted from the CG50 resin, which is a weak
carboxylic acid resin, using 1ml of 2/3M Boric Acid, previously
adjusted to pH 6.5. 1ml of eluate is also the ideal volume for the
CSCA assay.
Preparation of the resin
Recycling the resin between the contracted hydrogen form and the
expanded sodium form expels impurities and greatly improved the
efficiency of the resin. I repeated the following preparation at
fortnightly intervals, and each batch of resin was kept no longer than
two months.
The following preparation has been adapted from that first
described by Renzini, Brunori and Valori (1970).
1. The resin was soaked overnight in 2N HCl.(The same volume of
HC1 as resin was used.)
2. The HC1 was removed and the resin washed several times with
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distilled water. The water was renewed between washes. This removed
the fines contained in the resin.
3. The resin was thoroughly shaken in 2N NaOH (same volume as
resin). The NaOH was removed.
4. The resin was washed in distilled water until a neutral pH was
obtained.
5. The resin was thoroughly shaken in 2N HC1.
6. 4. was repeated.
7. 3-~ 6. were repeated three times.
8. The resin was thoroughly shaken in 0.4M disodium phoshate
buffer (pH 6.5) three times.
9. The resin was stored at 2-4°C.
Preparation of columns
A glass wool plug was placed at the end of each column (0.25 cm
i.d.) to retain the resin. The resin was loaded up to 5cm into the
columns, making sure that no air bubbles accumulated in the resin. The
columns were loaded immediately before use. Before the samples were
added, 10 mis of 0.4M disodium phosphate buffer (pH 6.5) was run
through the columns. The pH of the eluant was checked, and if not at
6.5, more buffer was run through until the pH was 6.5. This is the
optimum pH for the positively charged catecholamines to be retained by
the resin. The columns were then ready for use.
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High performance liquid chromatography with electrochemical detection for
the assay of catecholamines
Advantages of High Performance Liquid Chromatography (HPLC) over CSCA
In order for CSCA to remain a satisfactory, consistent assay
technique it was necessary to ensure that each reagent added to
induce the THI reaction was added at a defined and accurately
controlled time point. I was becoming increasingly frustrated by the
hydraulics and dispensing pipettes of the Unicam AC60 autoanalyser
becoming jammed. This frequently occurred in the middle of a
throughput of 24 samples and jeopardised the successful assay of all
samples still to pass under the dispensors. The volume of each reagent
was also becoming increasingly more difficult to control due to the
dispensing pipettes often failing to dispense their total volume.
These faults were undoubtedly due to the age of the autoanalyser and
its failing hydraulics.
I had become aware of the simplicity of HPLC as a means of
analysing catecholamines and on investigating further discovered that
it had many advantages over CSCA-:
1. The catecholamines are extracted in alumina. This proce dure is
much simpler and less time consuming than that previously described
using Amberlite CG50 resin.
2. Catecholamines are eluted from alumina using 0.1N perchloric acid
which could then be injected directly into the HPLC system. This
avoids the time consuming proceedures required to induce the THI reaction.
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3. HPLC separates noradrenaline and adrenaline and each is illustrated
as a separate peak on the chromatogram. The height of each peak is
directly proportional to the catecholamine concentration and enables a
much simpler calculation of unknown catecholamine concentrations,
which does not require computer analysis.
4. An internal standard is added to each plasma sample before
extraction. The values of the catecholamines are calculated using the
peak height of the internal standard. Each sample therefore has its
own standard and, during the calculation of catecholamine values, each
is automatically adjusted for any loss during the extraction
procedure. With CSCA there is no internal standard. A percentage
recovery of adrenaline and noradrenaline is calculated and every
sample in a batch adjusted accordingly. This does not allow for any
variations that may occur between individual sample.
These were the main reasons I had for converting to HPLC for the
analysis of catecholamines. Catecholamines were estimated by HPLC in
dog 12 and all subsequent dogs.
An introduction to HPLC with elecro-chemical detection
The first report of the application of HPLC with electro-chemical
detection (HPLC-E1CD) to the analysis of catecholamines was made by
Kissinger, Ref Shauge, Dreiling and Adams (1973), and its subsequent
use for the determination of plasma catecholamines was described by
Hallman, Farnebo, Hamberger and Jonsson (1978).
Several modes of HPLC have been used: ion-exchange, reverse-phase
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and reverse phase with ion-pairing (RP-IP) chromatography. I shall
breifly discuss the ion-exchange and reverse phase modes before
discussing RP-IP in more detail.
Cation-exchange chromatography
This mode of chromatography depends on the catecholamines being
retained by an ion-exchange resin and was the method used by
Kissinger etal (1973) and Hallman etal (1978). They used a relatively
large and irregularly shaped strong cation-exchange material but the
chromatograms obtained often showed broad peaks and gave a poor
separation of noradrenaline from the solvent front. This was overcome
by Hjemdahl (1984) and Allmark and Hedman (1979) who used a
microparticulate cation-exchange material. However, the ion-exchange
packings still have several disadvantages: They are less efficient,
less reproducible and less stable than reverse phase columns and the
number of packings available is limited.
Reverse-phase chromatography
The potential of this technique for catecholamine analysis was
first demonstrated by Molnar and Horvath in 1978. Reverse-phase
chromatography is so named because the column particles (stationary
phase) are coated with carbon chains, usually 18 moieties in length.
They provide efficient separation of compounds with varying
lipophilicity and this mode of chromatography is very versitile in
that the separation of compounds can be affected in many ways. Varying
the pH of the mobile phase (affecting ionization) in catecholamine
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analysis influences their retention. Although this mode of
chromatography is very efficient, it has certain disadvantages in
comparison with RP-IP chromatography. Many interfering substances tend
to be retained along with the catecholamines, and interfere with the
chromatogram, and there is often a poor separation of noradrenaline
from the solvent front.
Reverse-phase-ion pairing chromatography
The development of this mode of chromatography has greatly
improved the sensitivity, efficiency and versitility of HPLC for
catecholamine analysis (Moyer and Jiang, 1978). In RP-IP, ion-pairing
reagents are added to the mobile phase to increase retention, and
therefore separation, of charged solutes. The retention is believed to
occur through ion-pair formation in the mobile phase (Terweij-Groen,
Heemstra and Kraak,1979).
The main equilibria involved are as follows-:
1a. Ion-pair formation in the mobile phase with the anion-pairing
reagent, L~
CA+ (m) + L~ (m) «-»• ( CA+ L~ )(m)
1b. Reversible binding of the ion-pair to the hydrocarbonaceous
surface-:
( CA+ L" )(m) <--► ( CA+ L" )(s)
CA = catecholamine
m and s = mobile and stationary phase respectively.
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2. Dynamic ion exchange, the solute molecule forming a complex
with the ligand already adsorbed-:
CA+ (m) + L~ (s) (CA+ L" )(s)
3. Dynamic complex exchange between the ion-pair formed in the
mobile phase and the ion-pairing reagent bound to the column-:
( CA+ L" ) (m) + L" (s) <--> ( CA+ L" )(s) + L~ (m)
The ion-pairing reagent most frequently used is sodium octane-1-
sulphonate which gives an excellent selectivity with a minimum
equilibration time. Addition of methanol and citrate ions in the
mobile phase also affects retention. Citrate ions in the mobile phase
*
lower the retention of catecholamines by exerting an electrostatic
attraction on the "pairs" (Krstulovic, 1982).
Electrochemical detection
Electrochemical detection relies on catecholamines being oxidised
to the corresponding orthoquinones at the surface of a graphite
electrode-:
HO 0 R




The anodic current produced is directly proportional to the
number of solute molecules in contact with the electrode (Kissinger,
Bruntlett and Shoup, 1981). This anodic current can be converted into




Catecholamines undergo complex binding to aluminium oxide
(alumina). Previously alumina was "activated" as described by Anton
and Sayre (1962). Present preparations of alumina no longer require
activation. This method of extraction was chosen in favour to that
previously used for CSCA for the following reasons-:
1. The alumina does not require the time consuming preparation the
Amberlite CG50 resin requires.
2. Alumina extraction can be carried out in test-tubes. This avoids
the need to prepare and pack columns as with the Amberlite CG50
method.
3. As only 20>il of eluate is injected into the HPLC system, the
catecholamines need to be eluted in a very small volume of eluate. 1ml
of boric acid is required to elute the catecholamines from the
Amberlite CG50 resin column. 200jil of 0.1M perchloric acid will elute
the catecholamines from the alumina, increasing the concentration of
catecholamines injected, decreasing the need for a very high
sensitivity.
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The extraction procedure I adopted is a modification of those
described by Hjemdahl, Daleskog and Kahan (1979) and Davies and
Molyneuk (1982).
Extraction procedure
The adrenal venous blood samples were collected and stored as
described for CSCA. The reagents used were-:
1. 0.1M perchloric acid (PCA).
2. Tris buffer, pH 8.6 (12g Tris, 2g EDTA, 100ml distilled water, pH
corrected with HC1).
3. Internal standard (100ng per 200jil of dihydroxybenzylamine (DHBA)
in 0.1M PCA).
4. Alumina (Sigma, chromatographic, Acid Type WA-1). Stock solutions
of 500ngml~1 DHBA were kept refrigerated for up to one month. All
standards were made up in 0.1M PCA.
The following protocol was followed-:
1. 20-30mg of alumina was placed in conical bottomed test-tubes.
2. 2ml of sample plus 200pl of the DHBA internal was added to the
alumina. (This gives an internal standard chromatogram peak of 1Ong
DHBA.)
3. The pH was adjusted to 7.8-8.2 with Tris buffer.
4. The samples were mixed on a "Spiromix" blood mixer for 20 minutes.
5. The alumina was allowed to settle and the supernatant removed.
6. 1- 2ml ice-cold distilled water was added and mixed.
7. 5. and 6. were repeated to give three washes in the distilled water.
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8. The alumina was allowed to settle and as much of the supernatant
was removed as possible.
9. 200pl 0.1M PCA was added to the alumina.
10. The tubes were mixed in a Vortex shaker for 20 minutes.
11. The alumina was allowed to settle and the 0.1M PCA eluates
dispensed into clean test-tubes.
12. 20jul of eluate was injected into the HPLC system.
PCA both extracts and prevents oxidation of the catecholamines.
The HPLC-E1CD system
A schematic representation of the system used is illustrated in
figure M3.
The mobile phase used was an 0.1M acetate/citrate buffer, pH 5.2
(11.5g citric acid, 13.6g sodium acetate, 4.8g NaOH, 0.74g EDTA, 0.2g
sodium octane-1-sulphonate, in 2L of distilled water/10% methanol,
the pH was adjusted with glacial acetic acid). The buffer was filtered
and degassed before use, to minimise the occurrence of bubbles forming
on the glassy carbon electrode. This was done by by filtering the
buffer through a miHipore filter (0.22um) into a vacuum flask which
was evacuated using a water pump. A fresh buffer was made up every
month.
The liquid chromatograph comprised of the following-:
1. Solvent delivery system - Gilson 303 pump plus a Gilson 802
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FigureM3 Aschematicrepres ntationofthHigperformanceLiquidChromatographysyst musedft analysisofcatecholamine .
manometric module. Solvent delivered at 1mlmin-1 .
2. Sample injector - Rheodyne Model 7125 injection valve fitted
with a 20;ul sample loop.
3. Precolumn - 1.5mm ID, 20mm length, packed with Partisil - 10 -
SCX, Strong Cation Exchanger (Whatman).
4. Column - "Ultrasphere-ODS" 4.6mm ID, 25cm length, packed with
5>i diameter ultrasphere IP particles.
5. Detector system - B.A.S. LC-4B Ampometric Detector plus an
electrochemical detector fitted with a TL-5 cube, glassy carbon cell.
The oxidation potential applied was +0.72 volts.
6. Servoscribe flat-bed recorder.
Before any samples were injected into the HPLC system, the
electrode was "conditioned". This prevents any drift and noise. The
electrode was switched off, the voltage switched to +1.5 volts, the
offset switched off and the attenuation set at 500nAmp. The buffer
flow rate was set at 0.3mlmin-1, then the electrode switched on and
left for at least one hour. The electrode was then switched off, the
voltage switched to +0.72 volts, the offset to on and the attenuation
to the required setting (usually 5). The buffer flow rate was set at
Imlmin-1 and the electrode switched on. After a steady baseline was
obtained (10-30 minutes), the samples were injected.
An example of a typical chromatogram is shown in figure M4. It
was possible to inject samples between the adrenaline and DHBA peaks
of the prece ding chromatogram without the solvent front interfering
with the DHBA peak. The approximate retention time for noradrenaline
was 2 minutes, for adrenaline was 4 minutes and for DHBA was 6.5 minutes.
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Calculation of catecholamine values
The value of adrenaline and noradrenaline was calculated using
the following equation-:
x = Level of DHBA x Peak height of X
Peak height (CA)
Ratio Peak height (CA)
Peak height (DHBA)
X = Unknown value of the catecholamine
(CA) = Peak height of catecholamine standard
(DHBA) = Peak height of DHBA standard
The ratio was calculated at monthly intervals by compiling a
graph for varying concentrations of catecholamines and DHBA vs their
peak heights and calculating the ratio (see figure M5).
Table M1 shows a comparison of the catecholamine values obtained
by fluorimetry and HPLC in adrenal blood samples. The major difference
between the two was the percentage of noradrenaline present in each
sample. The total catecholamine values can be seen to agree very well.
I suspect that the differences in the percentage of noradrenaline lay
in the age of the autoanalyser and inconsistency in the volumes of
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Table M1
Comparison of catecholamine estimations by Fluorimetry and High
performance Liquid Chromatography (HPLC).
Values obtained by Values obtained by
Sample fluorimetry (ng) HPLC (ng)
NA A NA+A %Nk NA A NA+A £NA
1 57 190 247 23 50 205 255 20
2 190 435 625 30 133 476 609 22
3 31 66 97 32 18 77 95 20
4 42 75 117 36 25 109 134 19
5 25 209 234 11 58 229 287 20
6 20 154 174 11 44 168 212 26
7 116 230 346 34 62 234 296 21
8 78 209 287 27 57 232 289 20
9 191 331 522 37 119 422 541 22
10 201 389 590 34 124 475 599 21
11 361 632 993 36 183 767 950 19
12 263 633 896 29 150 633 783 19
Total 1573 3553 5126 1023 4027 5050
Mean ± 28.3 20.8
SE ± 2.6 + 0.6




Dogs and cats were anaesthetised with sodium pentobarbitone
(30mgkg-1 iv.). Anaesthesia was maintained by an additional iv.
injection if a corneal reflex became evident during the experiment.
Pentobarbitone was the anaesthetic of choice as work previously
carried out in this laboratory has shown that the adrenal medulla is
more responsive to baroreceptor stimulation under pentobarbitone, than
the other anaesthetic of choice, chloralose (Critchley, Ellis and
Ungar, 1980).
Respiration, acid-base balance and temperature control
The trachea was cannulated and connected to a Starling "Ideal"
pump. The lungs were ventilated with a metered oxygen-nitrogen
mixture. Regular arterial blood samples were obtained and PaC02 ,Pa02
and pH measured on a Radiometer BMS 3 analyser. The oxygen-nitrogen
mixture was adjusted to maintain PaC02 at 5kPa (39mmHg) in dogs, and
4kPa (30mmHg) in cats and Pa02 above 20kPa (150mmHg). Any base deficit
was corrected, to maintain pH at 7.M, by injecting an appropriate
volume of 1M sodium bicarbonate, according to the Singer-Hastings
nomogram (Singer and Hastings, 19-48). Respiration rate was fixed at 25
per minute. The stroke volume was adjusted, if required, to maintain
blood gas levels. Body temperature was held at 37°C by a heating lamp
and pad, linked to a rectal thermistor probe.
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Maintainance of systemic arterial blood pressure
Blood pressure was monitored throughout each experiment and, if
necessary, maintained by iv. administration of dextran (40? in saline
prewarmed to 37°C in a water bath). Blood pressure falls as a result
of blood loss during surgery, handling of viscera and prostaglandin
release by surgical trauma (Terragno, 1977). Bladder reflexes
resulting from a distended bladder also induce a fall in blood
pressure (Taylor, 1968) and the bladder was often drained using a
catheter or suprapubic puncture to avoid this. It was usually not
necessary to administer dextran prior to captopril administration.
Dextran was administered by a continuous iv. infusion following
captopril due to the hypotensive action of captopril, in order to
prolong survival of the anaesthetised preparation.
Bilateral carotid bifurcation perfusion
Surgery
Both carotid arteries were exposed. The superior thyroid arteries
were immediately tied off, and loose ligatures placed around the
common carotid arteries, the external carotid arteries (cranial to
the origin of the lingual arteries), the lingual arteries and the
vagi. Care was taken to dissect well away from the carotid sinuses
which are located at the carotid bifurcations, located at the point
where the naso-pharangeal nerve crosses the carotid artery. The
external carotid arteries were located by following the lingual
arteries down to the carotid arteries.
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Cannulation and perfusion
A diagram of the perfusion system for the carotid bifurcations
and collection of adrenal venous blood samples is shown in figure M6.
Both common carotids were cannulated both ways and blood from one
(usually the right) was perfused into both, towards the head, using a
Watson- Marlow perfusion pump. The left carotid artery was cannulated
to monitor systemic blood pressure. The external carotid arteries
were tied off. The lingual arteries were not ligated in order to
ensure an adequate blood flow through the carotid bifurcations. Both
vagi were cut to abolish secondary reflexes from the thoracic
receptors.
A pressure transducer was connected to the perfusion circuit to
record carotid perfusion pressure (CPP), and was linked via a servo
amplifier to the Watson-Marlow perfusion pump. The servo amplifier
exerts a negative feedback to control the speed of the perfusion pump,
to maintain a constant CPP, set by a "clock" potentiometer. The clock
potentiometer is calibrated in mmHg and the CPP could be varied by
adjusting the potentiometer clock.
Baroreceptor stimulation
Baroreceptor stimulation, or baroreceptor "tests" were performed
by lowering the CPP by 40mmHg for the required length of time,
usually ten minutes. A reflex increase of systemic blood pressure,
following baroreceptor stimulation, was evidence that baroreceptor
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FigureM6 Dioqram of perfusion of the carotid bifurcations



























stimulation was successful. Figure M7 shows a typical trace obtained
during baroreceptor stimulation, and illustrates the reflex increase
in systemic blood pressure which accompanies each successful
baroreceptor test.
Collection of adrenal venous blood samples
In the dog the venous effluent from the adrenal gland drains into
the adrenolumbar vein. This runs a short distance before fusing with
the inferior vena cava. In the cat it may fuse with either the
inferior vena cava or the renal vein. This distance of vessel,
referred to as the adrenal vein, is too short to cannulate and so the
adrenolumbar vein is cannulated in a retrograde fashion to allow
collection of adrenal venous blood. Figure M6 shows a diagram of the
cannulation.
The abdomen was opened and the adrenal gland located. The adrenal
vein was isolated, and a loose ligature placed around it. The
adrenolumbar vein was isolated, and two loose ligatures placed around
it. All small branches of the adrenolumbar vein, between the point of
cannulation and the gland, were tied off.
A soft, flexible polythene tubing, selected to fit the
adrenolumbar vein was used for cannulation. The adrenolumbar vein was
cannulated and the cannula pushed past the adrenal gland and
positioned so that its tip lay at the point where the vein leaves the
gland. Prior to tying off, the adrenal vein was occluded by pulling on
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flow through the cannula, this indicated that the cannula had been
pushed too far and was pulled back until flow resumed. The cannula
was then secured, and the adrenal vein tied off. A small hole was
punctured through the abdomen wall and the cannula pulled through.
The adrenal venous blood was collected in cooled, graduated
centrifuge tubes. The left saphenous vein was also cannulated, and
any adrenal blood not collected was immediately returned to the
animal via the saphenous vein, using a Watson-Marlow pump. Any
additional anaesthetic, drugs and dextran were also administered into
the saphenous vein.
Splanchnic nerve stimulation
Figure M8 shows the preparation of the left adrenal gland for
stimulation of the splanchnic nerve and collection of adrenal venous
blood.
The main splanchnic nerve trunk was located and a length
isolated. Two loose ligatures were placed around the nerve. Any
smaller branches of the nerve were isolated, tied off and severed, and
a region around the nerve was thoroughly crushed, using Spencer-
Wells forceps, to ensure maximum denervation of the adrenal medulla.
The main trunk was then cut some 1-1.5 inches from the gland, and a
bipolar stimulating electrode hooked under the nerve, towards the
pripheral cut end. The two loose ligatures were used to raise the
nerve over the electrode. The nerve was stimulated using a Tektronix
stimulator.
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Preparationofthel fadrenalglandfostimul tionfthsplanchnic nerveandcollectionofadrenalven usblo d. Ligation+cut Inferior— venacava LigatureStimulatingelectrode Ligation+cut Adreno-lumbarvein collecting- tube~ FigureM8Adrenal veinAdrenalala d
Summary of the experimental protocol for perfusion of carotid
bifurcations and collection of adrenal venous blood samples
1. Surgery was performed to:-
a. Cannulate the left saphenous vein
b. Prepare the carotid bifurcations for perfusion
c. Prepare the left adrenal gland for collection of adrenal venous
blood.
2. Half an hour was allowed for haemostasis.
3. 500 i .u.kg"'heparin was administered.
4. The animal was put onto the respiratory pump.
5. The carotid bifurcations were cannulated and perfused. Carotid
perfusion pressure and systemic blood pressure were recorded.
6. Both vagi were cut.
7. The adrenolumbar vein was cannulated, the adrenal vein tied off and
adrenal blood collected.
8. Perfusion of excess adrenal blood into the saphenous vein was
started.
9. Blood gases and acid-base balance were adjusted if necessary (this
was repeated frequently throughout each experiment).
10. The preparation was allowed up to 30 minutes to settle before
baroreceptor tests were performed.
Summary of the experimental protocol for stimulation of the
splanchnic nerve and collection of adrenal venous blood samples
1. Surgery was performed to:-
a. Cannulate the left saphenous vein.
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b. Prepare the left common carotid for cannulation (to record systemic
blood pressure).
c. Prepare the left adrenal gland for adrenal venous blood collection
and splanchnic nerve stimulation.
2. Half an hour was allowed for haemostasis.
3. 500 i.u.kg-1 heparin was administered.
4. The animal was put onto the respiratory pump.
5. The left common carotid was cannulated and systemic blood pressure
recorded.
6. The left adrenolumbar vein was cannulated, the adrenal vein
was tied off and adrenal venous blood collected.
7. The bipolar electrode was positioned under the main splanchnic
nerve trunk.
8. Perfusion of excess adrenal blood into the saphenous vein was
started.
9. Blood gases and acid-base balance were adjusted if necessary.
10. The preparation was allowed up to 30 minutes to settle before
splanchnic nerve stimulation was commenced.
Details of the experimental protocol adopted during baroreceptor
stimulation experiments
Unless otherwise stated in the "Results" section, the following
experimental procedure was adopted:-
1 . A control 1 minute adrenal blood sample was collected.
2. Baroreceptor stimulation was started and a stop-clock started
simultaneously.
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3. 1 minute adrenal venous blood samples were collected during
baroreceptor stimulation from 1-2, 5-6 and 9-10 minutes.
4. Baroreceptor stimulation was stopped and the preparation allowed 20
minutes to recover.
5. Steps 1-4 were repeated.
6. Drug A was administered. A list of the drugs used, the means
of administration and the time allowed for them to take effect is
listed later.
7. Steps 1-5 were repeated.
8. Drug B was administered.
9. Steps 1-5 were repeated.
10. Drug C was administered.
11. Steps 1-5 were repeated.
Where plasma renin activity was measured, 2ml carotid arterial
blood samples were collected during each adrenal blood collection
period. The samples were centrifuged as for adrenal blood samples and
the plasma removed and frozen. Plasma renin activity was measured by
radioimmunoassay (RIA).
Where adrenocorticosteroid output was measured (by RIA),
additional 1 minute adrenal blood samples were collected each time
step 1 was carried out.
I shall outline the main drugs used in parts 1-5 of the "Results"





Drug A - Captopril, 25 mg iv., allowed 20 minutes to take
effect.
Drug B - Angiotensin II - dosage indicated in the "Results"
section, continuous infusion, allowed 20 minutes to take effect.
Part two
1. Drug A - Captopril.
Drug B - Angiotensin II.
Drug C - Cycloheximide, 50 mgkg-1 iv., allowed 15 minutes to take
effect.
2. Drug A - Captopril.
Drug B - Adrenocorticotrophic hormone (ACTH),
1OOpg iv., allowed 20 minutes to to take effect.
3. Drug A - Cycloheximide.
Drug B - Captopril.
Drug C - Angiotensin II.
Part four
Drug A - Naloxone, 0.3mgkg-'' , continuous iv. infusion,
Imlmin-'' , allowed 15 minutes to take effect.
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Drug B - Captopril.
Drug C - Naloxone.
Part five
Drug A - Indomethacin, 5mgkg-1 iv., allowed 15 minutes to take effect.
Drug B - Captopril.
Details of the experimental protocol adopted during splanchnic nerve
stimulation experiments
Unless otherwise stated in the "Results" section, the following
experimental protocol was followed-:
1. A control 1 minute adrenal blood sample was collected.
2. Splanchnic nerve stimulation (10 volts, 2ms, 10 pulses per second)
was started and a stop-clock started simultaneously.
3. A 1 minute adrenal venous blood sample was collected 30 seconds
after onset of stimulation.
4. The stimulation was stopped and the preparation allowed 20 minutes
to recover.
5. Steps 1-4 were repeated.
6. Drug A was administered (see later).
7. Steps 1-5 were repeated.
8. Drug B was administered.
9. Steps 1-5 were repeated.
10. Drug C was administered.
11. Steps 1-5 were repeated.
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In the initial series of experiments, steps 1 -*1 were repeated for
four frequencies of stimulation - 2.5, 5, 10 and 20 pulses per second
and step 5 was omitted.
I shall outline the main drugs used in parts 3 ~ 5 of the
"Results" section. Any additional drugs or proceedures used will be
indicated in the relevent "Results" section. The same dosages, means
of administration and time allowed to take effect described previously
were used.
Part 3
1. Drug A - Captopril.
Drug B - Angiotensin II.







Drug A - Indomethacin.





Measurement of reflex changes in the resistance of the vascular
bed of the hind limb, in the anaesthetised dog.
Dogs were anaesthetised with sodium pentobarbitone, and surgery
performed to prepare the carotid arteries for bilateral carotid
bifurcation perfusion following the experimental procedure already
described.
The femoral arteries in both hind limbs were located and
dissected free, and loose ligatures placed around them. The
preparation was allowed 30 minutes for haemostasis before
administering heparin (500 i.u. kg-1). The carotid arteries were
cannulated for bilateral carotid bifurcation perfusion.
The femoral artery of the left limb was cannulated towards the
heart, and blood from this was perfused using a Watson-Marlow pump,
into the right limb, which was cannulated away from the heart. A
pressure transducer was connected to the perfusion circuit to monitor
hind limb perfusion pressure (HLPP). The HLPP was adjusted so that the
it was approximately equal to systemic blood pressure. As flow through
the perfused limb is constant, the HLPP can be taken as a measure of
vascular resistance.
In order to prevent collateral blood flow between the perfused
limb and the abdominal circulation, tape was tied tightly around the
upper thigh. Captopril was administered into the cannulated, saphenous
vein, of the non-perfused limb.
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Two minute baroreceptor tests were performed before and after
captopril administration, using the protocol already described, and
systemic blood pressure, carotid perfusion pressure and HLPP




Part 1 - Introduction and literature review
Increased circulating levels of All have long been implicated in
the aetiology of hypertension caused by an increase in circulating PRA
(reno-vascular hypertension) (eg, Haber, 1979). The discovery of
angiotensin converting enzyme (ACE) led to the development of the ACE
inhibitors for the treatment of reno- vascular hypertension. All is a
known vasoconstrictor (Bohr, 1974) and it is also known to activate
the sympathetic nervous system by an action on the central nervous
system (Strauss, Lamdin, Smith and Bleifer, 1958; Fitzsimons, 1980).
All can be generated within the brain in connection with a brain renin-
AII (R-AII) system (Severs and Daniels-Severs, 1973; Ganten and Speck,
1978) and All, injected intracerebralventricularly (i.e.v.), can
stimulate an increase in plasma catecholamines (CA) which can be
inhibited by captopril (Scholkens, Jung, Rascher, Shomig and Ganten,
1980). Both plasma noradrenaline (NA) and adrenaline (A) levels
increase after i.e.v. injection of All, indicating that both the
sympathoneural and sympathoadrenal axis is stimulated (Ganten, Unger,
Rockhold, Schaz and Speck, 1979). All injected i.e.v. also increases
blood pressure and heart rate (Scroop and Lowe, 1969; Ferrario,
Dickinson and McCubbin, 1970), an effect which can be blocked by
captopril (Scholkens etal, 1980). The location of the central R-AII
system correlates well with the central NA regions (Fischer-Ferrario,
Nahmod, Goldstein and Finkelman, 1971). Peripherally administered All
can also exert similar effects to i.e.v. injected All. It is thought
that All acts on the area prostrema in the floor of the 4th ventricle
(Joy and Lowe, 1970a; Katie, Joy, Laverty, Lave and Scrops, 1971).
This is outside the blood- brain barrier (Ferrario, Gildenburg and
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McCubbin, 1972) and is associated with medullary areas, particularly
the nucleus tractus solitarius which is involved in central control of
blood pressure (Joy and Lowe, 1970b; Barnes, Ferrario and Conomy,
1979). So both peripherally synthesised and central All can activate
the sympathetic nervous system which leads to increased
vasoconstriction, release of CAs from the adrenal medulla and also an
increase in All synthesis by sympathetic activation of renal renin
release (Johnson, Davis and Witty, 1971). There is a sympathetic
innervation of the juxtaglomerular apparatus (Barajas, 1964; Wagermak,
Ungerstedt and Ljingquist, 1976) and renal renin release can be
inhibited by blockade oj^ <*4r«r\ocep+ors (Loefler, Stockigt and
Ganong, 1972; Buhler, 1974).
It has been assumed that in cases of reno-vascular hypertension
the effectiveness of captopril as an antihypertensive can be explained
by its effectiveness in reducing both peripheral and central All
levels, causing an overall reduction in sympathetic tone. Since the
introduction of captopril for the treatment of reno-vascular
hypertension however, it has been discovered that captopril decreases
blood pressure in man and animals wether PRA is high, normal or low
(Haefely, 1972; Bengis, Coleman, Young and McCaa, 1978; Antonaccio,
Rubin and Horowitz, 1980; Dollery and Miyamori, 1980). Opinions differ
as to whether or not there is a significant correlation between
baseline PRA and blood pressure reduction in the acute response to
captopril (Andren, Karlberg, Ohman, Svensson, Asplund and Hansson,
1982). In long term treatment there appears to be no correlation
between drug response and PRA, and captopril is as effective in the
treatment of essential hypertension (renin independant) as
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renovascular hypertension (Brunner, Gavras, Waeber, Turin and Walters,
1980; Santucci, Aguglia, De-Mattia, Ficara and Balsano, 1982; Estrada,
Morin, Amenos, Alsina and Gorina, 1982). Captopril has an
antihypertensive effect in anephric patients (Vaughan, Carey, Ayers
and Peach, 1979). This shows that captopril can reduce blood pressure
in man, independantly of circulating renin and All concentrations. In
rats, after nephrectomy, despite the absence of renin in the
peripheral circulation, captopril still produces a fall in blood
pressure. Captopril also produces a substantial fall in blood pressure
in rats with late Goldblatt, 2-kidney, 1-clip hypertension and in
rats made hypertensive by the chronic administration of
deoxycorticosterone and a high salt diet, (Malik and Nasjletti, 1976).
Both these models of hypertension are believed to be renin
independant. In rats in which the R-AII system has been blocked by
saralasin, captopril also produces a further reduction in blood
pressure (Thurston and Swales, 1978). So it would appear that the
effectiveness of captopril is not solely dependant on its ability to
to reduce elevated circulating levels of All as originally assumed.
There is evidence that All regulates CA release from the adrenal
medulla, and removal of this regulation by captopril could be
important. Insulin hypoglycaemia, hypoxia, hypercapnia, haemorrhage,
cold shock and muscular exercise all stimulate CA release from the
adrenal medulla (see Callingham, 1975 for review). This compensatory
release of CAs is important in restoring homeostasis after such shocks
to the cardiovascular system, and it follows that any drug interfering
with such a release of CAs from the adrenal medulla could greatly
impair this necessary compensatory mechanism. The importance of CA
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secretion from the adrenal medulla in response to hypotensive
activation of the carotid sinus reflex was first demonstrated by
Bedford and Jackson in 1916 and Heymans in 1929. Both chemoreceptor
stimulation (Petropaulovskaya, 1953) and baroreceptor stimulation
(Anichkov, Malyghina, Poskalenko and Ryzhenkov, 1960) were
subsequently discovered to induce release of CAs from the adrenal
medulla. Many studies have since proved that there is an
adrenomedullary secretion of CAs following haemorrhage (Millar and
Benfey, 1958; Greever and Watts, 1959; Chiens, 1967; Feuerstein and
Gutman, 1971; Adamicza, Tarnoky and Nagy, 1980; England, Dempsher,
Byrnes, Presnell and Gann, 1981), carotid occlusion (Guazzi, Libretti
and Zanchetti, 1962; Oberg and White, 1970) and a specific lowering of
carotid perfusion pressure (Critchley etal, 1980).
Tobian (1965) first suggested there was an activation of the R-
AII system in hypovolemic and hypotensive states. In 1971 , Peach
demonstrated that All stimulates the release of CA from isolated
adrenal glands, and there is much evidence to suggest that All
stimulates sympathetic ganglion cells and the adrenal medullary
secretion of CAs in vivo (see Starke, 1972; Haefely, 1972; Reit, 1972
for reviews). All has also been shown to depolarise chromaffin cells
and stimulate CA release from the chromaffin cells in a calcium-
dependant manner (Poisner and Douglas, 1966).
Circulating All levels increase after haemorrhage in cats
(Feuerstein etal, 1977) and dogs (Harrison, Birbari and Seaton, 1973)
and blockade of the R-AII system inhibits the adrenomedullary response
to haemorrhage in cats and dogs (Harrison etal, 1973). Feuerstein etal
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(1977) showed that in the cat, blockade of the R-AII system by
bilateral nephrectomy or saralasin, and denervation of the adrenal
gland inhibits the release of CAs from the adrenal medulla in response
to haemorrhage. They concluded that this was due to a central
activation of sympathetic drive by All (see later).
There is also much evidence to suggest that All may facilitate
the activity of the splanchnic nerve and its subsequent stimulation of
adrenal medullary CA release. This is suggested by studies showing
that All potentiates the stimulated release of NA by peripheral
sympathetic nerves and sympathetic ganglion cells. (The evidence for
this will be reviewed in detail in Part III of this thesis). It is
also evident that All potentiates vasoconstriction induced by
sympathetic nerve activity. All potentiates the vasoconstriction
induced by sympathetic nerve stimulation in the rat mesenteric
vascular bed at doses which do not have a direct vasoconstrictor
effect (Clough, Collis, Conway, Hatton and Keddie, 1982). Captopril
inhibits the vascular response to NA in this preparation (Saruta,
Suzuki, Okimo and Kondo, 1982). Saralasin and captopril both reduce
the pressor responses to NA in the pithed rat and this effect is
abolished by nephrectomy (Clough etal, 1982) and captopril inhibits
pressor responses to peripheral sympathetic nerve activity in cats
(Boura, Hui, Rechtman and Walters, 1982). All not only enhances
cardiovascular responses to sympathetic nerve activity (Page, Kaneko
and McCubbin, 1966) but also those which follow excitation of
sympathetic ganglion stimulants (McCubbin and Page, 1963; Day and
Owen, 1970; Boura etal, 1982). The evidence indicates that inhibitors
of the R-AII system may impair vasoconstriction by interfering with
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both pre-and post-junctional action of All, and this demonstrates a
functional interaction between the R-AII system and sympathetic
nervous control of vasomotor tone which exists even when All levels
are not elevated. Various "non-All" actions of captopril have also
been suggested, involving interactions with prostaglandins,
bradykinin, opioid peptides and adrenocorticosteroids. These
interactions were investigated in this project and will be discussed
in detail in the relevant Parts (II-V) of this thesis.
It is apparent from the evidence discussed that the hypotensive
action of captopril does not depend only on its ability to reduce
elevated circulating All and the resultant central stimulation of
sympathetic drive by peripheral and/or central All.
This thesis is concerned primarily with the possible interactions
of captopril and All, on the reflex release of CAs from the adrenal
medulla following a lowering of carotid perfusion pressure
(subsequently refered to as "baroreceptor stimulation").
In summary All appears to facilitate the release of CAs from the
adrenal medulla either by a direct action on adronomedullary cells, or
indirectly via interactions with prostaglandins, opioid peptides,
bradykinin , adrenocorticosteroid secretion and the central nervous
system. All may also facilitate release of CA from the adrenal medulla
via an action on splanchnic nerve activity, and it has been shown to
facilitate other cardiovascular effects of the sympathetic nervous
system. Captopril, by reducing circulating All levels, could reduce CA
output from the adrenal medulla and sympathetic drive by a combination
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of mechanisms.
It is the aim of this project to investigate the possible
interactions of the R-AII system on both the basal output
(subsequently referred to as the resting release or output), and the
reflex release induced by baroreceptor stimulation, of CAs from the
adrenal medulla.
It is important to understand the extent to which captopril and
other drugs which interfere with the R-AII system impair the
physiological compensatory mechanisms which protect the body from the
types of cardiovascular stresses previously discussed. An
understanding of this would assist in the clinical prediction and
management of patients receiving drugs which interfere with the R-AII
system.
As has been mentioned, Feuerstein etal (1977) demonstrated that,
in the anaesthetised cat, haemorrhage induced release of CAs from the
adrenal medulla and this release was accompanied by an increase in
PRA. The CA release was inhibited by both nephrectomy and saralasin
administration. They concluded that the release of CAs was due to
activation of the renin-AII system, and All was acting centrally to
increase sympathetic drive, and hence adrenal CA release. In the light
of evidence that All has a direct facilitatory effect on adrenal CA
release, it seemed possible that the effect of All, following
baroreceptor stimulation could be at the level of the gland itself,
rather than at the level of the central nervous system. In their
experiments, Feuerstein etal (1977) began analysing CA release 10
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minutes after the onset of haemorrhage, it was unclear from their
data whether there was a significant increase in PRA up to 10 minutes
post haemorrhage. It was therefore of interest to investigate whether
or not there was an immediate release of catecholamines 1-10 minutes
after the onset of baroreceptor stimulation, and if so, if this
release was related to an increase in PRA.
The aims of the experiments in Part I of this thesis were
primarily to answer the following questions-:
1. Does captopril reduce the resting output of OAs from the
adrenal medulla, and/or the reflex release of OAs during a 10 minute
baroreceptor stimulation period ?
2. If so, is this inhibitory effect of captopril related to any
increase in plasma renin activity and can the inhibition be reversed
by exogenously administered All ?
Introduction to results
In all tables and figures, "n" refers to the total number of
baroreceptor tests performed and "total catecholamine release" refers
to the release of adrenaline and noradrenaline. Where "n" values are
omitted from figures, they can be found in the tables from which they
were compiled. Where statistical significance values are omitted from
figures, these can also be found in the relevant tables, and vice
versa. Statistical significance of results was assessed by the paired
t-test when n > 5. If no statistics are shown and n > 5, then
statistical analysis showed the results to be not significant (p >
0.05). Linear regression lines with 95% confidence limits were
constructed using a computer program.
In the tables where two values are given, separated by a comma
(i.e. see table 1.1), this refers to the two values obtained in
separate baroreceptor tests or splanchnic nerve stimulations. "Resting
release" or "resting output" of catecholamines refers to the release
prior to either baroreceptor or splanchnic nerve stimulation. "Change
in total catecholamine release" refers to the release of
catecholamines during baroreceptor or splanchnic nerve stimulation
minus the resting release of catecholamines, i.e. the reflex or
stimulated release. Systemic blood pressure is always expressed in
mmHg.
In all experiments, I refer to drugs being administered "after"
or "following" captopril. It should be noted that these drugs were
effectively administered with captopril, as the effects of captopril
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outlast the duration of any experiment.
Throughout the results sections I shall include "comments" on the
results given. Additional discussion shall be givenin the "discussion"
section which follows each "results" section.
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Part 1 - Results
l.A. The effect of captopril on release of catecholamines before
and after baroreceptor stimulation from the left adrenal gland of the
anaesthetised dog
In dogs 1-9, ten-minute baroreceptor tests were performed before
and after captopril administration. The effect of captopril on total
catecholamine release, before and after baroreceptor stimulation was
analysed. The results are shown in table 1.1, and illustrated in
figure 1.1.
The effect of captopril on the reflex increase in total
catecholamine release following baroreceptor stimulation was also
analysed and the results are shown in table 1.2 and figure 1.2.
The results show that there was a significant increase in total
catecholamine release 1-2, 5-6 and 9-10 minutes after the onset of,
and during, baroreceptor stimulation. Following captopril
administration, both the resting release of catecholamines and the
reflex release induced by baroreceptor stimulation were significantly
inhibited.
1.B. The effect of captopril on release of catecholamines before
and after baroreceptor stimulation from the left adrenal gland of the
anaesthetised cat
In three cats, ten minute baroreceptor tests were performed before
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Table1.1
Theeffectofcaptoprilnt acatecholam nerel seindog1-9 beforeandterbarorec ptorstimulati n(BRS).
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and after captopril administration. The effect of captopril on total
catecholamine release, before and after baroreceptor stimulation was
analysed. The results are shown in table 1.3.
The effect of captopril on the reflex increase in catecholamines
was also analysed. The results are shown in table 1.4.
The results show that there is an increase in total catecholamine
release 1-2, 5-6 and 9-10 minutes after the onset of, and during,
baroreceptor stimulation. Following captopril administration, the
reflex release of catecholamines was inhibited.
2.A. Plasma renin activity before and after baroreceptor
stimulation in the anaesthetised dog
In dogs 1-7, arterial plasma renin activity (PRA) was measured
prior to baroreceptor stimulation, and 1-2, 5-6 and 9-10 minutes after
the onset of, and during, baroreceptor stimulation, before and after
captopril administration. The results are shown in table 1.5 and
illustrated in figure 1 .3.
The results show that during baroreceptor stimulation there was
no significant increase in PRA. Figure 5 shows that captopril
significantly increased PRA prior to baroreceptor stimulation, and
levels remained elevated throughout the baroreceptor test. This is
probably due to captopril abolishing the negative feedback system that
normally exists, angiotensin II inhibiting further renin release (see
discussion). After captopril administration there was no increase in
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Table1.3
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PRA during baroreceptor tests, in fact there was a significant
reduction in PRA 1-2 minutes after the onset of baroreceptor tests.
2.B. PRA before and after baroreceptor stimulation in the
anaesthetised cat
In cats 1-3, arterial PRA was measured prior to baroreceptor
stimulation, and 1-2, 5-6 and 9-10 minutes after the onset of, and
during, baroreceptor stimulation. The results are shown in table 1.6.
The results show that there was no increase in PRA during
baroreceptor stimulation. Unlike the dog there was no increase in PRA
following captopril administration. This may not have come to light
due to the small number of samples analysed. I was informed that PRA in
cat 3 was very difficult to measure as it was at the minimum level of
the radioimmunoassays sensitivity. If more experiments had been
possible, perhaps an increase in PRA following captopril
administration would have been uncovered.
Comments
25mg (dogs) and 5mg (cats) of captopril was the dose of choice as
it has been shown to completely inhibit PRA and in these experimental
animals it completely inhibited the pressor response to doses of
angiotensin I.
The results shown in sections 1 and 2 of part 1 show that there
was a significant increase in catecholamine release 1-2, 5-6 and 9-10
minutes after onset of baroreceptor stimulation. This increase was not
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accompanied by an increase in PRA. This makes it unlikely that it is
an increase in circulating angiotensin II which is responsible for the
reflex release of catecholamines, as was suggested by Feuerstein etal
(1977).
The results also show that there was a significant increase in
catecholamine release 1-2 minutes after baroreceptor stimulation. This
immediate response makes it unlikely that de novo synthesised
angiotensin II was acting centrally to increase sympathetic drive and
thereby stimulating the reflex release of catecholamines from the
adrenal medulla, as suggested by Feuerstein etal (1977). We suggest
that if such a mechanism did exist there would be evidence of an
increase in PRA and reflex catecholamine release would be delayed.
We took as a working hypothesis, at this stage of the research,
that it was a minimum circulating level of angiotensin II which was
the essential criterion for the adrenal gland to respond to the
reflex stimuli. Removal of this minimum level of angiotensin II by
captopril rendered the gland unable to respond fully to the reflex
stimuli. We hypothesised that angiotensin II was exerting a permissive
effect on adrenal catecholamine release at the level of the gland
itself and not centrally.
3.A. The effect of a continuous i.v. infusion of angiotensin II
on adrenal catecholamine release before and after baroreceptor
stimulation, following captopril administration, in the anaesthetised dog
We wished to investigate if restoring a very low, non pressor
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level of angiotensin II (All) could restore the release of
catecholamines which captopril had inhibited.
In dogs 1-5, following captopril administration, a continuous
infusion of l-5ngmin-1 All was administered and the baroreceptor
tests repeated.
The effect of this infusion of All on total catecholamine release
was analysed and the results are shown in table 1.7 and illustrated
in figure 1.4. Figure 1.4 was compiled from the data contained in
tables 1.1 and 1.7.
The results show that the All partially restored both the resting
release of catecholamines and also the reflex release. When comparing
the release of catecholamines after All infusion with the releases
after captopril administration, All can be seen to reverse the
inhibition by captopril, although not completely.
The effect of All on the changes in total catecholamine release
following baroreceptor stimulation was also analysed. The results are
shown in table 1.8 and illustrated in figure 1.5.
The results show that All partially reversed the inhibition, by
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3.B. The effect of a continuous infusion of All on adrenal
catecholamine release before and after baroreceptor stimulation,
following captopril administration, in the anaesthetised cat
In cats 1-3, following captopril administration, a continuous
infusion of 1-5ngmin-'' All was administered and the baroreceptor tests
repeated. The effect of All on total catecholamine release and the
reflex changes in catecholamine release were analysed. The results are
shown in tables 1.9a and 1.9b and illustrated in figure 1.6. The
results show that All reversed the inhibition by captopril of both the
resting and reflex releases of catecholamines. In figure 1.6 and
subsequent figures the "increment" refers to total catecholamine
release during baroreceptor stimulation minus resting release.
Comments
It will have been noticed that there is a great variation between
animals in the values of total catecholamine release. This has
resulted in very large standard errors in most of the data I
analysed. Many studies have quoted a 10—30 fold difference in
baseline adrenal catecholamine release between different animals (see
Heesch and Bishop, 1982 for references). The differences probably
arise from differences in condition, anaesthesia and surgical
preparations etc. which occur between whole animal preparations. This
was a problem that could not be avoided.
The results described in section 3 support our initial hypothesis
that a minimum level of circulating All is required for the adrenal
gland to respond to the reflex stimuli. Removal of this All inhibits,
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and subsequent replacement restores, catecholamine release.
The concentration of All used in these experiments was very low
and had no effect on systemic blood pressure (see following results
section).
4.A. The effect of captopril and subsequent All administration
on systemic blood pressure, before and after baroreceptor stimulation
in the anaesthetised dog
The effect of captopril on resting systemic blood pressure (SBP),
and the reflex increase in SBP induced by baroreceptor stimulation,
was analysed in dogs 1-9. The results are shown in table 1.10 and
illustrated in figures 1.7a and 1.7b. In dogs 1-5 the effect of the
All infusion on SBP was also analysed. The results are included in
table 1.10.
The results show that captopril significantly decreased resting
SBP and the reflex pressor response to baroreceptor stimulation.
The results show that the concentration of All infused did not
increase either resting SBP or the reflex pressor response. From
table 1.10 it would appear that All further decreased resting SBP,
when compared with the resting SBP immediately preceeding (after
captopril) and the reflex pressor response. This was probably not due
to an effect of All but to the fact that All was administered some six
hours after anaesthesia was first induced. At this stage of most
experiments, SBP was beginning to fall anyway, due to the length of
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Figure 1-7
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The effect of captopril on systemic blood pressure (S.B.P) before and
after baroreceptor(BR) stimulation (Aland on the pressor response
to BR stimulation (B).
106
time the preparation had been in use.
4.B. The effect of captopril and subsequent All administration on
SBP before and after baroreceptor stimulation, in the anaesthetised
cat
The effect of captopril, and subsequent All infusion, on resting
SBP and the reflex pressor response to baroreceptor stimulation, was
analysed in cats 1-3. The results are shown in table 1.11.
The results show that, as in the dog, captopril decreased SBP
and, to a lesser extent, the reflex pressor response to baroreceptor
stimulation. All did not increase SBP above control values.
Comments
These results show that as expected, captopril lowers SBP. The
hypotensive effect measured in these experiments is probably not the
maximum hypotensive effect that captopril would normally produce. This
is because we always started a continuous infusion of dextran, as
described in the "methods" section, at the same time captopril was
administered. This prevented any severe falls in SBP, as this would
reduce the survival time of the anaesthetised preparation.
The results show that the same concentration of All which
restored both resting and reflex catecholamine release, after
captopril administration, did not increase either resting SBP or the
reflex pressor response. This supports our hypothesis that it is a
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minimum, non pressor, level of circulating All which is required for
the adrenal gland to respond to the reflex stimuli.
Feuerstein etal (1977) suggested that, after baroreceptor
stimulation, the main site of action of All was the central nervous
system. Presumably the increase in sympathetic drive induced by All
would affect the vasculature and the adrenal medulla. If so, captopril
would be expected to have a comparable inhibitory effect on the reflex
pressor response and reflex adrenal catecholamine release induced by
baroreceptor stimulation. From tables 1.1 and 1.2, it can be seen that
captopril inhibits reflex catecholamine release by approximately 12%.
From table 1.10, it can be seen that captopril inhibits the reflex
pressor response by approximately 21%. So captopril has a greater
inhibitory effect on adrenal catecholamine release. This indirectly
supports our hypothesis that All is exerting a permissive effect at
the level of the adrenal gland rather than centrally.
5. The effect of captopril, followed by a continuous infusion of
All, on adrenal venous blood flow
During the experiments performed, after captopril administration,
we observed an increase in adrenal blood flow.
To investigate the effect of captopril on adrenal venous blood
flow, the effects of captopril and the subsequent administration of
All on adrenal blood flow in dogs 1-9 was analysed. The results are
shown in table 1.12.
109
Table1.12 AdrenalbloodflowIndogs1-9(D1 9),be oreandaftebarorec ptor stimulationBRS),beforeandftecaptoprlladministrati nand subsequentinfu ionofangiotensinII. Time
Drugafterons tAdren lbloodflow(mlmln-')Mean TreatmentofBRS±SE (mlns)D12D31D56D789 01.1,1.10.8,0.53.7,3.222.9,2.92.53.8,1 02.1,1.932±0 3(n-15) 1-25.0,1.12.8.71.9,5.21.3.7,3.656. ,6 53.8,3.01.9t0(n-15)*" Control5-61.7,1.8.6,0.81.8,3.83.3.8,3.51 95.5,5.76.2, .12 91.0t0(n-15)"« 9-101.9, .6.1,2.03.8,3.02.3.8,3 015.5,5.73.0,3.103 6i0(n-15)*" 05.8,6.21.9,1.01.0,2.83.5,2.82 71.2, .16.0, 81.5,3.02.9, 73 5±0(n-17)" Captoprll1-26.2,6.52.2,1.57.0,3.25.8,6.037.2, 08.0,7.21.2,3.58.85±0 5(n-17)"* (25mg)5-65.9.6.01.9,0.62.3,3 01.5,1.3.6.0, .07. ,6.13.2,2.85.3,51t0(n-17)*** 9-105.5,5.71.5,0.72.7,2.11.0,2 821.8,2.06.8,5.2.5,1 35.8,5.63 9±0(n-17)"* 01.11. ,1.91.2,3.02.0,1.51.9,1.51.9±0.1(n-9)» All1-21.80.7,1.6. , .03 8,1.02.5,2.3.0t0.6(n-9)• d-5ngmln-l)5-61.70.6,3.01.5,3 52.8,0.82.3,2.62.8±0 5(n-9)» 9-101.7.6,2.1. ,2 62.3,0 72.2,2.92.6±0.1(n-9)» Statisticalsignificance(datbeforeBRcomparedwithdataafterBRS, captoprlldatabeforeBRScomparedwithcontroldatabeforeBRS andAlldatabeforeBRScomp redwithcapt prlldatabeforeBRS)-: • -p>0.02 »»-p>0.01 »«•-p>0.001
The results show that there was a significant increase in adrenal
blood flow during baroreceptor stimulation both before and after
captopril and All administration. Captopril induced a significant
increase in resting blood flow, prior to baroreceptor stimulation. All
significantly decreased resting adrenal blood flow, reversing the
effect of captopril.
6. The effect of resting systemic blood pressure on resting
adrenal venous blood flow
The observation that captopril induced an increase in adrenal
blood flow despite its hypotensive effect was surprising as we
expected a decrease in blood flow to occur with a decrease in SBP.
To investigate this, a resting systemic blood pressure - blood
flow graph was constructed for dogs 1-9. The linear regression lines
with 95% confidence limits are shown in figure 1.8. The data used to
compile this figure can be found in tables 1.10 and 1.12.
The graph shows that there is a positive relationship between
adrenal blood flow and resting SBP. This would account for the
significant increase in adrenal venous blood flow following
baroreceptor stimulation induced pressor responses.
Captopril produced a significant elevation of the linear
regression line, indicating that All may have an inhibitory role in
the maintainance of adrenal blood flow. An alternative explanation is
that the blood becomes diluted due to the continuous infusion of
111
Figure1-8









dextran administered after captopril administration. Blood flow is
inversely proportional to the viscosity of the blood, and table 1.13
was constructed to investigate if there was a reduction in haematocrit
after captopril administration.
Table 1.13 shows that there was a significant reduction in
haematocrit following captopril administration, probably due to
dilution of the blood by dextran. It seems possible that some of the
increase in adrenal blood flow after captopril administration was due
to the reduction in adrenal venous blood haematocrit. The dextran
infusion was usually slowed down or stopped after All infusion. The
reduction in adrenal blood flow following All may be due to this
decrease in dextran infusion. A real effect of captopril on adrenal
blood flow, however, cannot be ruled out.
7. The effect of adrenal venous blood flow on catecholamine release
In order to exclude the possibility that the increase in adrenal
catecholamine release following baroreceptor stimulation was due to
the simultaneous increase in adrenal blood flow, a catecholamine
release - blood flow graph was constructed for dogs 1-9 (for control
values only). The linear regression line, with 955& confidence limits
is shown in figure 1.9. The figure was compiled from data contained in
tables 1.1 and 1.12.
The graph shows that the total catecholamine release is
independant of blood flow. The increased reflex release of
catecholamines, after baroreceptor stimulation is therefore not due to
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Linear regression line for adrenal blood flow
vs catecholamine output (pre-captopril control
values only) for dogs 1-9.
95% confidence lim
(n = 11)
T 1 1 1
12 3 4
Adrenal blood flow (mlmin-')
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the simultaneous increase in adrenal blood flow.
8. The effect of resting systemic blood pressure on resting
adrenal catecholamine output before and after captopril
administration
In order to exclude the possibility that the reduction in adrenal
catecholamine release following captopril administration was due to
the decrease in SBP induced by captopril, a resting SBP -
catecholamine release graph was constructed. The linear regression
lines with 95? confidence limits are shown in figure 1.10. The figure
was compiled from data contained in tables 1.1 and 1.10.
The graph shows that total catecholamine release is independant
of the resting SBP. Captopril produced a significant depression of
the linear regression line. After captopril, although not
significant, a decrease in SBP produced a tendency towards an
increase in total catecholamine release. These results exclude the
possibility that the inhibition of adrenal catecholamine release
induced by captopril was due to the simultaneous reduction in SBP.
9. The effect of resting systemic blood pressure on the reflex
increase in systemic blood pressure following baroreceptor
stimulation
It was of interest to investigate if the resting SBP had an
effect on the reflex pressor response induced by baroreceptor
















Linearregressionliforr st gsyst micbloodpre surev .t lcatecholamine (CA)releasebeforeandftercapfopriladmi istration
response, this could explain the reduction in the reflex pressor
response following captopril administration.
To investigate this a resting SBP - pressor response graph was
constructed using the control values contained in table 1.10. The
linear regression line with 95$ confidence limits is shown in figure
1.11.
The figure shows that there is not a significant relationship
between resting SBP and the reflex pressor response. There is,
although not significant, a tendency towards a positive relationship
between resting SBP and the reflex pressor response. The reduction in
SBP induced by captopril could contribute to its reduction the
reflex pressor response.
10. The effect of captopril on the resistance of the vascular
bed of the hind limb in the anaesthetised dog
As will be reviewed and discussed in detail in "Part 3" of this
thesis, there is much evidence to suggest that All exerts a
facilitatory effect on stimulation-induced noradrenaline release from
most sympathetic nerve endings. All has a similar effect on the
release of acetylcholine from both sympathetic and cholinergic
ganglia. From Tables 1.1 and 1.2 it can be calculated that captopril
inhibits resting catecholamine release and the change in catecholamine
release following baroreceptor stimulation by approximately 30$ and
72$ respectively. From table 1.10 it can be calculated that captopril
inhibits resting SBP and the reflex pressor response to baroreceptor
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stimulation by approximately 1955 and 21% respectively. It is evident
that captopril inhibits the blood pressor responses less than the
release of catecholamines. It was of interest to investigate the
effect of captopril on the vascular responses of the hind limb, which
is adrenergic.
In four dogs, the reflex SBP and hind limb perfusion pressure
(HLPP) responses to baroreceptor stimulation were studied, before and
after captopril administration. As flow through the perfused limb is
constant, the perfusion pressure was taken as a measure of vascular
resistance (see "Methods - Whole animal experiments"). The results are
shown in tables 1.14 and 1.15.
The results show that, as has been observed, captopril
significantly inhibits the reflex pressor response to baroreceptor
stimulation. Captopril did not, however, significantly affect the
reflex increase in hind limb perfusion pressure. These results
indicate that the renin - All system has varying influences on reflex
vascular resistance changes in different vascular beds.
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Table 1.14
The effect of captopril on systemic blood pressure and hind limb perfusion
pressure following baroreceptor stimulation.
CONTROL CAPTOPRIL





























































































CPP » carotid perfusion pressure
SBP =» systemic blood pressure
HLPP - hind limb perfusion pressure
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Table 1.15
The effect of captopril on the change In systemic blood pressure and hind limt
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CPP = carotid perfusion pressure
SBP = systemic blood pressure
HLPP = hind limb perfusion pressure
Statistical significance (captopril data compared with control data)-:
* = p < 0.01
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Part 1 - Summary of results
1. Captopril reduced both the resting release of catecholamines
from the adrenal medulla, and the reflex release of catecholamines
induced by baroreceptor stimulation, in anaesthetised dogs and cats
(25mg and 5mg of captopril respectively).
2. Plasma renin activity did not increase during the ten-minute
baroreceptor tests.
3. An exogenous infusion of angiotensin II (All) (1-5ngmin-1)
partially reversed the inhibitory effect of captopril on resting and
reflex adrenal catecholamine release in the anaesthetised dog. The
reversal was more complete in the anaesthetised cat.
M. Captopril reduced both resting systemic blood pressure and the
reflex pressor response to baroreceptor stimulation in anaesthetised
dogs and cats.
5. The level of All which reversed the effects of captopril on
adrenal catecholamine release had no effect on resting systemic blood
pressure or the reflex pressor response to baroreceptor stimulation.
The following points refer to anaesthetised dogs only
6. Captopril increased adrenal blood flow. Dilution of the blood
by dextran may contribute to this effect. All reversed the effect of
captopril on adrenal blood flow. Baroreceptor stimulation increased
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adrenal blood flow.
7. The Increase in adrenal blood flow during baroreceptor
stimulation may be explained by the reflex increase in systemic blood
pressure, as there was a positive relationship between resting
systemic blood pressure and adrenal blood flow.
8. Adrenal catecholamine release is independant of adrenal blood
flow, and so the catecholamine release induced by baroreceptor
stimulation was not a result of the simultaneous increase in adrenal
blood flow.
9. Adrenal catecholamine release is independant of systemic blood
pressure, so the reduction in adrenal catecholamine release after
captopril administration was not a result of the simultaneous
reduction in systemic blood pressure.
10. There is a positive relationship between resting systemic
blood pressure and the reflex pressor response induced by
baroreceptor stimulation. The reduction in resting systemic blood
pressure by captopril may contribute to its reduction in the reflex
pressor response to baroreceptor stimulation.
11. The renin-AII system has varying influences on reflex vascular
resistance changes in the different vascular beds described.
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Part 1 - Discussion of results
The results show that baroreceptor stimulation induced a reflex
release of catecholamines from the adrenal medulla, as first
demonstrated by Bedford and Jackson in 1916 and Heymans in 1929.
These results support the findings of other workers, that haemorrhage
induces a reflex release of catecholamines from the adrenal medulla
(see "Introduction and literature review").
These results exclude the possibility that such a reflex release
of catecholamines is the result of the simultaneous increase in
adrenal blood flow that occurs, as it is shown that adrenal
catecholamine release is independant of adrenal blood flow.
As was discussed in the "Introduction and literature review",
activation of the renin-AII system has long been implicated in the
response to hypovolemic and hypertensive states. Blockade of the renin-
AII system has been shown to inhibit the adrenomedullary response to
prolonged haemorrhage in cats and dogs (Harrison etal, 1973;
Feuerstein etal, 1977). What had not been investigated was the role
the renin-AII system plays in the acute response to such reflex
stimuli. The results show that captopril inhibited the immediate
release of catecholamines which occurs 1-2 minutes after the onset of
baroreceptor stimulation. The possibility that this was due to the
simultaneous hypotensive effect of captopril was ruled out, as it can
be seen that adrenal catecholamine release is independant of resting
systemic blood pressure. The effect of captopril on both the resting
and reflex release of catecholamines was partially reversed, in the
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dog, by the infusion of a ncn-pressor level of All. The reversal was
more complete in the cat. The experiments carried out on the cat were
the first ones done, and hence a new batch of All was used. It
subsequently became clear that the activity of All deteriorated over a
period of time unless stored at a slightly acidic pH. It is possible
that the activity of All in the initial series of experiments carried
out in dogs, that the activity of All was less than that administered
to the cats. This may explain why the All was more effective at
reversing the effects of captopril in the cats. In "Part 3" it will be
shown that this level of All was more effective at reversing the
effect of captopril on splanchnic nerve stimulation-induced adrenal
catecholamine release, and this may be due to the increased
precautions taken when storing All.
These results suggest that a minimum, non-pressor level of All is
required for the adrenal gland to respond to the reflex stimulus, and
that All has a direct facilitatory effect on both resting and reflex
adrenal catecholamine release.
These conclusions are compatible with the findings and
conclusions of Hatton, Clough, Adiguin and Conway (1982). They used
lower body negative pressure to stimulate sympathetic reflexes in
anaesthetised cats. This induced a transient decrease in systemic
blood pressure (SBP). All-converting enzyme inhibitors (ACEI's) and
saralasin produced a greater, more sustained fall in SBP and this was
not associated with a decrease in efferent nerve activity. This
indicates that they were exerting their effects on the peripheral
actions of All. They concluded that All, at a level which does not
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exert a direct vasoconstriction, interacts with the sympathetic
nervous system to maintain arterial pressure when homeostatic
reflexes are activated, and that the reduction in the efficiency of
these reflexes by ACEI's may contribute to their hypotensive effect.
My results support these conclusions, and suggest that a non-
pressor level of All also interacts with the sympathetic nervous
system at the level of the adrenal gland.
Feuerstein etal (1977) attributed the adrenal response to
haemorrhage in the cat to an activation of the renin-AII system, as
they detected an increase in plasma renin activity (PRA) following
haemorrhage. Studying their results, there appeared to be no
significant increase in PRA up to ten minutes after haemorrhage, and
they began their readings for PRA and adrenal catecholamine release at
this time, but their results show a maximum release of catecholamines
ten minutes after haemorrhage. Ten to twenty minutes after haemorrhage
they demonstrated a significant rise in PRA.
My results show that there was no increase in PRA during the ten
minute baroreceptor tests and there was an immediate reflex release
of catecholamines 1-2 minutes after the onset of baroreceptor
stimulation. They do confirm that the integrity of the renin-AII
system is required for the adrenal response to baroreceptor
stimulation, but not that the response is attributed to an activation
of the renin-AII system. Furthermore, they suggest that a minimum,
non-pressor level of All is required for the adrenal gland to respond
to the reflex stimulus, and that All has a direct permissive effect on
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both resting and reflex adrenal catecholamine release. Removal of
this level of All by captopril would prevent the transmission of the
adrenal reflex and subsequent replacement of All would restore the
adrenal reflex. The result show that this is the case.
Feuerstein etal (1977) also concluded that, following
haemorrhage, All was acting centrally to increase sympathetic drive,
and hence adrenal catecholamine release via activation of the
splanchnic nerve. My results suggest that the effect is not a central
one, but a direct effect at the level of the adrenal gland, a minimum
level of All being required for the normal response of the adrenal
gland to sympathetic drive. This is supported by the work of Hatton
etal (1982) who showed that the hypotensive effect of ACEI's and
saralasin, in the anaesthetised cat, was not associated with a
decrease in efferent nerve activity.
As described in the "Results" section, captopril inhibited
adrenal catecholamine release by 30-70$, while inhibiting the reflex
pressor response by only 20-30$. Additionally, this reduction in the
reflex pressor response may be partially explained by the hypotensive
effect of captopril, as the results presented in 1.9 demonstrate that
there is a tendency for a reduction in resting SBP to reduce the
reflex pressor response. These results indirectly support my
conclusions that the effect of All is at the level of the adrenal
gland, as if the effect was a central activation of sympathetic drive
the effect of captopril on the reflex pressor response and the reflex
adrenal response would be expected to be comparable.
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Corwin, Seaton, Hamaji and Harrison (1985) published evidence
which they considered compatible with the theory of Feuerstein etal
(1977), that it is a central activation of central drive that is
responsible for the adrenal response to haemorrhage in the
anaesthetised dog. Their conclusions were based on the observation
that an i.e.v. injection of All restored the adrenal response to
haemorrhage in nephrectomised dogs. As was discussed in the
"Introduction and literature review", there is little doubt that, even
in the absence of nephrectomy, an i.e.v. injection of All will induce
an increase in adrenal catecholamine release, and this could result in
a reversal of the effects^either nephrectomy or saralasin. Although
Corwin etal demonstrated that an i.e.v. injection of All will support
adrenal catecholamine release following haemorrhage, these results do
not confirm conclusively that this is the physiological response to
haemorrhage.
It is evident that PRA does increase some 10-20 minutes after
haemorrhage (Feuerstein etal, 1977), and it is possible that the renin-
AII system is activated after prolonged baroreceptor stimulation and
that this is necessary to maintain arterial pressure when baroreceptor
stimulation is prolonged.
It is not possible, from the results presented here, to rule out
the possibility that All is acting centrally, but the results of a
further series of experiments, described in "Part 3", do support the
conclusions I have made here, that the facilitatory effect of All is
a direct one at the level of the adrenal gland.
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The results show that captopril Induces an increase in PRA. This
is usually observed following captopril administration and is
probably due to an interruption of the negative feedback loop by which
All stimulates renin release (Silberbauer etal, 1982). As will be
discussed in "Part 5", captopril has been shown to stimulate
prostaglandin (PG) synthesis and PGs, especially PG^iare potent
stimulators of renin release (Frolich, 1980). This may contribute to
the observed increase in PRA following captopril administration. What
is more important is that, as in the control situation, there is no
increase in PRA during baroreceptor stimulation, after captopril
administration.
Insulin hypoglycaemia, hypoxia, hypercapnia, cold shock and
muscular exercize all stimulate adrenal catecholamine release
(Callingham, 1975). R. C. Torazi remarked in a panel discussion (see
Br. j. Clin. Pharmac., 1982 14, 139s-140s) that captopril blunted the
pressor response to dynamic exercise in patients. This effect could
also be explained by captopril impairing the facilitatory effect of
All on adrenal catecholamine release, rendering the gland unable to
respond normally to dynamic exersize.
Weinberger (1982) reported that captopril induced a marked
decrease in plasma noradrenaline levels in hypertensive patients and
suggested that this was related to the fact that All induces release
of noradrenaline from nerve endings (see "Part 3"). It is possible
that the reduction in plasma noradrenaline was due to captoprils'
effect on resting adrenal catecholamine release, as there is much
evidence to suggest that All has no physiological effect on resting
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release of noradrenaline from nerve endings (see "Part 3 -
Introduction and literature review).
Loute, Guffens, Waucquez, Firre, Legrand, Klels and Adam (1984)
reported that captopril effectively lowered blood pressure to normal
and reduced urinary secretion of noradrenaline in a patient suffering
from phaeochromocytoma. Donker (1984) reported that in another case of
hypertension due to phaeochromocytoma, saralasin infusion reduced
blood pressure and urinary noradrenaline secretion. Both Loute etal
(1984) and Donker (1984) were unable to explain these observations.
They could be explained by the results presented here. It is possible
that captopril and saralasin were exerting these effects by inhibiting
the facilitatory effect of All on the phaeochromocytoma affected
chromaffin cells. It may be that such cells are more responsive to
circulating All.
Lilly, Engeland and Gann (1982), reported that, in the
anaesthetised dog, the adrenal medullary response to haemorrhage was
potentiated after a second small haemorrhage was induced. They
suggested that there is a factor associated with haemorrhage that
potentiates the adrenal medullary response to a second small
haemorrhage. I observed throughout this research, that the second
control baroreceptor test usually induced a greater release of adrenal
catecholamine release (eg, see table 1.1). Table 1.1 also shows that
this effect was not observed following captopril administration and so
it is possible that All may be the factor Lilly etal were describing.
ACEIs have also been shown to lower blood pressure, in patients,
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more in an erect than in a recumbent position (Marganti, Pickering,
Lopez-Ovejaro and Laragh, 1980). This could be due to a reduction in
the normal reflex adrenal resonse to adopting an erect pose from a
recumbant position, although I found little evidence to suggest that
captopril induces postural hypotension, except perhaps in the aged
(this was suggested to me in a conversation with a general
practitioner).
The results show that there was a significant increase in adrenal
blood flow during baroreceptor stimulation. The reflex pressor
response could contribute to this effect as shown in figure 1.8,
which shows that an increase in systemic blood pressure induces an
increase in adrenal blood flow. This increase in adrenal blood flow
following baroreceptor stimulation may be physiologically important,
facilitating removal of the released catecholamines away from the
adrenal gland, preventing accumulation of vasoactive catecholamines
in the adrenal veins. It woud also provide additional oxygenation of
the gland which would support its increase in metabolic activity.
Captopril was shown to increase adrenal blood flow. Table 1.13
shows that there was an decrease in adrenal blood haematocrit
following captopril administration. Dilution of the blood by dextran
could explain this effect and contribute significantly to the increase
in adrenal blood flow observed after captopril administration. An
infusion of dextran was always started at the same time as captopril
administration to prevent any severe fall in blood pressure which
would have limited the survival of the anaesthetised preparation. All
did apparently reverse this effect of captopril on adrenal blood flow
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which may be due to the fact that the dextran infusion was usually
slowed down or stopped after All administration. It is possible,
however, that captopril was itself inducing an increase in adrenal
blood flow. As will be described in "Part 5", captopril may induce
release of prostaglandins from the adrenal medulla and prostaglandins
may play a role in maintaining adrenal blood flow. The possibility
that captopril reduces adrenal venous resistance, which would
facilitate an increase in adrenal blood flow, is also investigated in
"Part 5".
In conclusion, the results suggest that the integrity of the renin-
AII system is required for the adrenal gland to respond to baroreceptor
stimulation in the anaesthetised dog and cat. A minimum, non-pressor
level of All may be required for the gland to respond to the reflex
stimulus, and activation of the renin-AII system is not required for the
immediate adrenal response. The effect of All is likely to be a direct
facilitatory one on adrenal catecholamine release at the level of the
adrenal gland and not through central activation of sympathetic drive,




Part 2 - Introduction and literature review
We hypothesised that one possible mechanism by which captopril
could reduce catecholamine output from the adrenal medulla was via an
inhibition of adrenocorticosteroids (ACS) secretion.
This was suggested by work previously carried out in this
laboratory by Critchley, Ellis, Henderson and Ungar (1982), which
suggested a possible role for the pituitary-adrenocortical axis in the
reflex release of catecholamines from the adrenal medulla of the dog.
Anichkov, Malyghina, Poskalenko and Ryzhenkov (1960) and Marotta
(1972) had previously shown that carotid chemoreceptor stimulation
causes a release of ACTH from the anterior lobe of the pituitary
gland, resulting in a release of ACS. Critchley etal (1982) noted that
release of catecholamines from the adrenal medulla in response to
carotid body hypoxia outlasted the stimulus. Adrenal denervation
abolished the immediate release of catecholamines, whilst the
prolonged release was abolished by cycloheximide, a drug that inhibits
release of ACS in response to adrenocorticotrophic hormone (ACTH)
(Garren, Ney and Davis, 1965). Cycloheximide did not affect the
immediate release of catecholamines and denervation did not affect the
prolonged release.
It had previously been shown that hydrocortisone could stimulate
release of catecholamines from the isolated perfused adrenal gland in
a dose-dependant manner and in concentrations normally detected in
adrenal venous blood (Critchley, Henderson, Moffatt, Waite and West,
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1975). ACTH had also been shown to induce a release of catecholamines
from the adrenal medulla in the anaesthetised dog (Critchley and
Ungar, 197*0. Critchley etal showed that ACTH potentiated the release
of catecholamines induced by baroreceptor stimulation, and the release
of catecholamines followed a similar time course to that shown by
prolonged chemoreceptor stimulation. They concluded that a component
of the reflex adrenal catecholamine release is mediated by ACTH and
ACS secretion.
It has been known for some time that corticosteroids induce the
action of phenylethanolamine N-methyl transferase (PNMT) which
converts noradrenaline to adrenaline in mammalian chromaffin cells
(Wurtman, Pohorecky and Baliga, 1972). Wurtman, Caspar, Pohorecky and
Bartter (1968) studied the effects of hypophysectomy and ACTH on the
adrenal release of catecholamines, in response to insulin-
hypoglycaemia, in the dog. They reported that hypophysectomy reduced
PNMT activity and also reduced both the resting and reflex release of
adrenaline. Release could be restored by administration of ACTH. They
concluded that these results could be explained by the induction of
PNMT by ACS. Critchley etal (1982) showed that the results of Wurtman
etal (1968) could be recalculated to show that ACTH affected the
release of noradrenaline as well as adrenaline. They suggested that
induction of PNMT by ACS could be secondary to an effect on the
release of catecholamines.
There is much evidence to support the suggestion that ACS affect
the release of catecholamines from the adrenal medulla via an
interaction with the renin-angiotensin (All) system. There is also
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much evidence to suggest an interaction of the renin-AII system with
the activity of ACS. Cortisol may also play a role in the restoration
of blood volume after haemorrhage (Ganten, Unger, Rockhold, Schaz and
Speck,1979). Lilly, Engeland and Gann (1982) demonstrated that
haemorrhage induced a release of adrenal Cortisol and catecholamines
in anaesthetised dogs.
Intracerebroventricular (icv.) injection of All into conscious
rats has been shown to induce an increase in plasma and adrenal
corticosterone. This effect is mediated by ACTH as hypophysectomy
abolishes the response (Daniels-Severs, Ogden and Vernikos-Danellis,
1971). An icv. infusion of All in conscious dogs also causes a
significant increase in plasma ACTH (Ramsey, Keil, Sharpe and
Shinsako, 1978) and there is evidence that All may stimulate ACTH
release by a direct action on the anterior pituitary (Maran and
Yates, 1977). An icv. injection of renin has also been shown to result
in an increase in plasma catecholamines and corticosterone, in both
normal and sodium-depleted dogs. This effect can be blocked by icv.
injection of captopril (Scholkens, Jung, Rascher, Shomig and Ganten,
1980). This increase in plasma corticosteroid levels, induced by
renin, is probably mediated by ACTH (Reid and Day, 1977).
Corticosterone has also been shown to increase brain
angiotensinogen (Wallis and Printz, 1980) which would increase All
biosynthesis, as brain All appears to stimulate an increase in plasma
catecholamine and corticosterone levels, I suggest these interactions
would provide a self-potentiating mechanism by which the renin-AII
system and the pituitary-adrenocorticotrophic axis increase blood
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pressure and maintain the circulating blood volume.
It is still not clear if All stimulates Cortisol biosynthesis.
Early studies using dispersed human adrenal cells or in vivo
infusions, were unable to show a significant stimulation of Cortisol
by All (Ames, Borkowski and Sicinski, 1976; Williams and Braley,
1977). Douglas, Brown and White (1984) did demonstrate that binding of
All to normal human fasciculata cells and Cortisol producing adenoma
cells was accompanied by corresponding changes in Cortisol production.
Specific binding of All to adrenal receptor sites has been
demonstrated in the bovine, rat and dog adrenal cortex (Lin and
Goodfriend, 1970; Glossman, Baukel and Catt, 1974; Douglas, Aguilera,
Kondo and Catt, 1978). All has been shown to stimulate Cortisol
secretion in bovine and dog adrenals (Carpenter, Davis and Ayres,
1961; Kaplan and Bartter, 1962) suggesting that there may be some
species specificity (this will be discussed further in the
"Discussion" section for "Part 2").
All may potentiate the action of ACTH on the adrenal cortex.
Slater, Barbour, Henderson, Casper and Bartter (1963) and Bravo,
Khosla and Bumpus (1975) demonstrated that, in the dog, All
potentiates the response of ACTH on Cortisol secretion. Fraser,
Buckingham, Mason and Semple (1978) were unable to stimulate Cortisol
production by All infusions alone in dexamethasone supressed normal
volunteers, but when the All was infused over a baseline of ACTH
stimulation, Cortisol secretion was potentiated. Parker, Lifrak,
Kawahara, Geduld and Kozbur (1983). using dog adrenal cell
suspensions, observed only a minimal Cortisol secretion when All was
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infused alone, but demonstrated that All potentiated ACTH induced
Cortisol secretion. Both All and ACTH were infused at physiological
concentrations and they suggested that this may explain the increase
in adrenal androgens seen in some pathological conditions
characterised by an increase in plasma renin activity. Morera, Andoka
and Chauvin (1984) have also demonstrated that All potentiates ACTH-
induced cyclic AMP production in bovine cortico-adrenal cells in
primary culture, and that saralasin inhibits this effect.
Marotta (1972) demonstrated that, in dogs,
11-hydroxycorticosterone in adrenolumbar blood increased within one
minute after infusion of ACTH or induced hypoxia. He suggested that
this was due to central stimulation of ACTH acting on the adrenal
cortex but it is possible, considering the very short time involved
and the evidence already discussed, that the release induced by
hypoxia was due to activation of the renin-AII system, All affecting
ACS release directly.
As mentioned previously, the pituitary-adrenocortical axis also
affects the renin-AII system although, unlike Alls potentiating
effect on this axis, the axis appears to exert mainly an inhibitory
effect on the renin-AII system.
Andoka, Chauvin, Marie, Saez and Morera (1984) demonstrated that
ACTH decreases the number of All binding sites in bovine adrenal
glomerular cells, an effect which could be mediated by cyclic AMP.
Aguileri, Fujita and Catt (1981) presented evidence that ACTH produced
a decrease in plasma renin activity which appeared to correlate with
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the number of All receptors on glomerulosa cells. They postulated that
the decrease in All receptors was secondary to the suppression of the
renin-AII system but Andoka etal (1984) reinterpretated this as a
direct action of ACTH on All receptors in the adrenal cortex. Both
explanations are possible as in vitro binding studies have shown that
when All levels are elevated, the number of All receptors on the
adrenal cortex increase (Aguilera, Hauger and Catt, 1978; Devyrick
etal, 1978).
These inhibitory effects of ACTH on the renin-AII system would
appear not to support a facilitation of All stimulated catecholamine
secretion from the adrenal medulla. They may demonstrate a complex
negative feedback system with the pituitary-adrenocortical axis
dampening the already proposed self-potentiating mechanism by which
the renin-AII system and this axis interact to maintain or increase
blood pressure.
The adrenocortical system does not exert entirely inhibitory
effects on the renin-AII system however. As previously mentioned,
corticosterone has been shown to increase brain angiotensinogen
(Wallis and Printz, 1980) which would result in an increase of brain
All. Corticotrophin releasing factor (CRF) is anatomically distributed
in brain regions suspected of participating in the regulation of the
autonomic nervous system (Vale, Rivier, Brown, Spiess, Koob,
Swansson, Bilezikjian, Bloom and Rivier, 1983) and CRF can act
centrally, in the rat, to increase adrenal catecholamine secretion
(Brown and Fisher, 1984), increasing noradrenaline more than
adrenaline, an effect similar to that seen following cold exposure,
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tail suspension and ether exposure in the rat.
Corticosterone has been shown to increase the sensitivity of
vascular smooth muscle to vasopressor agents such as All (Dietz,
Schomig, Haebara, Mann, Rascher, Luth, Grunherz and Ross, 1978).
It would appear that there is a complex interaction between the
renin-AII system and the adrenocortical system. One possible
explanation combining the evidence discussed here could be that in
times of stress, eg. cold exposure, haemorrhage etc., both systems are
activated in a self-potentiating manner to restore eg. blood volume.
After this, perhaps circulating All and corticosteroids reach a
critical level at which the adrenocortical system begins to dampen or
"apply the brakes" on the potentiating effects of the renin-AII
system, until "homeostasis" is restored.
The aim of this series of experiments was to investigate a
possible interaction between the pituitary-adrenocortical axis and
the action of All on baroreceptor stimulation-evoked adrenal
catecholamine release. As was discussed previously, haemorrhage has
been shown to induce a release of both catecholamines and Cortisol in
dogs (Lilly etal, 1982), and this, together with the evidence of
Critchley etal (1982), already discussed, suggests that All may
possibly induce adrenal release of catecholamines indirectly through
facilitation of corticosteroid secretion and/or release. All and
corticosteroids may therefore interact to facilitate the reflex
release of catecholamines from the adrenal medulla.
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The aims of this series of experiments were to answer the
following questions-:
1. Does cycloheximide, administered before and after captopril,
affect the resting adrenal release of catecholamines and the reflex
release induced by baroreceptor stimulation and the ability of All to
restore the adrenal response after captopril administration ?
2. Can the inhibition of resting and reflex adrenal catecholamine
release, by captopril, be restored by the administration of ACTH ?
3. Does captopril affect Cortisol or corticosterone secretion
from the adrenal cortex ?
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Part two - Results
1 . The effect of cycloheximide on the release of catecholamines
from the adrenal medulla, following captopril and subsequent All
administration
Cycloheximide has been shown to inhibit the release of
adrenocorticosteroids (ACS) in response to adrenoeorticotrophic
hormone (ACTH) (Garren, Ney and Davis, 1965). It has also been shown
to inhibit the release of catecholamines in response to ACTH
(Critchley, Ellis, Henderson and Ungar, 1982). Critchley etal (1982)
demonstrated that 50mgkg-1 cycloheximide reduced, though not
significantly, the adrenal catecholamine response to baroreceptor
stimulation.
It was of interest to investigate the effect of 50mgkg-1
cycloheximide on adrenal catecholamine release after captopril
administration and during subsequent All infusion. In one dog (dog 10)
the effect of cycloheximide on the reflex adrenal catecholamine
release, prior to captopril administration, was studied. This was done
to verify the observations made by Critchley etal (1982).The results
are shown in table 2.1.
The results show that cycloheximide increased the resting
catecholamine release and inhibited, but did not abolish, the reflex
release of catecholamines.
In dogs 2-5, 50mgkg~"' cycloheximide was administered after
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Table 2.1
The effect of cycloheximide on catecholamine release in dog 10,
before and after baroreceptor stimulation (BRS).
Time
Drug iafter onset Total Increment Mean Mean
Treatment of BRS CA from CA incrememt
(mins) release control release from control
0 24,23 23.5
1-2 37,82 13,59 59.5 36
Control 5-6 68,82 14,59 75 36.5
9-10 93 69 93 69
0 46 46
cycloheximide 1-2 80,16 19,15 48 17
(50mgkg-1) 5-6 68,50 7,4 59 5.5
9-10 66 20 49 20
Table 2.2
The effect of cycloheximide on total catecholamine release In dogs 2-5
before and after baroreceptor stimulation (BRS), following captopril






(mins) Dog2 Dog3 Dog4 Dog5
Mean
± SE
Captopril, 0 14 1 18 11 11.0 ± 3.6
All and 1-2 14 3 8 16 10.3 ± 3-0
cycloheximide 5-6 16 2 0 11 9.7 ± 4.1
(50mgkg-1) 9-10 16 0 0 7 7.7 ± 4.6
(See table 1 .1- for a comparison of these results with the results
obtained prior to cycloheximide administration. )
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captopril administration and during All infusion. The effect of
cycloheximide on resting release and the reflex release of
catecholamines was analysed. The results are shown in table 2.2. These
results can be directly compared with the results shown in table 1.7.
The results show that, in the presence of captopril and All,
cycloheximide inhibits resting adrenal catecholamine release and
totally abolishes the reflex release of catecholamines induced by
baroreceptor stimulation.
2. The effect of cycloheximide on resting systemic blood pressure
and the reflex pressor response to baroreceptor stimulation
The effect of cycloheximide on the resting SBP and the reflex
pressor response to baroreceptor stimulation was analysed in dogs 2-
5. The results are shown in table 2.3. I have compared the effects of
cycloheximide with those of All in dogs 2-5. For a full comparison
with the effects compared with control and post-captopril SBPs I refer
the reader to table 1.10.
The results show that cycloheximide had no effect on either
resting SBP or the reflex pressor response to baroreceptor
stimulation.
Comment
These results indirectly support the hypothesis that, if there is
an interaction between All, ACS and catecholamine release, the
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Table2.3 Theeffectof(50mgkg-'1)cycloheximidec clo),inthpres nceaptopriland angiotensinII(All)onresti gsystemicblo dpre sureSBP)nthf x pressorresponsetoba orecept rstimulati n(BRS). DogRestingSBPSBPfollowingBRSIncrement number AllcycloAllCycloAllCyclo 2^5,40J470,905025,5010 360,607090,8511030,2510 170,5550120,110150,5560 515,35560,707515,3530 Mean51.386.9.335.60 ±1.26 6±7.311.6±5.110.
interaction is occuring at the level of the adrenal gland. If the
interaction was at the level of the central nervous system, both the
reflex release of catecholamines and the reflex pressor response to
baroreceptor stimulation would be affected by cycloheximide. The
results show that, after captopril and All administration,
cycloheximide inhibited the resting release of catecholamines and
totally abolished the reflex release. It did not have any effect on
resting SBP or the reflex pressor response.
3. The effect of cycloheximide on adrenal venous blood flow
ACTH has been shown to increase adrenal blood flow (e.g. Edwards,
Hardy and Malinowska, 1975), so it was of interest to investigate the
effect of cycloheximide on adrenal blood flow.
In dogs 2-5,the effect of cycloheximide on resting adrenal blood
flow was analysed and compared with adrenal blood flow in the presence
of captopril and All (see table 1.12).
The resting adrenal blood flows (mlmin-'') following cycloheximide
administration were as follows
Dog 2 = 2.1, dog 3 = 5.4, dog 4 = 1.2 and dog 5 = 2.0, mean = 2.7±0.9.
This compares with a mean of 1.7±0.22 (n=8) for adrenal blood flow
immediately prior to cycloheximide administration (see table 1.12).
The results show that there is no evidence for a significant
effect of cycloheximide on adrenal blood flow.
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4. The effect of ACTH on resting and reflex catecholamine
release, following captopril administration
We had hypothesised that part of the permissive effect of All on
adrenal catecholamine release was an indirect one, through
facilitation of ACS secretion. If this were so, ACTH would be expected
to reverse the inhibitory effect of captopril on adrenal catecholamine
release. To investigate this possibility, in dogs 7,8,9,11 and 12,
100pg ACTH was administered following captopril administration.
The effect of ACTH on resting catecholamine release before and
after baroreceptor stimulation, and in the presence of captopril was
analysed. The results are shown in table 2.4. (In dog 7, the samples
obtained following ACTH administration were lost, but I have included
the remaining results. Dog 7 was omitted in the statistical evaluation
of the results.)
The effect of ACTH on the change in catecholamine release
following baroreceptor stimulation, and in the presence of captopril
was analysed. The results are shown in table 2.5. The results were
combined and illustrated in figure 2.1.
The results show that ACTH had little effect on resting
catecholamine release in these dogs, but restored the reflex release
of catecholamines previously inhibited by captopril. Like All, ACTH
did not restore the reflex response completely.
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5. The effect of ACTH on resting systemic blood pressure and the
reflex response to baroreceptor stimulation
The effect of ACTH on resting systemic blood pressure (SBP) and
the reflex pressor response to baroreceptor stimulation was analysed
in dogs 7, 8, 9, 11 and 12. The results are shown in table 2.6.
Table 2.6 shows that, as has been previously demonstrated,
captopril inhibits both the resting SBP, and the reflex pressor
response to baroreceptor stimulation. There was no significant
additional effect of the subsequent administration of ACTH on either
resting SBP or the reflex pressor response.
Comments
ACTH is administered some six hours after the onset of
anaesthesia. All failed to restore SBP after captopril administration
at this time point, in fact there was evidence of a further decrease
in resting SBP and the reflex SBP response following All
administration (see table 1.10). As was discussed, this was probably
not due to All itself, but to the SBP already falling due to the
length of time the preparation had been in use. If this is taken into
consideration, then if ACTH was having no effect on SBP, both the
resting SBP and the reflex pressor response would have been expected
to fall after ACTH administration. The results show that there was in
fact no change in either resting SBP or the reflex pressor response
after ACTH administration. I suggest that ACTH may have increased SBP,
but this increase was masked by the fall in SBP that usually occured
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around 6-7 hours after the start of each experiment. ACTH may have
protected the preparation from this fall in blood pressure.
6. Adrenal Cortisol and corticosterone output and plasma
concentration before and after captopril administration, and after a
subsequent infusion of All
If, as we hypothesised, All is exerting a permissive effect on
adrenal catecholamine release through facilitating
adrenocorticosteroid (ACS) secretion, captopril would be expected to
decrease ACS secretion, and a subsequent infusion of All expected to
reverse the effect of captopril.
Corticosterone output (pgmin-^kg-1) and concentration
(ugml-1plasma) were analysed in adrenal venous blood, before and after
captopril administration, and after the subsequent infusion of All, in
dogs 13-18. The results are shown in table 2.7 and illustrated in
figure 2.2. Cortisol output and concentration were analysed also. The
results are shown in table 2.8 and illustrated in figure 2.3.
The results show that captopril had little effect on
corticosterone output. It did, however, significantly decrease
corticosterone concentration, although All did not reverse this
effect. Captopril increased Cortisol output, although All did not
significantly reverse this effect. Captopril did not significantly




Adrenal corticosterone concentration (pgml~1plasma) and output Q-igmin-1 kg~1 )
in dogs 13-18, before and after captopril administration, and after a
subsequent infusion of angiotensin II (All).
Dog number
and drug Corticosterone Plasma volume Corticosterone
treatment concentration per minute output
Control
13 2.94,2.16 2.8,2.8 0.33,0.24
14 4.59,5.31,4.31 1.1,1.0,1.7 0.28,0.30,0.39
15 2.44,2.36 0.8,1 .2 0.08,0.11
16 2.71,1.75 2.4,3.6 0.26,0.25
17 2.74,1 .72 2.5,2.5 0.33,0.20
18 3.67,3.68 1.3,0.8 0.16,0.10
Mean ± SE 3.10 ± 0.31 1.88 ± 0.26 0.23 ± 0.30
(n-13)
Captopril
13 1.96,2.14 4.6,4.6 0.36,0.39
14 2.10,2.87 3.9,2.4 0.46,0.38
15 1.09,0.84 1.9,1.6 0.08,0.05
16 1 .77,2.29 3.3,2.8 0.3,0.2
17 2.25,1 .81 2.5,1 .7 0.27,0.15
18 3-41,2.74 1.5,1 .8 0.20,0.14
Mean ± SE 2.10 ± 0.21 2.72 ± 0.33 0.25 ± 0.04
(n-12) *
All (5ngmin~1)
13 3.44,4.06 2.4,2.0 0.33,0.32
1 4 2.66,1.83 2.0,3.7 0.30,0.38
15
16 3.13,1.74 1.5,2.3 0.19,0.16
17 3.08,1 .79 1.3.1 .2 0.19,0.10
18 1 .26,1.01 1.8,1.8 0.08,0.06
Mean ± SE 2.4 ± 0.32 2.0 ± 0.23 0.21 ± 0.04
(n-10)
Statistical significance (captopril data compared with control data)-
* = p > 0.02
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Figure 2-2
The effect of captopril(25mg) and angiotensin II (All),
in the presence of captopril, on the output of cortico-
sferone (A.) and the concentration of corticosterone(B.)
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Adrenal Cortisol concentration (pgml-1plasma) and output (pgmin-1kg-1)
In dogs 13-18, before and after captoprll administration, and after a
subsequent infusion of angiotensin II (All).
Dog number
and drug Cortisol Plasma volume Cortisol
treatment concentration per minute output
Control
13 4.63,4.56 2.8,2.8 0.52,0.51
14 8.63,10.4,9.99 1.1,1.0,1 .7 0.53,0.58,0.94
15 5.39,4.74 0.8,1 .2 0.17,0.22
16 2.69,1 .87 2.4,3.6 0.30,0.30
17 2.61,2.1 2.5,2.5 0.31,0.25
18 3.99,4.71 1.3,0.8 0.17,0.13
Mean ± SE 5.10 ± 0.79 1.88 ± 0.26 0.38 ± 0.06
(n-13)
Captopril
13 3.38,2.84 4.6,4.6 0.62,0.52
1 4 5.89,8.27 3.9,2.4 1.28,1.09
15 2.92,2,28 1 .9,1 .6 0.21,0.14
16 2.75,2.42 3-3,2.8 0.41 ,0.31
17 3.90,5.34 2.5,1 .7 0.47,0.43
18 4.73,4.94 1.5,1.8 0.28,0.25
Mean ± SE 4.13 ± 0.51 2.72 ± 0.33 0.50 ± 0.10
(n-12)
All (5ngmin-1 )
13 6.39,6.73 2.4,2.0 0.61 ,0.54
1 4 10.7,6.12 2.0,3.7 1.19,1.25
15
16 4.32,2.94 1.5,2.3 0.30,0.31
17 5.05,8.09 1.3,1 .2 0.31 ,0.46
18 2.40,3.11 1 .8,1 .8 0.14,0.19




The effect of captopril (25mg) and angiotensinII[AII]
(5ngmin"), in the presence of captopril, on the output
of Cortisol (A.) and the concentration of Cortisol (B.)
from the left adrenal gland of the anaesthetised dog.
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These results show that captopril had opposing effects on ACS
output and concentration, increasing ACS output and decreasing ACS
concentration. Whether it is the output of ACS from the adrenal gland
or the concentration of ACS arriving at the adrenal medulla, that is
important in the postulated stimulation of adrenal catecholamine
release will be discussed in the "discussion" section.
7. The effect of ACTH administration on Cortisol secretion
The output and plasma concentration of Cortisol in adrenal venous
blood 10-40 minutes after ACTH administration was analysed in dogs
48, 49 and 51. The results are shown in table 2.9.
No statistical analysis of these results was possible due to the
limited values available, but the results show that there was an
increase in Cortisol output and concentration 10 minutes after ACTH
administration, and indicate that ACTH-induced Cortisol secretion was
greatest 20-40 minutes after ACTH administration. In dogs 7, 8, 9, 11
and 12 the first baroreceptor tests were carried out 20-30 minutes
after ACTH administration. These results indicate that at the time
the baroreceptor tests were performed, steroid secretion had been
stimulated by ACTH.
8. The effect of ACTH on adrenal blood flow
The effect of ACTH on adrenal blood flow was analysed in dogs 8,
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Table 2.9
The effect of ACTH administration on adrenal Cortisol output
Time after ACTH administration (min)
Dog number 0 10 20 30 10
Cortisol 18 0.57 0.80 0.81 0.66 0.77
output 19 0.50 0.17 0.57 0.59 0.68
(pgmin-1kg~1 ) 51 0.23 0.38 0.67 0.60
Mean ± 0.13 ± 0.55 ± 0.69 ± 0.62 ± 0.73
SE 0.10 0.13 0.08 0.02
Dog number
Cortisol 18 13.1 13.1 11.8 13.8 16.2
concentration 19 1.21 3.96 5.05 5.37 6.20
(jigml~1 plasma) 51 1.02 1.62 6.69 1.91
Mean ± 7.11 ± 7.23 ± 8.85 ± 8.03 ± 1 1 .2
SE 3.0 2.91 3.0 2.89
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9, 11, 48, 49, 50 and 51. The results are shown in table 2.10.
The results show that ACTH did not induce a significant increase
in adrenal blood flow, although the results indicate that there may be
a tendancy for ACTH to increase adrenal blood flow.
9. The effect of adrenal blood flow on Cortisol and
corticosterone output
The effect of adrenal blood flow on Cortisol and corticosterone
output was analysed. A plasma volume vs corticosteroid output graph
was constructed. The linear regression lines with 95$ confidence
limits are shown in figure 2.4. The control data used to compile this
figure can be found in tables 2.7 and 2.8.
Figure 2.4 shows that corticosteroid output is not significantly
dependant on adrenal blood flow.
10. The relationship between Cortisol output and concentration
on adrenal catecholamine release
In dogs 29, 49 and 51 ACTH, was administered and catecholamine
and simultaneous Cortisol output was monitored. It was therefore
possible to analyse the relationship between Cortisol output and
concentration and catecholamine release in these dogs. The results are
illustrated in figures 2.5 and 2.6 which show linear regression lines
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Table 2.10
The effect of ACTH on adrenal blood flow
Adrenal blood flow (mlmin-1)
Time (min) after
administration 0 10 20 30 MO
of ACTH
Dog number
8 4.8 10.7 8.0 9.0
9 3.0 2.6 4.4 3.0
11 4.0 4.6 4.7 5.0
48 1.5 2.2 1 .8 1 .7 1 .6
49 4.4 4.3 3.9 3.8 3.7
50 4.2 5.4 5.5 6.2 5.0
51 2.3 2.8 2.3 3.1 3.0
Mean ± 3.7 ± 4.66 ± 4.37 ± 4.54 ± 3.33 :
SE 0.46 1.10 0.78 0.92 0.71

























Linear regression line for Cortisol output vs.catecholamine

















Linear regression line for Cortisol concentration in adrenal
venous blood plasma vs. adrenal catecholamine output
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Cortisol concentration (pgrnl-'plasma)
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with 95$ confidence limits for Cortisol output and concentration
(prior to captopril administration), respectively, vs catecholamine
output. These figures were constructed from the data contained in
table 2.11. Figures 2.5 and 2.6 show that the large variation in
catecholamine output between animals resulted in large 95$ confidence
limits. Figure 2.5 indicates that Cortisol output is not related to
catecholamine output. Figure 2.6 indicates that, although not
significant, there is a trend towards increasing plasma Cortisol
concentrations increasing adrenal catecholamine output.
11. The effect of ACTH on the ratio of adrenaline:noradrenaline
in adrenal venous blood
As has been discussed in the "Introduction and literature
review", the effect of adrenocorticosteroids on adrenal catecholamine
secretion may be secondary to an effect on the enzyme PNMT, which
converts noradrenaline to adrenaline. If the effect was on PNMT alone,
ACTH should only affect adrenaline release, and there would be
evidence of an increase in the ratio of adrenaline:noradrenaline
following ACTH administration.
The effect of ACTH on the ratio adrenaline:noradrenaline in dogs
29, 49 and 51 was analysed. The results are shown in table 2.12.
The results show that ACTH did not increase the ratio of
adrenaline:noradrenaline and hence its effect on catecholamine release
is not due to induction of PNMT by adrenocorticosteroids.
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Table 2.11
Catecholamine output, Cortisol output and Cortisol concentration
before and after ACTH administration, in dogs 29, 49 and 51
Drug Sample




Control 1. 52 86 88
2. 58 93







Control 1. 0.18 0.30
2. 0.19 0.50 0.23







Control 1. 1.49 4.02
2. 2.29 4.21 4.87










Dog 29 Dog 49 Dog 51 (n-10)
5.13 4.16 6.30 4.66 ± 0.29
















Part 2 - Summary of results
1. Cycloheximide (50mgkg~1), administered after captopril and
during All infusion inhibited resting adrenal catecholamine release
and totally abolished the reflex release induced by baroreceptor
stimulation. The same dose of cycloheximide, administered before
captopril, did not inhibit the resting release of catecholamines and
reduced, and did not abolish the reflex release. This indicates that
inhibition of adrenocorticosteroid secretion, in response to ACTH, by
cycloheximide and inhibition of All synthesis by captopril both
independantly inhibit adrenal catecholamine release in response to
baroreceptor stimulation. When both adrenocorticosteroid secretion and
All synthesis are inhibited simultaneously, despite infusion of a low
level of All, the reflex release of catecholamines is abolished.
2. Cycloheximide had no effect on resting systemic blood pressure, or
the reflex pressor response to baroreceptor stimulation.
3. ACTH (1OOpg) partially reversed the inhibitory effect of
captopril on reflex adrenal catecholamine release in response to
baroreceptor stimulation. ACTH-induced steroid secretion had
increased by the time baroreceptor tests were performed.
4. ACTH had no effect on systemic blood pressure but may have
prevented the further fall in systemic blood pressure usually observed
some time after captopril administration.
5. Captopril did not affect adrenal corticosterone output, but
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significantly reduced corticosterone concentration in adrenal venous
blood. Captopril increased adrenal Cortisol output and reduced
Cortisol concentration in adrenal venous blood.
6. ACTH did not significantly increase adrenal blood flow
although there was a tendency towards an increase following ACTH
administration.
7. Cortisol and corticosterone output, prior to captopril
administration, was independent of adrenal plasma volume.
8. Adrenal catecholamine output was not related to adrenal Cortisol
output, although there was a tendency for an increase in Cortisol
concentration in adrenal venous blood to induce an increase in adrenal
catecholamine release.
9. ACTH did not increase the ratio of adrenaline:noradrenaline in
adrenal venous blood and so the increase in adrenal catecholamine
release following ACTH administration was not due to induction of
PNMT by adrenocorticosteroids.
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Part 2 - Discussion of results
Cycloheximide inhibits the release of adrenocorticosteroids (ACS)
in response to ACTH (Garren etal, 1965) probably by inhibiting the
synthesis of new protein. Roth and Hughes (1972) demonstrated that a
pharmacological dose of All stimulates the biosynthesis of the enzymes
involved in noradrenaline synthesis and that cycloheximide abolished
All-induced increases in noradrenaline synthesis, whilst having no
effect on basal noradrenaline synthesis. Other studies have, however,
demonstrated that the effect of All on noradrenaline biosynthesis is
not seen at physiological levels of All (see "Part 3 ~ Introduction
and literature review").
In dog 10, it was seen that cycloheximide, administered before
captopril did not inhibit the resting output of catecholamines but
did inhibit the reflex release in response to baroreceptor
stimulation. If the effect of cycloheximide on new protein synthesis
is considered, the results could indicate that cycloheximide was
inhibiting catecholamine release through inhibition of the enzymes
involved in de novo biosynthesis of catecholamines. This is unlikely,
however, as considerable ammounts of catecholamines are stored in the
adrenal medulla and so release does not depend on de novo
biosynthesis. In addition, if this was the case, cycloheximide alone
would be expected to completely abolish reflex catecholamine release,
and this was not observed. Critchley etal (1982) also demonstrated
that cycloheximide reduced, though not significantly, reflex adrenal
catecholamine release.
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The results suggest, therefore, that inhibition of ACTH-induced
ACS secretion may inhibit reflex catecholamine release, and that ACS
may exert a facilitatory effect on reflex catecholamine release.
In dogs 2-5, cycloheximide was administered after captopril, and
during the All infusion. It severely inhibited resting release of
catecholamines and totally abolished the residual reflex release of
catecholamines remaining after captopril administration.
This suggests that when both ACTH-stimulated ACS secretion and
All synthesis are inhibited, the independant inhibitory effects of
captopril and cycloheximide are potentiated, resulting in virtually
total inhibition of reflex catecholamine release. This inhibition is
so severe, that the level of All which normally reverses the effect of
captopril was unable to overcome it.
Our hypothesis was that All may exert a facilitatory effect on
ACS secretion which in turn may exert a facilitatory effect on
catecholamine release. As I have shown and will be discussed later,
captopril does reduce corticosterone and Cortisol concentration in
adrenal venous blood, and catecholamine release tends to increase
with increasing Cortisol concentration. In addition, as was discussed
in the "Introduction and literature review", ACTH and corticosteroids
have been shown to stimulate adrenal catecholamine release. This
evidence, together with the results discussed for cycloheximide
effects, supports our hypothesis.
The evidence suggests that captopril may inhibit a direct
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facilitatory effect of All on adrenal catecholamine release (see
Feldberg and Lewis, 1964; Peach, 1971; Starke, 1972; Haefely, 1972;
Reit, 1972 and "Part 1" of this thesis) and also an indirect
facilitatory effect of All via ACS secretion, which may exert a
facilitatory effect on adrenal catecholamine release.
As will be discussed later, there is evidence that the
facilitatory effect of All on Cortisol secretion may be only effective
in the presence of ACTH (Slater etal, 1963; Bravo etal, 1975; Parker
etal, 1983; Morera etal, 1984). This may explain why the combined
effects of both captopril and cycloheximide abolish the reflex adrenal
release of catecholamines, as the combined effects of ACTH and All had
both been inhibited.
The results indicate that the proposed facilitatory effect of ACS
on catecholamine release is predominantly on the reflex release
induced by the baroreceptor tests, as cycloheximide had little effect
on resting catecholamine release. This is supported by my results
which show that ACTH reverses the inhibitory effect of captopril on
reflex release of catecholamines, whilst having little effect on the
resting release (the results also show that there was ACTH-stimulated
ACS secretion by the time baroreceptor tests were performed). It is
also supported by the studies of others which have demonstrated ACTH
release from the pituitary and subsequent ACS secretion following
chemoreceptor stimulation (Anichkov etal, 1960; Marotta, 1972),
insulin- hypoglycaemia (Wurtman etal, 1968) and haemorrhage (Ganten
etal, 1979; Lilly etal 1982). This evidence and that described in the
"Introduction and literature review", combined with my own, suggest
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that both the renin-AII system and the pituitary adrenocortical axis
are important in the adreno-medullary response to hypotension.
They may also facilitate the effects of each other, cooperating to
restore eg. blood volume. My results also show that ACTH alone may
have prevented the further fall in blood pressure usually observed
after captopril administration. They also show that ACTH did not
increase the ratio of adrenaline:noradrenaline in adrenal venous blood
and so the effects of ACTH on adrenal catecholamine release cannot be
explained by ACS induction of PNMT.
If the hypothesis that All is exerting an indirect effect on
adrenal catecholamine release through facilitation of ACS is correct,
captopril would be expected to reduce ACS secretion from the adrenal
cortex.
The results show that captopril did significantly reduce
corticosterone plasma concentration, and reduced Cortisol plasma
concentration to a lesser extent. There was an indication, although
not significant, that All partially reversed these effects. Captopril
did, however, have no effect on corticosterone output and
significantly increased Cortisol output.
It must be considered, therefore, which is the most important in
stimulating catecholamine release, the concentration of ACS in the adrenal
blood, or the total ACS output.
As I described in "An introduction to the adrenal gland (blood
supply)" blood passing through the sinuses connecting the cortex with
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the medulla, comes into intimate contact with chromaffin cells and,
as described by Coupland (1975), these cells are affected by high
concentrations of ACS which accumulate in the immediate vicinity of
the cells, and it is this concentration that effects catecholamine
synthesis. I therefore consider that it is the plasma concentration
of ACS which will affect catecholamine synthesis, and that the
reduction of this by captopril contributes to its inhibitory effect on
catecholamine output. In addition, it has been shown that captopril
significantly increased adrenal blood flow, and as ACS output was
calculated by multiplying concentration by blood flow, these increases
in adrenal blood flow were responsible for the apparent increases in
ACS output.
The results therefore indicate that captopril may reduce the
postulated facilitatory effect of Cortisol and corticosterone on
catecholamine secretion, by reducing the plasma concentration of
Cortisol and corticosterone bathing the chromaffin cells.
Figures 2.5 and 2.6 show that after ACTH administration, although
not significant, there is a tendency for catecholamine output to
increase with an increase in plasma Cortisol concentration but not
with Cortisol output, which also indicates that it is the
concentration which is important.
These results are supported by the work of Critchley etal (1982)
who demonstrated that cycloheximide abolished the prolonged adrenal
release of catecholamines stimulated in response to carotid body
hypoxia in the anaesthetised dog. As described in the "Introduction
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and literature review", Critehley etal (1982) also showed that the
results of Wurtman etal (1968) could be recalculated to show that
ACTH stimulated release of adrenaline and noradrenaline and so the
effect was not totally related to induction of PNMT as Wurtman etal
suggested. Critchley etal (1975) had also demonstrated that Cortisol
could stimulate release of catecholamines from the isolated perfused
canine gland in a dose-dependant manner and in concentrations normally
detected in adrenal venous blood.
Edwards, Hardy and Malinowska (1975) and Bloom, Edwards and Hardy
(1977) reported that in the conscious calf, Cortisol release during
hypoxia or hypercapnia was not related to catecholamine release.
Henderson (1980) reported that no catecholamine output was detected
after Cortisol infusion in feline adrenal glands. The effect of
corticosteroids on adrenal catecholamine release may therefore be
species dependant.
My results and the additional evidence discussed, suggest that,
in the anaesthetised dog, stimulation of the pituitary adrenocortical
axis in response to cardiovascular stress induces an increase of
Cortisol and corticosterone from the adrenal cortex which facilitates
catecholamine release from the adrenal medulla. They also suggest
that this effect is facilitated by the presence of All which
facilitates catecholamine release by a direct action on the adrenal
medulla, and indirectly through facilitating adrenocorticosteroid
release from the adrenal cortex.
From figures 2.2 and 2.3, it can be seen that captopril
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significantly reduced corticosterone plasma concentration, while
reducing, though not significantly to p > 0.05, Cortisol concentration.
Neither of these effects was significantly reversed by the low level
of All infused, although there was a tendancy towards a reversal. It
may be that increasing levels of All may have exerted a greater
effect.
It is of interest that captopril had a greater effect on
corticosterone than Cortisol concentration. As captopril inhibits All
synthesis, this suggests that All may have a more profound effect on
corticosterone secretion in the dog. This is supported by additional
available evidence which I shall now discuss.
The zona glomerulosa of the adrenal cortex is the site for
aldosterone secretion (Martin, 1975). Figure 2.7 shows part of the
major biosynthetic pathway for aldosterone. From the figure it can be
seen that corticosterone is a major precursor for aldosterone
synthesis. Corticosterone is also released from the zona glomerulosa.
Cortisol is not synthesised or secreted by the zona glomerulosa.
Cortisol is synthesised and secreted by the zona fasciculata of
the adrenal cortex (Martin, 1976). Figure 2.8 shows a major
biosynthetic pathway for Cortisol. From the figure it can be seen
that Cortisol is ultimately synthesised from corticosterone. In the
rat, corticosterone is the major glucocorticoid secreted by the zona
fasciculata, but in humans and other animals (including the dog)
corticosterone is converted to Cortisol which is the main, or only,
glucocorticoid secreted (Martin, 1976).
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Figure 2-7











Biosynthetic pathway for corticosterone and Cortisol














Aldosterone and corticosterone secretion from the zona
glomerulosa is primarily determined by All, K+ and ACTH (Huijmans,
Falke and Degenhart, 1984) and the stimulation of secretion is Ca++-
dependant (Braley, Menachey, Brown and Williams, 1984). Braley and
Williams (1977) and Shima, Kawashima and Hirai (1978) found no
evidence of corticosterone stimulation by All in rat fasciculata
cells, but All did stimulate corticosterone from the glomerulosa
cells.
Cortisol secretion from the zona fasciculata is mainly ACTH
dependant (Parker etal, 1983; Huijmans etal, 1984). All may also
play a role in Cortisol secretion from the zona fasciculata in some
species. Slater etal (1963) and Bravo etal (1975) demonstrated that
All may play a role in Cortisol secretion in the dog. Carpenter etal
(1961) and Kaplan and Bartter (1962) also demonstrated that All
stimulates Cortisol secretion in bovine and dog adrenals.
The evidence therefore suggests that, in the dog, All is a major
stimulus for corticosterone secretion from the zona glomerulosa and
plays a minor role in Cortisol secretion from the zona fasciculata.
This may explain why I found that captopril reduced corticosterone
adrenal plasma concentration to a more significant extent than
Cortisol concentration.
As mentioned, the effect of All on Cortisol secretion may be
species dependant. McKenna, Island, Nicholson and Liddle (1978)
demonstrated that pharmacological doses of All stimulated Cortisol
production in slices of adrenal tissue from patients with Cushings
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disease. Williams and Braley (1977) were unable to demonstrate
Cortisol production in response to physiological doses of All, in
collagenase-dispersed human fasciculata cells. So it is not clear
whether All does play a role in Cortisol secretion from human
fasciculata cells.
Douglas etal (1978) found that All receptors are significantly
more concentrated in rat glomerulosa than fasciculata. This would
indicate that All receptors do exist in rat fasciculata, although
Braley and Williams (1977) and Shima etal (1978) found no evidence of
corticosterone secretion by All in rat fasciculata cells. Valloton,
Capponi and Grillet (1981) found evidence of All receptors in bovine
fasciculata cells, and Douglas etal (1984) found evidence of an All
receptor, on human and primate collagenase adrenal fasciculata, that
shares many properties with the glomerulosa receptor site.
So it would appear that the effect of All on Cortisol secretion
may be species dependant. There is evidence that All may only be
effective in stimulating Cortisol secretion when it is in the presence
of ACTH. Parker etal (1983), using dog adrenal cell suspensions,
demonstrated that Cortisol secretion was not stimulated by All alone,
but it was stimulated when All (4 x 10~1®M) was combined with ACTH
(10_13m) and these are both physiological concentrations. Slater etal
(1963) and Bravo etal (1975) also demonstrated that, in the dog, All
potentiates the response of ACTH on Cortisol secretion. Morera etal
(1984) demonstrated that All potentiates ACTH-induced cyclic AMP
production in bovine cortico- adrenal cells, an effect which was
inhibited by saralasin. Fraser etal (1978) demonstrated that Cortisol
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production, in dexamethasone supressed normal volunteers, was not
stimulated by All alone, but was when All was infused over a baseline
of ACTH stimulation. These observations may explain why the studies
using in vitro fasciculata cell preparations were unable to
demonstrate Cortisol secretion by All alone.
My observation that cycloheximide potentiated the effects of
captopril on adrenal catecholamine release are compatible with a
potentiation of ACTH induced Cortisol secretion by All.
The results show that Cortisol output was approximately two times
that of corticosterone output. This was also observed by Tait, Tait
and Bell (1980) who demonstrated that steroid production rates in
fasciculata cells in the presence of ACTH or other stimuli exceed the
production rates observed in glomerulosa cells.
The results in table 2.10 show that ACTH did not promote a
significant increase in adrenal blood flow, although there was a
tendancy towards an increase. Other workers have found that ACTH, at
doses which stimulate Cortisol secretion have little effect on adrenal
blood flow (Coupland, 1975), although others have detected significant
increases in adrenal blood flow following ACTH administration. There
are also conflicting opinions as to the effect of ACTH-induced
increases in adrenal blood flow on ACS secretion. Figure 2.4 shows
that, prior to captopril administration, Cortisol and corticosterone
output was not related to adrenal blood flow. This indicates that ACS
release is not dependant on diffusion into adrenal blood. Marotta
(1972) studied the release of 11-hydroxycorticosteroids (11-0HCS)
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(Cortisol and corticosterone (see figure 2.8)) in the intact
anaesthetised dog made hypoxic or infused with ACTH. He detected an
increase in 11-OHCS secretion within two minutes of applying the
stimuli, and this was accompanied by an increase in adrenal blood
flow. He suggested that the sudden increase in adrenal blood flow may
rapidly release preformed steroids stored in the adrenal cortex. He
did, however, discuss that the increase in adrenal blood flow could
not alone account for the elevation in 11-OHCS, since in the hypoxic
dogs, the increase in flow was small compared to the increase in
secretory rates. This is compatible with my own findings. Marotta
(1972) also demonstrated that in dogs infused with acetyl-g-
metacholine (AM) (which stimulates the central pole of the
hypothalamus), adrenal blood flow had decreased before peak 11-OHCS
secretory rates had been reached. L'Age, Gonzalez-Luque and Yates
(1970) also demonstrated that in dexamethasone treated dogs, AM caused
an increase in adrenal blood flow without appreciably affecting
Cortisol secretion, and so the release of steroids following AM
administration is independant of its effect on adrenal blood flow. The
available evidence suggests that an increase in adrenal blood flow may
not be important for ACS secretion from the adrenal cortex.
The results shown in table 2.3 show that cycloheximide
administration, in the presence of captopril and All, had no effect
on the reflex pressor response to baroreceptor stimulation, although
it abolished the reflex release of catecholamines. This provides
indirect evidence that the combined facilitatory effects of the renin-
AII system and the pituitary adrenocortical axis is at the level of
the adrenal gland, and not on central activation of sympathetic drive.
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If this was the ease, the reflex pressor response to baroreceptor
stimulation would also have been inhibited by cycloheximide.
In conclusion, these results indicate that, in the anaesthetised
dog, in addition to a direct effect on adrenomedullary catecholamine
release, All may exert an indirect effect through stimulation of
adrenocorticosteroids. These may then facilitate adrenal
catecholamine release. In situations of cardiovascular stress, both
the renin-AII system and the pituitary adrenocortical axis may





Part 3 ~ Introduction and literature review
It is possible that eaptopril may inhibit the release of
catecholamines from the adrenal medulla via an action on splanchnic
nerve activity.
Soon after synthetic All became available, it was found to
facilitate sympathetic neuroeffector transmission (Zimmerman, 1962;
McCubbin and Page, 1963; Benelli, Bella and Gandini, 1964). For a
review of the effects of All on the sympathetic nervous system, I
refer the reader to (Starke, 1977a). I shall discuss here the evidence
supporting a facilitatory role of All in sympathetic neuro-effector
transmission and the possible implications for a similar role for All
in facilitating splanchnic nerve stimulation of catecholamine release
from the adrenal medulla.
All could facilitate sympathetic neuro-effector transmission via
a number of mechanisms-:
1. By a post-synaptic effect on the sensitivity of effector tissues to
catecholamines.
2. By a presynaptic effect on basal catecholamine release.
3. By a presynaptic effect on stimulation-evoked release of
catecholamines.
4. By a presynaptic effect on neuronal uptake of catecholamines.
5. By an effect on noradrenaline biosynthesis in nerve terminals.
1. Facilitation of the sympathetic nervous system by All has been
shown to be partly due to a direct action on the effector organ eg.
186
smooth muscle cells (Panisset and Bourdois, 1968; Day and Moore,
1976). At low doses All causes a partial depolarisation of cell
membranes, bringing the cells closer to the firing level of action
potentials (Sjostrand and Swedin, 1974). All can facilitate both pre-
and post-junctional effects of adrenergic transmission in the rat
mesenteric bed (Malik and Nasjletti, 1976; Zimmerman, 1978; Campbell
and Jackson, 1979). The vasoconstriction of the rat mesenteric bed
induced by exogenous noradrenaline can be blocked by angiotensin
converting enzyme inhibitors (ACEIs) (Saruta, Suzuki, Okimo and Kondo,
1982; Clough etal, 1982).
Clough etal (1982) demonstrated that, in pithed rats, the pressor
responses induced by exogenous noradrenaline can also be reduced by
.ACEIs and saralasin. In this preparation ACEIs and saralasin also
reduced the pressor responses induced by stimulation of the
sympathetic nervous system. This indicates that inhibitors of the
renin-AII system may inhibit neurogenic vasoconstriction by
interfering with both pre- and post-junctional effects of All.
2. Hughes and Roth (1971), using the rabbit coeliatartery
preincubated with 3H noradrenaline, showed that as little as 10~loM
All accelerated the basal outflow of tritium. The effects on the
noradrenaline overflow could be retained after neuronal and extra-
neuronal uptake of noradrenaline was blocked. This indicates a
facilitatory effect of All on basal release of noradrenaline. In many
other tissues, however, a high concentration of All is required to
obtain even small increases in basal overflow (see Starke, 1977a).
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Much of the available evidence indicates that the most important
facilitatory effect of All is on stimulation-evoked release of
noradrenaline.
3. Zimmerman and Whitmore (1967) first showed that All augments
the overflow of noradrenaline evoked by sympathetic nerve stimulation.
All enhances the stimulation-evoked overflow of noradrenaline from the
hind paw, kidney of the dog, rabbit heart, coelicicand pulmonary
arteries, portal vein and vas deferens. Studies using tissues pre-
labelled with tritiated noradrenaline have shown that All enhances
the stimulation-evoked overflow of radioactivity (see Starke, 1977a).
This prejunctional effect of All is probably its most important
facilitatory effect on sympathetic nerve activity, as it enhances the
release of noradrenaline by nerve impulses at doses which do not
affect the basal overflow of noradrenaline and do not affect the
release of noradrenaline induced by tyramine or amphetamine, and
therefore the uptake of noradrenaline by nerve terminals (Starke,
1971; Chevillard and Alexandre, 1972). The effect on stimulated
release of noradrenaline is not secondary to an enhancement of
noradrenaline synthesis since release of exogenously administered
noradrenaline is also increased (see Starke, 1977a). Not only blood-
borne, but also locally formed All may facilitate noradrenaline
transmission (Malik and Nasjletti, 1976). There is evidence that the
presynaptic All receptor may differ from the myocardial and smooth
muscle All receptor (Zimmerman, 1973; Blumberg, Ackerly and Peach,
1975).
The reason that some workers have been unable to demonstrate a
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facilitatory effect of All on prejunctional noradrenaline release may
be because the facilitatory effect of All is pronounced at low
frequencies of stimulation, but declines at high frequencies (Hughes
and Roth, 1971; Henderson and Hughes, 197*0. This is compatible with
the view that All selectively enhances Ca++ dependant secretion. Bell
(1972), using electrophysiological studies on guinea-pig vas deferens
and uterine artery, found that the extra-junctional potential (e.j.p.)
evoked by a single nerve impulse was not enhanced by All. All did
facilitate the effects of successive e.j.p.s during low frequency
stimulation. If it is assumed that facilitation in a train of impulses
reflects increased intra-neuronal levels of Ca++, until at high
frequencies the "release receptors" are saturated, then these results
indicate that All promotes the ammount of Ca++ available for release
processes (Starke, 1972).
All has also been shown to facilitate the average release of
noradrenaline per nerve impulse (Zimmerman, Gomer and Chialiao, 1972).
It has also been shown, in the rabbit atria, that All enhances the
overflow of both noradrenaline and dopamine-g-hydroxylase, which is a
marker enzyme for storage vesicles (Ackerly, Blumberg and Peach,
1976). This suggests that All enhances Ca++-dependant exocytotic
release of noradrenaline.
4. Studies concerning the effects of All on neuronal uptake of
noradrenaline have yielded contradictory results, even in the same
experimental organ (see Starke, 1977a), and it seems unlikely that, at
physiological concentrations, All exerts an inhibition on neuronal
uptake mechanisms. Only at very high concentrations eg. greater than
189
10-SM, All slightly decreases neuronal uptake (Schumman, Starke,
Werner and Hellerforth, 1970; Henderson and Hughes, 1974) and an
appreciable effect of lower concentrations is doubtful (Thoenen,
Hurlimann and Haefely, 1965; Gommer and Zimmerman, 1973; Day and
Moore, 1976). Up to 5 x 10-6M All fails to reduce the release of
noradrenaline by tyramine (Starke, 1971; Chevillard and Alexandre,
1972) and All has actually been shown to enhance the post-synaptic
effects of tyramine (Benelli etal, 1964; Kaneko, Takeda, Nakajima and
Ueda, 1966; Chevillard and Alexandre, 1972). The available evidence
does not support an effect on neuronal uptake by All.
5. Roth and Hughes (1972) demonstrated that All stimulates the
biosynthesis of the enzymes involved in noradrenaline biosynthesis.
Puromycin and cycloheximide block the synthesis of new protein and
abolished All increases in noradrenaline synthesis, whilst having no
affect on basal noradrenaline synthesis.
In the rabbit coeliacartery, vas deferens and many other tissues,
All does not effect noradrenaline synthesis, and it is doubtful if All
exerts this effect physiologically.
As has been discussed in Part 1 of this thesis, All stimulates
catecholamine release from the adrenal medulla. It has also been shown
to stimulate activity in other sympathetic ganglia cells (Reit, 1972;
Starke, 1972). All depolarises isolated chromaffin cells (Douglas,
Kanno and Sampson, 1967) and, like All-evoked noradrenaline release
from sympathetic nerve endings, All evoked catecholamine release from
the adrenal medulla is Ca++- dependant (Poisner and Douglas, 1966).
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It has been demonstrated that All has analogous effects on
cholinergic and noradrenergic nerve endings in that it enhances the
stimulation-evoked overflow of acetylcholine but not the basal
overflow. It can enhance stimulation-evoked acetylcholine overflow
from both sympathetic and parasympathetic ganglia, and the stimulation-
evoked acetylcholine overflow from the guinea-pig ileum and cerebral
cortex (Panisset, 1968).
The aims of this series of experiments were two-fold-:
1. From the evidence presented here, it appeared possible that All may
facilitate splanchnic nerve activity.
2. It was still not possible to positively rule out the
possibility, suggested by Feuerstein etal (1977), that following
baroreceptor stimulation, All was acting centrally to increase
sympathetic drive and hence reflex adrenal catecholamine release.
The effect of captopril (and saralasin) on the denervated adrenal
gland, and its responses to splanchnic nerve stimulation were studied
to investigate these two possibilities.
The experiments were designed to answer the following questions-:
1. Does captopril (and saralasin) inhibit the release of
catecholamines evoked by splanchnic nerve stimulation, from the
denervated adrenal gland ?
2. If so, does exogenously administered All restore splanchnic nerve
stimulation-evoked catecholamine release ?
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Part 3 ~ Results
1. The effect of the renin-angiotensin system on adrenal
catecholamine release in response to splanchnic nerve stimulation
1.a. The effect of the frequency of stimulation of the
splanchnic nerve on adrenal catecholamine release in the
anaesthetised dog
The effect of the frequency of stimulation of the splanchnic
nerve on total catecholamine release, before and after captopril
administration and a subsequent infusion of All, in dogs 19-24 was
studied. The results are shown in table 3.1.
The effect of the frequency of stimulation on the change in
catecholamine release induced by splanchnic nerve stimulation (10
volts,2ms) was also analysed. The results are shown in table 3.2 and
illustrated in figure 3.1.
The results show that there was an increase in adrenal
catecholamine release with an increase in frequency between 2.5 and
10 pulses per second (pps). A maximum release can be seen to occur at
10pps, 20pps having no additional effect. In subsequent experiments,
the splanchnic nerve was stimulated at 10pps with 10 volts (v).
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Table 3.1
The effect of captopril on total catecholamine release in dogs 19-24 (D19-24)




Total catecholamine release (pmolmin kg )
Mean
D19 D20 D21 D22 D23 D24 + SE
Control
C 152 212 11 124 103 31 105.5 + 30.7
. +S,2.5pps 122 250 24 93 65 42 99.3 + 33.6
C 216 353 6 91 120 11 132.8 + 54.2
+S ,5.Opps 494 392 54 148 159 75 220.3 + 73.5
C 225 439 168 116 29 195.4 ± 68.9
+S,10.Opps 451 523 275 261 244 350.8 + 57.0**
C 304 514 17 168 182 21 201.0 + 76.7
+S,20.Opps 477 530 20 208 344 253 305.3 + 76.4*
Captopril
C 196 239 28 83 17 112.6 ± 44.8
+S,2.5pps 83 240 19 52 33 85.4 + 40.1
C 216 510 12 98 186 30 175.3 + 74.7
+S ,5.Opps 1 44 446 50 100 115 92 157.8 + 59.0
C 99 369 16 113 174 23 132.3 + 53.2
+S,10.Opps 82 350 13 147 261 107 160.0 + 50.7
C 91 440 29 69 158 33 136.7 + 63.6
+S,20.Opps 101 407 22 88 21 4 185 169.5 + 55.3*
AH
(5ngmin ) C 28 139 378 78 155.8 ± 77.5
+S,2.5pps 26 118 467 86 272.5 + 185
C 24 177 71 90.7
+S,5.Opps 47 250 91 129.3
C 31 262 145 146
+S,10.Opps 11 330 220 222.3
C 48 285 248 193.7
+S,20pps 186 308 299 264.3
+S = During splanchnic nerve stimulation (10v) pps = pulses per second
C = Control
Statistical significance (+S vs C and captopril data vs control data)
* = p > 0.05
** = p > 0.01
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Table 3.2
The effect of captopril on the change In catecholamine release Induced by




catecholamine release (pmolmin kg )
Mean
D19 D20 D21 D22 D23 D24 + SE
Control
+S ,2.5pps -30 38 13 -30 -38 11 -6.2 ± 12.7
+S ,5.Opps 278 39 48 57 39 64 87.5 ±38.3
+S,10 .Opps 226 84 121 107 1 45 215 149.7 ± 23.9
+ S ,20 .Opps 173 16 190 40 162 232 135.5 ± 35.5
Captopril
+S,2.5pps -113 1 -9 -30 16 -27.0 ± 22.8
+S ,5 .Opps -72 -64 38 2 -71 62 -17.5 ± 24.3
+S,10.Opps -17 -19 122 34 87 184 65.2 ± 33.0
+S,20.Opps 10 -33 198 19 56 152 67.0 ± 36.51
AH
_
(5ngmin ) +S ,2.5pps -2 -21 89 8 18.5 ± 24.3<
+S,5.Opps 23 73 20 38.7
+S,10.Opps 86 68 75 76.3
+S ,20.Opps 138 23 51 70.7
+S = During splanchnic nerve stimulation (10v) pps = pulses per second
C = Control
Statistical significance (captopril data vs control data)
* = p < 0.05
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Figure3-1 Theeffectoffrequ ncysplanchninervstimulatiooadr n lc techolami e(CA) releaseandtheff ctofcaptoprilfoll wedbyangiot nsinII(AH)nrele seevoked bysplanchnicnervestimulation,(10volts).
1.b. The effect of captopril on adrenal catecholamine release,
before and after splanchnic nerve stimulation
The effect of captopril on adrenal catecholamine release, before
and after splanchnic nerve stimulation was studied in dogs 25-28. The
effect of captopril on total catecholamine release before and after
splanchnic nerve stimulation in dogs 25-28 was analysed and pooled
with the results obtained from dogs 19-24 for stimulation at 10pps.
Table 3.3 shows the results for dogs 25-28, and the mean results for
dogs 19-28, and the results are illustrated in figure 3.2. The results
show that captopril significantly inhibited both the resting release
of catecholamines and the release induced by splanchnic nerve
stimulation.
2. The effect of a continuous infusion of All on adrenal
catecholamine release, before and after splanchnic nerve stimulation,
and after captopril administration
The effect of a continuous infusion of Sngmin-1 All on adrenal
catecholamine release, before and after splanchnic nerve stimulation
was studied in dogs 21,23 and 24. The results for dogs 21,23 and 24
are shown in tables 3.1 and 3.2. In dogs 26-28, continous infusions of
10,30 and 100 ngmin-1 All were administered following captopril
administration. These results are shown in table 3.4. The results
contained in tables 3.1, 3-2 and 3.^ were combined and illustrated in
figure 3.3.
It was not possible to statistically evaluate these results, due
to the small sample numbers involved, but the results suggest that
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All restored both the resting release and stimulated release of
catecholamines. Figure 3.3 shows that for 5,10 and 100 ngmin-1
infusions of All, these effects tend towards being dose-dependant.
3. The effect of saralasin on adrenal catecholamine release,
before and after splanchnic nerve stimulation
It was of interest to investigate the effect of the All-
antagonist saralasin on adrenal catecholamine release, to compare its
effect with captopril and rule out the possibility that the effects
of captopril were unrelated to its inhibition of the renin-AII
system.
The effect of saralasin on both the resting release of
catecholamines and the release induced by splanchnic nerve
stimulation, was investigated in dogs 29-31• Control adrenal blood
samples before and after splanchnic nerve stimulation were obtained,
then a continuous infusion of 10pgmin~1kg~1 saralasin was
administered and the stimulation tests repeated 10 and 20 min.
later. The infusion of saralasin was then stopped, and the stimulation
tests repeated 25 minutes later.
The effect of saralasin on total catecholamine release, before
and after splanchnic nerve stimulation was analysed. The effect of
saralasin on the change in catecholamine release following splanchnic
nerve stimulation was analysed. The results are shown in table 3-5.
The results shown in table 3.5 are illustrated in figure 3.4.
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Table 3.5
The effect of saralasin on adrenal catecholamine release before and after
splanchnic nerve stimulation (1 Opps, 1 Ov) in dogs 29—3(D29-31).




Control C 52,58 67,282 272,226 159.5 + 45.7
+S 92,197 91,290 320,409 233.2 + 52.7
Saralasin c 30,39 262 202,239 154.4 + 49.9
(1Opgmin-1kg-1) +s 49,67 133 260,236 149.0 + 42.9*
Saralasin c 54,56 213,619 282,458 280.3 ± 91 .7
infusion off +s 86,164 279,756 323,479 347.8 ± 98.6





+S 40,139 24,8 48,183 73.7 + 28.8
Saralasin
(1Opgmin-1kg-1) +S 19,28 -129 58,-3 -5.4 + 32.4**
Saralasin
infusion off +S 32,108 66,13 7 41,137 67.5 + 18.8
+S = During splanchnic nerve stimulation (10pps,10v)
C = Control
Statistical significance (Saralasin data compared with control data)-:
* = p < 0.02
** = p < 0.01
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Figure 3-4
The effect of saralasm on total catecholamine (CA) release before
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The results show that in these dogs, saralasin did not affect the
resting release of catecholamines but inhibited the release of
catecholamines evoked by splanchnic nerve stimulation. After the
saralasin infusion was turned off, there was an increase in resting
catecholamine output and the release of catecholamines evoked by
splanchnic nerve stimulation was restored.
Comment
It may be that the large variations in catecholamine release seen
between dogs, together with the limited sample number, obscured any
effect that saralasin may have had on the resting release of
catecholamines, as in dog 29, saralasin did reduce the resting output
of catecholamines in both samples analysed (see table 3-5). This is
also suggested by the increase in the resting release once the
saralasin infusion was turned off. This type of overshoot usually
occurs after a system has been depressed. The possibility that the
lack of effect on resting output could have been due to some partial
agonist activity of saralasin seems unlikely in view of the profound
inhibitory effect on stimulated release.
4. The effect of captopril and the subsequent All infusion on
the blood pressure responses to splanchnic nerve stimulation
There was a small increase in systemic blood pressure (SBP)
during splanchnic nerve stimulation. In the results section (10) of
Part 1, I demonstrated how All has a varying influence on the vascular
resistance in different vascular beds. It was of interest to
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investigate the effect of captopril and All on the blood pressure
responses to splanchnic nerve stimulation.
The effect of captopril and the subsequent All infusion on the
SBP responses induced by baroreceptor stimulation were analysed in
dogs 19-28. The results are shown in table 3.6.
The results show that although captopril reduced the resting SBP,
it had no effect on the SBP response to splanchnic nerve stimulation.
This is a similar result to that demonstrated with the hind limb
perfusion pressure response to baroreceptor stimulation. All had no
additional effect on either resting SBP or the SBP response to
splanchnic nerve stimulation.
5. The effect of splanchnic nerve stimulation on adrenal blood flow
The effect of splanchnic nerve stimulation on adrenal blood flow,
before and after captopril and a subsequent infusion of All, was
studied in dogs 19-28. The results are shown in table 3.7.
The results show that, unlike baroreceptor stimulation,
splanchnic nerve stimulation did not induce an increase in adrenal
blood flow. In these dogs, captopril and All did not induce a















































































































































Statisticalsignificance(captoprildacomp redw thon olta)-: * -p<0.001
Table 3.7
The effect of splanchnic nerve stimulation on adrenal blood flow, before
and after administration of captoprll and the subsequent Infusion of All
HOngmin-'), in dogs 19-28.
Dog Adrenal blood flow
number (mlmin-1)
Control Captopril All
C +S C ♦ S C +S
19 6.4 7.0 2.7 2.7 3.2 3.4
20 2.5 2.5 3.3 3.1
22 0.8 3.5 2.8 2.5 1.4 1 .2
23 5.8 5.8 4.7 6.6 2.8 2.5
24 5.5 5.1 3.8 4.0 2.7 2.4
25 6.7 5.5 7.6 6.5 5.5 5.0
25 6.0 5.0
26 2.4 2.2 2.7 2.1 3.8 4.3
26 2.5 2.5 3.5 3-6
27 5.4 1 .9 6.0 6.5 5.5 5.3
27 5.0 4.5 5.5 5.5
28 7.0 6.2 8.7 8.2 9.5 9.9
28 6.2 5.7 10.2 11 .0
Mean 4.8 4.4 5.1 5.2 4.3 4.3
± SE ± 0.6 ± 0.5 ± 0.7 ± 0.8 ± 0.9 ± 0.9
(n-13) (n-13) (n= 1 2) (n-12) (n-8) (n-8)
C = Control +S = During splanchnic nerve stimulation
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Part 3 - Summary of results
1. Splanchnic nerve stimulation (10volts,2ms) in the denervated
adrenal gland induced a release of catecholamines from the adrenal
medulla. The release was frequency dependant between 2.5 and 10pps and
maximal at 10pps.
2. Captopril (25mg) inhibited both the resting adrenal
catecholamine release and the release evoked by splanchnic nerve
stimulation.
3. Angiotensin II (5, 10 and 100ngmin-1) reversed the inhibitory
effect of captopril on both resting and stimulated adrenal
catecholamine release, in a dose dependant manner.
4. Saralasin (10/Jgmin-1 kg-1 ) inhibited adrenal release of
catecholamines evoked by splanchnic nerve stimulation.
5. Captopril had no effect on the systemic blood pressure
response to splanchnic nerve stimulation.
6. Splanchnic nerve stimulation did not induce an increase in
adrenal blood flow.
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Part 3 ~ Discussion of results
As has been discussed in "Part 1", Feuerstein etal (1977)
proposed that the effect of angiotensin II (All) on adrenal
catecholamine release, following haemorrhage, was due to a central
activation of sympathetic drive. The results of "Part 1" indicated
that, alternatively, All was exerting a direct effect on adrenal
catecholamine release and that a minimum, non-pressor level of All was
required for the gland to respond to the reflex stimuli.
These results provide additional support for this conclusion.
They show that in the denervated adrenal gland, captopril inhibited
the resting adrenal catecholamine release, an effect which was
reversed by a non-pressor level of All. In this case, release cannot
have been due to a central activation of sympathetic drive, as the
gland was denervated, as described in the "Methods" section. This
indicates that the effect of All is a direct facilitatory one at the
level of the adrenal gland. It supports the hypothesis that a minimum
level of All is required for the gland to respond fully to neural
drive.
The results show that All increased catecholamine output in a
dose dependant manner for 5, 10 and 100ngmin-^. In the "Introduction
and literature review, the evidence supporting a role for All in
facilitating sympathetic neuro-effector transmission was discussed.
It has been shown to facilitate noradrenaline release from other
sympathetic ganglia (Reit, 1972; Starke, 1972) and to enhance
stimulation-evoked acetylcholine overflow from parasympathetic
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ganglia (Panisset, 1968).
The results described here suggest that All has a facilitatory
effect on adrenal catecholamine release evoked by splanchnic nerve
stimulation. It was not possible to determine if there was a
prejunctional effect on acetylcholine overflow in these experiments.
As has been discussed previously, All does facilitate adrenal
catecholamine release by a direct effect on the adrenal gland and does
depolarise chromaffin cells (Douglas etal, 1967), hence it does exert
a "post-junctional" effect if the adrenal medulla is considered a
specialised sympathetic ganglion. All may facilitate stimulation-
evoked acetylcholine release from the splanchnic nerve terminal in an
analagous fashion to its effect on other nerve terminals, but this
cannot be concluded from these experiments so this is a speculative
suggestion. As was discussed in the "Introduction and literature
review", most of the available evidence indicates that the most
important facilitatory effect of All on sympathetic nerve terminals is
on stimulation-evoked release of noradrenaline. My results suggest
that All also facilitates basal catecholamine release from the adrenal
medulla, as All restored the resting release of catecholamines
previously inhibited by captopril.
We stimulated the greater splanchnic nerve trunk, which has been
shown to evoke an output of catecholamines twice that detected after
stimulation of all remaining splanchnic nerve fibres in dogs (Douglas,
1975), and so were stimulating a very high proportion of the maximum
amount of catecholamines possible. The most effective frequency of
splanchnic nerve stimulation in most species lies within the range 15-
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40pps (Douglas, 1975) and is frequency dependant. In these
experiments, we observed a maximum stimulation between 10-20pps, and
release was frequency dependant between 2.5 and 10pps.
The resting output of catecholamines from the denervated glands
of these dogs was relatively high compared with those previously
observed. Tables 3.1 and 3-2 show that before and after captopril
administration, splanchnic nerve stimulation at 2.5pps failed to
induce catecholamine release, in fact there was an inhibition of
release. These results suggest that there may be an inhibitory
component of splanchnic nerve stimulation, uncovered by denervation,
and not overcome until the nerve was stimulated at 5.0pps. This is a
tentative suggestion and it would require further investigation to
verify this.
The All antagonist, saralasin also inhibited the adrenal release
of catecholamines evoked by splanchnic nerve stimulation, which
confirms that the effect of captopril is mediated through an
inhibitory effect on angiotensin converting enzyme.
Captopril did not affect the small systemic blood pressure
response to splanchnic nerve stimulation. This indicates that as for
the perfused hind limb vascular bed, All has no effect on the
vascular bed involved in the small blood pressure response to
splanchnic nerve stimulation. It does, as described in "Part 1",
affect the pressor response to baroreceptor stimulation which
confirms that All has varying influences on the vascular resistance
of different vascular beds.
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Unlike baroreceptor stimulation, splanchnic nerve stimulation did
not increase adrenal blood flow. This is probably due to the great
differences in the stimulation parameters involved during splanchnic
nerve stimulation and baroreceptor stimulation, the latter evoking a
more "physiological" stimulation of the adrenal gland. The direct
stimulation of the splanchnic nerve may have involved a greater
number of vasoconstrictor fibres, but the actual reason for this
difference cannot be accurately determined, as it is not possible to
compare accurately the stimulation parameters involved in this direct
stimulation and those involved after an increase in total sympathetic
tone following a decrease in carotid perfusion pressure.
The results show that despite denervation, there was still a
considerable resting output of catecholamines from the adrenal
medulla. Coupland (1975) described how resting output can be reduced
when the splanchnic nerves are sectioned and is therefore partly due
to ongoing secretomotor tone from the central nervous system. The
remaining secretion is often resistant to cholinergic antagonists. It
was not possible to measure catecholamine output before and after
splanchnic nerve denervation in these experiments as this would have
involved two stages of surgery which was not possible. In the
denervated gland, resting output may be driven by humoral influences
including steroids, All and prostaglandins (see "Part 5"). This is
supported by the results discussed in "Part 2", which demonstrated
that even in the innervated gland, coadministration of captopril and
cycloheximide severely inhibited the resting release of
catecholamines.
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In conclusion, the results suggest that a non-pressor circulating
level of All has a direct facilitatory effect on adrenal
catecholamine release. This effect of All does not depend on central
activation of sympathetic drive. As with sympathetic nerves and other
sympathetic ganglia, All may facilitate splanchnic nerve activity.
213
Introduction to Parts 4 and 5
Having fulfilled the main objectives of this research project, I
had only a limited ammount of research funding remaining. I had the
choice of either investigating one more area of interest in detail or
carrying out introductory experiments in two areas. I chose to do the
latter as I was very interested in the possible interactions between
both prostaglandins and endogenous opioid peptides and adrenal
catecholamine release. It appeared possible that captopril may affect
the synthesis of prostaglandins and the breakdown of endogenous opioid
peptides, and this may contribute to some of the effects of captopril.
The experiments described in parts 4 and 5 were therefore performed on
limited numbers of dogs and must therefore be regarded as introductory
experiments, additional to the main core of this research.
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Part 4 - Introduction and literature review
Captopril has been shown to inhibit the action of the
carboxypeptidase enzyme responsible for the metabolism of endogenous
opioid peptides in vitro (Arregiu, Lee, Emson and Iversen, 1979), and
also to reduce the metabolism and increase the analgesic potency of
met-enkephalin (Stine, Yang and Costa,1979). Rubin, Millar, Sturani,
Lawrie and Reid (1984) presented evidence which suggested that
naloxone may attenuate some of the cardiovascular effects of captopril
in man (see discussion).
Opioid peptides were first detected in the brain (Stjarne, 1973;
Hughes, Smith, Kosterlitz, Fathergill, Morgan and Morris, 1975; Yang,
Hong and Costa, 1977). I shall review the more recent evidence that
demonstrates their presence in the splanchnic nerves and the adrenal
medulla and that they exert an inhibitory effect on the release of
catecholamines from the adrenal medulla.
It appears possible that captopril, by inhibiting the metabolism
of the opioid peptides, may increase their inhibitory effects on the
release of catecholamines from the adrenal medulla, and this could
contribute to the inhibitory effects of captopril on the adrenal
catecholamine release.
Schultzberg, Lundberg, Hokfelt, Terenius, Brandt, Elde and
Goldstein (1978) demonstrated the presence of enkephalins in the
superior cervical ganglion, inferior mesenteric ganglion and the
coelic superior mesenteric ganglion of the guinea pig and rat, and
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demonstrated their presence in the adrenal medulla of the rat, guinea
pig and cat. These observations have subsequently been confirmed by
others (Di Guilio, Yang, Lutold, Fratta, Hong and Costa, 1980; Lewis,
Stern, Kimura, Rossier, Stein and Udenfriend, 1980). In addition to
the enkephalins, dynorphine, a potent opioid heptadecapeptide which
was first isolated from porcine pituitaries (Goldstein, Tachibana,
Lowney, Hunkapillar and Hood, 1979), has been detected in the bovine
adrenal medulla (Dumont, Day and Lemaire, 1983). It has been found to
be the second most abundant opioid peptide in the adrenal medulla
after leu-enkephalin and its secretion from isolated chromaffin cells
has been demonstrated (Lemaire, Denis and Day, 1982; Denis, Day and
Lemaire, 1982).
Most of the available evidence seems to indicate that the
enkephalins are stored within adrenaline containing chromaffin cells
and not costored with noradrenaline in the bovine adrenal medulla
(Livett, Day, Elde and Howe, 1982; Pelto-Huikko, Salminen and
Hervonen, 1982). Lang, Taugner, Gaida, Ganten, Kraft, Unger and
Wunderlich (1983) demonstrated that bovine chromaffin medullary cells
respond to nicotinic stimulation by releasing enkephalins and
adrenaline in proportions similar to the cellular content of both
whereas a much higher proportion of noradrenaline is released under
these conditions (Livett, Dean, Whelan, Udenfriend and Rossier, 1981),
indicating costorage of enkephalins mainly within adrenaline
containing cells. Dynorphine has also been detected exclusively in
bovine adrenaline containing chromaffin cells (Dumont etal, 1983).
Schultzberg etal (1978) however, demonstrated that in the cat and
guinea pig, enkephalin-like immunoreactivity was widespread and
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evident in both noradrenaline and adrenaline containing cells, whereas
in the rat only a few medullary cells showed enkephalin-like
immunoreactivity, and these were noradrenaline containing cells. In
rats, however there was evidence of enkephalins within adrenaline
containing cells after denervation of the adrenal gland. The evidence
suggests there may be species differences in the location of
enkephalins within the adrenal medulla.
Enkephalins are also stored in the axon terminals of the
splanchnic nerve (Schultzberg etal, 1978; Di Guilio, Yang, Fratta and
Costa, 1979) and they are the most abundant of the neuro-peptides both
in the adrenal medulla and the splanchnic nerves (Livett etal, 1982;
Udenfriend and Kilpatrick, 1983; Viveros and Wilson, 1983). The
inhibitory effects of morphine on the release of catecholamines from
the adrenal medulla may be enhanced with stimulation of the splanchnic
nerve (Anderson and Slotkin, 1976), and evidence indicates that the
enkephalins stored in the splanchnic nerves may act as co-
transmitters , decreasing the activity of nicotinic stimulation of the
adrenal medulla by down regulating the nicotinic receptor sites. In
addition opioid peptide levels in the adrenal medulla are positively
related to the activity of the splanchnic nerves (Schultzberg etal,
1978).
Elliott (1912) first demonstrated that morphine affected the
release of adrenaline from the adrenal medulla, but since then both in
vitro and in vivo experiments indicate that opioid peptides inhibit
the stimulated release of catecholamines from the adrenal medulla.
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In vivo, administration of morphine decreases, and naloxone, an
opiate antagonist, increases plasma catecholamine levels. Earlier
studies using morphine, and other opiate agonists, led to
controversial results, probably due to the dose and time related side
effects elicited by such agonists (Borrell, Lorens and Borrell, 1974;
Domino, Vasko and Wilson, 1976). For example, in dogs, morphine can be
seen to increase, decrease or not affect plasma catecholamine levels
depending on the dose and experimental conditions used (Taborsky,
Halter and Porter, 1981). It has also been shown that in the cat,
morphine has a biphasic effect on blood pressure, dependant on the
dose used (Wallenstein, 1979). Such problems are not encountered with
naloxone which is now more often used to study the effects of opioid
peptides on plasma catecholamine levels.
Naloxone does not seem to modify the peripheral levels of
noradrenaline in man (Data, Gerber, Crump, Frolich, Hollifield and
Nies, 1978), but Mannelli, Maggi, De Feo, Cuomo, Delitala, Gusti and
Serio (1984) have shown that in man, naloxone does cause an increase
in plasma adrenaline levels fifteen minutes after administration,
which indicates an effect on the adrenal medulla. This increase in
plasma adrenaline was, although significant, not enough to modify the
blood pressure and heart rate.
In vitro studies also suggest an inhibitory role for endogenous
opiates on the release of catecholamines from the adrenal medulla.
Yoshizaki (1973) demonstrated that morphine could affect
catecholamine release from denervated adrenal glands, indicating that
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they can affect catecholamine release from the adrenal medulla
directly, independant of splanchnic nerve activity. This was confirmed
by Anderson and Slotkin (1976) who demonstrated that in both
innervated and denervated adrenal glands, morphine induces an increase
in catecholamine release. This would explain why morphine causes a
depletion of catecholamines in the adrenal medulla of new- born rats
even though splanchnic innervation was not yet functional (Anderson
and Slotkin, 1975). They also demonstrated that the release of
catecholamine was accompanied by a compensatory induction of tyrosine
hydroxylase and dopamine hydroxylase. This effect on dopamine
hydroxylase was unlikely to be due to ACTH as morphine treatment
resulted in an increase in the enzyme activity as early as 24 hours
after the first injection, an effect which cannot be duplicated by
ACTH administration (Weinshilboum and Axelrod, 1970). As dopamine
hydroxylase is a marker enzyme for storage vesicles, Anderson and
Slotkin suggest that morphine induces an increase in storage vesicle
synthesis.
Konishi, Tsunoo and Otsuka (1979) reported that enkephalins
inhibited cholinergic transmission in the sympathetic ganglia of
guinea pigs, and in 1980, Kumakura, Karoum, Guidotti and Costa
demonstrated that nicotinic stimulation of catecholamine release from
isolated bovine chromaffin cells could be reduced by leu- and met-
enkephalin. The concentrations of the opioid peptides used were very
high, however, and subsequent studies demonstrated that their effects
could not be reversed by naloxone and showed no stereospecificity
(Lemaire, Day, Dumont, Chovinard and Calvert, 1984). This suggests
that inhibition of the nicotinic responses in vitro by leu- and met-
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enkephalin are probably not mediated via the conventional high
affinity stereospecific opiate receptors (Livett, Boska, Dean, Mizobe
and Lindenbaum, 1983). Costa, Guidotti, Hanbauer and Saiani (1983)
agree with this suggestion, noting that the opiate recognition sites
of the adrenal medulla have a high affinity for met-enkephalin (which
is stored in the splanchnic nerves). They confirmed that they cannot
be classified with any one of the classical criteria which
characterise opiate receptors by the narcotic agonists and/or
antagonists that bind preferentially to the receptor (Snyder and
Goodman, 1980).
Lemaire, Livett, Tseng, Mercier and Lemaire (1981) also
demonstrated a dose-dependant inhibition, by opioid peptides, of the
responses of isolated bovine chromaffin cells to acetylcholine. Again
the concentrations involved were extremely high.
Costa etal (1983) reported evidence to show that the opiates not
only act on acetylcholine-mediated catecholamine release from primary
cultures of chromaffin cells, but also modulate the physiological
release of catecholamines from the adrenal medulla in vivo. They
demonstrated that in the dog, naloxone facilitated the release of
opioid peptides and catecholamines from the adrenal medulla following
splanchnic nerve stimulation. They had also previously shown that the
content of met-enkephalin in the adrenal gland and other sympathetic
ganglia is lower in spontaneously hypertensive rats (SHR) than
normotensive rats (Di Guilio etal, 1979). The decrease in enkephalin
mediated inhibition of catecholamine release from the adrenal medulla
could contribute to the hypertension in SHR.
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As has been discussed, All facilitates the activity of the
sympathetic nervous system and release of catecholamine from the
adrenal medulla. The evidence discussed here suggests an opposite
role for the opioid peptides which inhibit the release of
catecholamines from the adrenal medulla. There has been little or no
work done on any possible interaction between the activities of All
and opioid peptides, but as mentioned, captopril does inhibit the
activity of carboxypeptidase and may induce an increase in either
splanchnic nerve or adrenal medullary opioid peptides, and it is
possible that this could contribute to its inhibitory effect on
catecholamine release.
The aim of this series of experiments was to investigate:-
1. The effects of naloxone on the resting, and baroreceptor
stimulation induced, release of catecholamines from the adrenal
medulla.
2. If naloxone could reverse the inhibitory effects of captopril
on catecholamine release.
3. The effect of naloxone on the adrenal release of
catecholamines induced by splanchnic nerve stimulation.
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Part 4 - Results
1 . The effect of naloxone administration, following captopril
administration on adrenal catecholamine release before and after
baroreceptor stimulation
The effect of naloxone administration (0.3mgmin-1, continuous
infusion), following captopril administration, on adrenal
catecholamine release before and after six minute baroreceptor
stimulation was studied in dog 32. The effect of naloxone on total
catecholamine release, and the release induced by baroreceptor
stimulation was analysed. The results are shown in table 4.1. The
effect of captopril and naloxone on resting release of catecholamines,
and the release 1-2 minutes after the onset of baroreceptor
stimulation is illustrated in figure 4.1.
The results show that captopril inhibited and naloxone restored
both the resting release of catecholamines and also the reflex
release induced by baroreceptor stimulation.
2. The effect of naloxone administration, before and after
captopril administration, on adrenal release of catecholamines,
before and after baroreceptor stimulation
In dogs 33-35 the following experimental proce dure was adopted-:
Control six minute baroreceptor tests were performed, then the
naloxone infusion was started and the baroreceptor tests repeated 15
minutes later. The naloxone infusion was stopped and the baroreceptor
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tests repeated 30 minutes later. Captopril was administered and the
tests repeated. The naloxone infusion was restarted, the tests
repeated, then stopped once more and the tests repeated.
The effect of naloxone, before and after captopril administration
and before and after baroreceptor stimulation, on resting
catecholamine release and the change in release induced by
baroreceptor stimulation was studied in dogs 33—35. The results are
shown in table 4.2 and illustrated in figure 4.2.
Comments
The sample numbers in this study were very small and so only
limited statistical evaluation was possible. They show that prior to
captopril administration, naloxone alone induced an increase in
resting adrenal catecholamine release (figure 4.2a). Turning off the
naloxone infusion did not change the resting release but this was
reduced by the subsequent administration of captopril. It should be
noted that captopril did not reduce resting catecholamine release
below the control values. Turning the infusion of naloxone on again
did not restore the resting release of catecholamines, and the effect
of turning the naloxone infusion back off was an increase in resting
levels.
Due to the small sample numbers and the large variations in
catecholamine release between dogs, I can only infer that naloxone has
a facilitatory effect on resting catecholamine release. Subsequent
captopril administration resulted in a decrease in resting
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Figure 42
The effect of turning on and off an infusion of naloxone
(O-Bmgrnin"') before and after captopriL (25mg ) administration,
on resting catecholamine (CA) release [A.] and the increase






















































































































(Figure compiled from data contained in table 4-2)
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catecholamine release. This is compatible with parallel but opposite
effects of naloxone and captopril on resting adrenal catecholamine
release.
The results also show (figure 4.2b) that prior to captopril
administration, naloxone alone induced an increase in the release of
catecholamines induced by baroreceptor stimulation. Turning off the
naloxone infusion did not change this reflex release but this was
reduced by captopril administration, although not to below control
values. Turning the infusion of naloxone back on again tended to
reverse, although not completely the effect of captopril. Turning the
infusion back off reverses the effect of the previous naloxone
infusion.
Again, I can only infer that naloxone has a facilitatory effect
on the reflex release of catecholamines, before and after captopril
administration. In the light of the observation that after the initial
infusion of naloxone, captopril did not reduce either resting or
reflex release of catecholamines below control values, it is possible
that a residual effect of naloxone remained, even though the infusion
of naloxone had been turned off. These results are compatible with
parallel but opposite effects of naloxone and captopril on the reflex
release of catecholamines.
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3. The effect of naloxone, before and after captopril administration
on the release of catecholamines evoked by splanchnic nerve
stimulation
The effect of naloxone administration before captopril
administration was studied in dog 36. A control stimulation test was
performed, then an infusion of naloxone was started and the tests
repeated 15 minutes later. The naloxone infusion was switched off,
and 20 minutes later captopril was administered and the tests
repeated 20 minutes later. The same proceedure was carried out in dog
37, except that the naloxone infusion was turned back on again and the
tests repeated.
The effect of naloxone on resting adrenal catecholamine release
and the release induced by splanchnic nerve stimulation (10pps,10v)
was analysed. The results are shown in table 4.3 and the results for
dog 37 illustrated in figure 4.3 (the two values for each drug
treatment were meaned).
The results show that naloxone induced an increase in both the
resting and stimulation induced release of catecholamines. Captopril
inhibited both the resting and stimulation induced release, and the
subsequent infusion of naloxone reversed these effects of captopril.
It should be noted, that as in the previous set of experiments,
following the initial infusion of naloxone, captopril did not reduce
resting catecholamine release below control values. It is again
possible that there was some residual effect of naloxone remaining
even though the naloxone infusion had been turned off. These results
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are compatible with parallel but opposite effects of naloxone and
captopril on the release of catecholamines from the denervated adrenal
gland.
4. The effect of naloxone on systemic blood pressure, before and
after captopril administration
Rubin etal (1984) suggested that co-administration of naloxone
may attenuate the effects of captopril on blood pressure in man. It
was therefore of interest to study the effect of naloxone on systemic
blood pressure (SBP) before and after captopril administration in the
anaesthetised dog.
The effect of naloxone on resting SBP, before and after captopril
administration was studied in dogs 33.34,36 and 37. The results are
shown in table 4.4.
The results show that naloxone had little effect on resting SBP
prior to captopril administration, and when administered after
captopril, naloxone did not reverse the hypotensive effect of
captopril.
5. The effect of dietary sodium on the inhibitory effects of
captopril on adrenal catecholamine release and systemic blood
pressure
It has been discussed in "Part 1 - Introduction and literature
review", that in man, the hypotensive effect of captopril is not
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always related to baseline plasma renin activity (PRA). It was
therefore of interest to investigate the effect of baseline PRA on the
inhibitory effects of captopril in the anaesthetised dog.
5.a. The effect dietary sodium on plasma renin activity
Dogs 33.38 and 39 were fed with a salt free diet for one week
prior to each experiment day. The daily salt free diet consisted of-:
Tripe (100g boiled twice in tap water and once in distilled water) to
which was added 80g caloreen (a glucose polymer), 30g casilan
(instant milk protein) and 50g sago (boiled in distilled water). Each
dog also received 300ml milk to which was added 50ml prosparol
emulsion (arachis oil).
Dogs 32,34 and 40 were fed on a high sodium diet for two days
prior to each experiment day. The daily diet consisted of a can of
"Pedigree Chum - Beef and Heart" which was found to contain the
highest sodium content in the "Pedigree" range, fresh liver (cooked
in salted water) and salt tablets with milk.
The effects of these diets on PRA was analysed, and the results
are shown in table 4.5.
The results show that PRA in the salt depleted dogs was higher
than in salt loaded dogs. This was expected as low sodium intake is a
stimulus for increased renin secretion. Captopril increased PRA as
has previously been discussed (Part 1), though it increased PRA more
in the salt depleted dogs. After captopril administration, PRA in the
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salt loaded dogs remained lower than in the salt depleted dogs.
5.b. The effect of dietary sodium on the inhibitory effect of
captopril on adrenal catecholamine release
The effect of dietary sodium on the inhibitory effect of
captopril on adrenal catecholamine release, before and after six
minute baroreceptor stimulation, was analysed in dogs 32-34, 38 and 39
(the catecholamine assay in dog 40 was unsuccessfull). The results are
shown in table 4.6.
Comment
These results were difficult to analyse due to the small
groups of values involved, and to the fact that in dog 34,
captopril had been administered after naloxone and there was
obviously a residual effect of naloxone, on catecholamine
release, remaining. The resting catecholamine output also
varied between dogs. If the changes in catecholamine output
induced by baroreceptor stimulation are considered alone,
however, from the results it can be seen that captopril reduced
catecholamine release by approximately 101 pmolmin-1 kg-"' and
44.6pmolmin~^kg-^, 1-2 and 5-6 minutes after baroreceptor
stimulation respectively, in the salt depleted dogs. It can be
seen that captopril reduced catecholamine release by
approximately 23pmolmin~1kg-^ in the salt loaded dogs, 1-2
minutes after baroreceptor stimulation. This is expected as the
effect of captopril is mainly due to its inhibition of All
synthesis, and it would be expected to be more effective when
PRA is elevated, as in the salt depleted dogs. These results could,
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however, be overinterpretated due to the small sample numbers,
especially of the salt loaded dogs. I therefore would not like to
suggest that these results gave an accurate assessment of the effect
of dietary sodium on the ability of captopril to reduce catecholamine
release.
5.c. The effect of dietary sodium on the hypotensive action of
captopril
The effect of dietary sodium on the effect of captopril on
resting systemic blood pressure (SBP) was analysed in dogs 32-34,38
and 39. The results are shown in table 4.7.
Once again, for the reasons given previously I would not like to
suggest that these results give an accurate assessment of the effects
of dietary sodium on the hypotensive effect of captopril. The results
do suggest that resting SBP is lower in salt loaded dogs than in salt
depleted dogs. It should be noted, however, that even in the low renin
state, captopril still exerted a profound effect on both SBP and
adrenal catecholamine release, indicating that an elevated PRA state
is not required for these effects of captopril (see discussion).
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Part 4 - Summary of results
1. Naloxone (0.3mgrain_1) administered before captopril increased
both the resting release of catecholamines and the reflex release in
response to baroreceptor stimulation. Administered after captopril,
naloxone restored the reflex release of catecholamines inhibited by
captopril.
2. Naloxone, administered before and after captopril, increased
the resting release of catecholamines and the release evoked by
splanchnic nerve stimulation, from the denervated gland.
3. Naloxone, administered before or after captopril, did not
affect resting systemic blood pressure.
4. Plasma renin activity (PRA) was higher in dogs fed on a low
salt diet than those fed on a salt loaded diet. There was some
indication that the inhibitory effect of captopril on adrenal
catecholamine release and systemic blood pressure was slightly greater
in the high PRA state. The effect of captopril in the low PRA state
were profound, however, indicating the inhibitory effects of captopril
are not dependant on elevated PRA, although this may potentiate the
effects.
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Part 4 - Discussion of results
As discussed in the "Introduction and literature review", there
is much evidence demonstrating the presence of opioid peptides in the
adrenal medulla and splanchnic nerve terminals. Also discussed was
the evidence indicating that opioid peptides inhibit cholinergic
transmission in sympathetic ganglia, acetylcholine mediated
catecholamine release from chromaffin cells and catecholamine release
from the intact adrenal gland. In addition, Chaminade, Foutz and
Rossier (1984) have demonstrated that most of the enkephalin-like
material is in the form of large enkephalin containing peptides,
particularly proenkephalin. They demonstrated that splanchnic nerve
stimulation induced a release of met-enkephalin and proenkephalin
that paralleled the output of catecholamines.
The evidence suggests that opioid peptides, released from
chromaffin cells along with catecholamines, exert an inhibitory
influence on adrenal catecholamine release. I could find little
reference to work investigating the effect of naloxone on adrenal
catecholamine release in the anaesthetised dog. The only
corroborative evidence I found was by Costa etal (1983) who
demonstrated that in the dog, naloxone facilitated the release of
opioid peptides and catecholamines from the adrenal medulla,
following splanchnic nerve stimulation. They also demonstrated that
in the dog, during splanchnic nerve stimulation, as with
catecholamine release, adrenal enkephalin release increased in a
stimulus dependant fashion. They observed release when the splanchnic
nerve was stimulated at 9Hz and 10 volts, similar parameters to those
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used in my experiments.
The results show that naloxone increased resting, baroreceptor
reflex- and splanchnic nerve-stimulated catecholamine release in the
anaesthetised dog. When administered after captopril, this effect of
naloxone resulted in a reversal of the inhibitory effect of captopril
on adrenal catecholamine release.
Captopril has been shown to inhibit the carboxypeptidase enzyme
or "enkephalinase" responsible for the breakdown of endogenous opioid
peptides (Arregiu etal, 1979). This would result in an increase in
endogenous opioid peptide levels. Swerts, Perdrisot, Malfroy and
Schwartz (1979) investigated whether or not enkephalinase was
identical with the angiotensin-converting enzyme (ACE). They reported
that the same enzyme is probably responsible for the cleavage of
enkephalins in striatal and lung preparations and the striatal
enkephalinase exhibits characteristics analagous to those of purified
ACE. Captopril did inhibit both enkephalinase and ACE, though it was
more potent at inhibiting ACE. This indicates that while differences
do exist between the two enzymes, captopril does inhibit the
enkephalinase and it is possible this could contribute to its effects.
Rubin etal (1984) proposed that, if captopril were to act
partially through an effect on endogenous opiates, then naloxone may
attenuate the hypotensive effect of captopril. Although their results
were inconclusive, they reported that there was an indication that
coadministration of naloxone did attenuate the effect of captopril on
blood pressure in human volunteers. They suggested that part of the
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effect of captopril may be related to its ability to inhibit
enkephalinase.
My results show that naloxone on its own increased resting,
reflex and stimulated release of catecholamines, effects which opposed
those of captopril. It would be easy to misinterpret results which
indicate that, when administered after captopril, naloxone reversed
the effects of captopril, to mean that this was due to the effect of
captopril on enkephalinase. In the case of effects on the adrenal
medulla, this can be explained by parallel but opposite effects of
naloxone and captopril on adrenal catecholamine release.
The results support the additional evidence which suggests that
endogenous opioid peptides, released along with catecholamines from
the adrenal medulla and from the splanchnic nerve, inhibit resting
adrenal catecholamine release and release evoked by baroreceptor
stimulation and splanchnic nerve stimulation, from both innervated
and denervated adrenal glands, respectively.
The results do not rule out the possibility, however, that part
of the inhibitory effect of captopril on adrenal catecholamine release
may be mediated through an inhibitory effect on enkephalinase.
The results show that, in the anaesthetised dog, naloxone
administration, before or after captopril, did not affect resting
systemic blood pressure and did not attenuate the hypotensive effect
of captopril. This result contradicts those of Rubin etal (1984) which
may be due to species differences. Rubin etal (1984) also investigated
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whether or not naloxone could unmask a tachycardia in response to the
hypotensive effect of captopril. Opioid receptor agonists had been
shown to lower blood pressure without producing a compensatory
tachycardia in animals and man (Rubin, MacLean and Reid, 1983). The
hypotensive effect of captopril is not accompanied by a reflex
tachycardia, which is consistent with a decrease in baroreceptor
reflex activity (Shepherd, Campbell and Reid, 1982). If captopril were
to act through an effect on endogenous opiates then, it was proposed,
coadministration of naloxone may unmask a tachycardia. Rubin etal
reported, however, that this did not occur. This cardiovascular effect
of captopril was not therefore related to its ability to inhibit
enkephalinase.
In conclusion, in the anaesthetised dog, naloxone increases
resting adrenal catecholamine release and the release evoked by both
baroreceptor stimulation and splanchnic nerve stimulation, from both
innervated and denervated glands, respectively. These effects are
opposite to those of captopril. The results suggest that endogenous
opioid peptides, stored in the chromaffin cells of the adrenal medulla
and in splanchnic nerve terminals and released with catecholamines,
exert a tonic inhibitory effect on resting adrenal catecholamine
release. Endogenous opiates, released from the adrenal medulla with
catecholamines following baroreceptor stimulation or splanchnic nerve
stimulation may exert a negative feedback on catecholamine release.
The catecholamines stored in splanchnic nerve terminals and released
with noradrenaline, may decrease nicotinic stimulation of the adrenal
medulla. All and endogenous opioid peptides therefore exert opposing
effects on adrenal catecholamine release and this may provide a "fine
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tuning" of adrenal catecholamine release.
Captopril may increase adrenal and splanchnic nerve endogenous
opioid peptide levels which may contribute to its inhibitory effect
on adrenal catecholamine release, but this remains purely
speculative. The results do not indicate that, in the anaesthetised
dog, this effect of captopril contributes to its hypotensive action.
Salt depletion has been shown to activate the renin-AII system in
man (Haber, 1976; Conway, Hatton, Keddie and Davies, 1979; Niarchos,
Pickering, Case, Sullivan and Laragh, 1979) and in the dog (Kawamura
etal, 198-4). It was of interest to investigate if the effects of
captopril were related to PRA. The results show that salt depletion
did increase PRA in the dogs studied when compared with the PRA of
dogs fed on a high salt diet. These results were difficult to analyse
for the reasons stated in the "Results, 5.b.". Although inconclusive,
however, the results did suggest that captopril had a slightly greater
inhibitory effect on adrenal catecholamine release and a greater
hypotensive effect in the salt depleted, high PRA state. The results
show, however, that captopril still exerts a considerable inhibitory
effect on both adrenal catecholamine release and systemic blood
pressure in the low PRA state. This shows that an elevated All level
is not a requirement for the effectiveness of captopril as was
discussed in "Part 1 - Introduction and literature review". This is
consistent with the hypothesis that it is a minimum circulating level
of All which is important for the response of the adrenal gland to
reflex stimuli and splanchnic nerve activity. It may also suggest that
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some "non-renin" related effects of captopril may exist, such as an
effect on endogenous opioid peptides or prostaglandin synthesis




Part 5 - Introduction and literature review
There is evidence to suggest that the "non-renin" mediated
antihypertensive effect of captopril could be due to the ability of
captopril to increase the synthesis of vasodilating prostaglandins.
The evidence supporting this theory is very strong, but as I
read around the literature it became obvious that the actions of
prostaglandins on sympathetic nerve activity, adrenal medullary
secretion of catecholamines and renal renin release are very complex
and the available evidence is often very contradictory. I shall
therefore discuss the evidence in some detail. I shall first discuss
the evidence supporting a putative role of prostaglandins in the
antihypertensive action of captopril.
To understand the mechanism by which captopril stimulates
prostaglandin synthesis it is important to understand the
biosynthetic pathway of prostaglandins. This pathway has been worked
out in many laboratories and I refer the reader to Samuelsson,
Ramwell and Paoletti (1976-1983), for a more detailed review of the
following summary.
Arachidonic acid (AA) is a poly-unsaturated fatty acid stored in
the phospholipid storage pool of every cell in the body. AA is
released from the cell via the activation of a phospholipase (PL)
enzyme, predominantly PLA2. AA is then converted to prostaglandin (PG)
G2 by a cyclo-oxygenase enzyme, which can be acetylated and
inactivated by aspirin and indomethacin. PGG2 can be converted to PGE2
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or PGF2a bY peroxidation and isomerization. PGE2 is a potent
vasodilator, while PGF2a is a vasoconstrictor. Both, however, are
rapidly metabolised in a single passage through the pulmonary
vasculature and their vascular effects are probably not
physiologically significant, although locally synthesised PGE2 and
PGF2a may have a significant effect on individual vascular beds. PGG2
can also be converted to Thromboxane A2 by a thromboxane synthetase or
to prostacyclin (PGI2) by a prostacyclin synthetase. Thromboxane A2 is
predominantly synthetised in the platelet and is a potent stimulant of
platelet aggregation, and although it can be synthesised by other
tissues and is a potent vasoconstrictor, it is probably not a
vasoconstricting hormone. PGI2 is produced predominantly by the
vascular endothelium and is a potent and probably important
vasodilating hormone and inhibitor of platelet aggregation.
Captopril stimulates prostaglandin biosynthesis through an
activation of PLA2 and therefore through an increase in the rate of
release of AA (Zusman, 198*1; Galler, Folkert and Schlondorff, 1981).
If an increase in the vasodilating prostaglandins, PGE2 and PGI2 in
particular, was the only or most significant effect of captopril on
prostaglandin activity, then this would indeed contribute to the
antihypertensive activity of captopril. In the kidney, the vascular
endothelium, mesangial cells of the glomerulus, epithelial cells of
the Bowmaris capsule, the renomedullary interstitial cells and the
epithelial cells of the collecting tubules have all been shown to be
capable of synthesising prostaglandins (Zusman, 1983). Zusman (1984)
demonstrated that captopril stimulated PGE2 biosynthesis thirty-fold
in the renomedullary interstitial cell tissue culture, and it has also
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been shown to increase PGI2 and PGE2 biosynthesis in isolated renal
glomeruli, and to stimulate the biosynthesis of these vasodilating
prostaglandins in vascular endothelium.
Captopril may also indirectly increase prostaglandin biosynthesis
through increasing plasma bradykinin activity. Angiotensin converting
enzyme (ACE) is identical to the kinase which inactivates bradykinin
and ACE inhibitors therefore impair the catabolism of bradykinin and
have been shown to increase plasma kinin activity (McCaa, Hall and
McCaa, 1978; Swartz, Williams, Hollenberg, Moore and Dluhy, 1979;
Swartz, Williams, Hollenberg, Levine, Dluhy and Moore, 1980).
Bradykinin itself is a potent vasodilator and has been shown to
increase biosynthesis and release of vasodilating PGs from renal and
other tissues and this effect is enhanced by captopril (Murthy,
Waldron and Goldberg, 1978). Kinins, however, are local modulators
rather than circulating hormones and many other enzymes are capable of
inactivating them through kinase activity. It is probably for these
reasons that some workers have been unable to demonstrate a
significant change in plasma bradykinin levels following captopril
administration (see Zusman, 1984). Administration of antikinin
antibodies in spontaneously hypertensive and 2-kidney, 1-clip
hypertensive rats has been shown to attenuate the response to
captopril (Carretero, Scicli and Maitra, 1981), which may indicate
that an increase in tissue kinins may contribute to captopril's
hypotensive action, or indicate a parallel hypotensive action of
kinins themselves.
So captopril is capable of increasing PG biosynthesis both
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directly and indirectly. Vinci, Horowitz, Zusman, Pisano, Catt and
Keiser (1979) first demonstrated that arterial concentrations of PGE2
were increased during ACE inhibitor administration. Swartz, Williams,
Hollenberg, Crantz, Levine, Moore and Dluhy (1980) reported that
captopril increased the excretion of the 13,1*1 dihydro-15-keto
metabolite of PGE2 in subjects on both low and high sodium diets and
that the depressor effect of captopril correlated closely with the
changes in the excretion of this metabolite, but not with plasma
bradykinin levels. Abe, Ito, Sato, Haruyama, Sato, Omata, Hiwatari,
Sakurai, Imai and Yoshinaga (1980) also reported an increase in
urinary PGE2 secretion following captopril administration in essential
hypertensive patients, and indomethacin reduced the hypotensive effect
of captopril. Silberbauer, Stanek and Tempi (1982) reported that after
acute indomethacin pretreatment, the acute hypotensive effect of
captopril was reduced in both normotensive and essential hypertensive
patients. Indomethacin also reduced the changes in All levels and
plasma renin activity observed following captopril administration.
From the evidence discussed here it could be concluded that the
ability of captoptil to increase circulating PG synthesis contributes
to its hypotensive effect.
I shall now discuss the actions of PGs on 1) Sympathetic
nerve activity, 2) Adrenal medullary secretion of catecholamines, 3)
Renal renin release and the possible interactions of captopril on
these actions of PGs.
1. There is much evidence to suggest that PGs exert an
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inhibitory effect on the release of noradrenaline from sympathetic
nerve terminals. This effect was first demonstrated by Hedquist and
Brundin (1969) and Hedquist (1969). They reported that in the isolated
spleen of the cat, both PGEi and PGE2 reduced the overflow of
noradrenaline evoked by sympathetic nerve impulses. Such impulses
stimulate the synthesis of PGE2 and PGEi (Hedquist, 1970; Hedquist,
1973) and so these PGs, mobilised by sympathetic nerve stimulation,
were proposed to exert a negative feedback on further release of
noradrenaline.
PGE2 has been shown to inhibit the stimulated release of
noradrenaline in the cat mesenteric artery and spleen, rat iris and
cerebral cortex, guinea-pig vas deferens, rabbit pulmonary artery,
kidney and oviduct and human arteries, veins and oviduct. PG
synthesis inhibitors enhance the stimulated release of noradrenaline
in these preparations (see Starke, 1977b). Most of the evidence is
compatible with the idea that activation of pre-synaptic PG receptors
decreases the availability of Ca++ for stimulus-secretion coupling
(see Starke, 1977b).
So PGEi and PGE2 appear to inhibit the release of noradrenaline
from post-ganglionic nerve terminals. If captopril increases the
biosynthesis of PGs, it may be expected to enhance the inhibitory
effects of PGs on stimulation-evoked noradrenaline release. At the
blood vessels, this would result in a reduction of sympathetic
vasoconstriction both by reducing circulating All (which facilitates
stimulation-evoked noradrenaline release (see Part 3))» by increasing
PG release and also by increasing circulating levels of vasodilating
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PGs such as PGE2 and PGI2. This is compatible with a contributary
role of PGs in the hypotensive action of captopril.
PGs appear to exert a quite different effect on sympathetic
ganglia.
2. I found much contradiction in the literature on the effects of
PGs on the adrenal medulla.
In 1968, Kayaalp and Turker demonstrated that PGE-) , acetylcholine
(Ach) and dimethylphenylpiperazinium (DMPP) increased the perfusion
pressure in the dog autoperfused hind limb due to release of
catecholamines from the adrenal medulla. Hemicholinium-3 (HC-3), which
inhibits the synthesis of Ach abolished the effect of PGE-] but did not
affect the response to Ach or DMPP. This indicated that PGE-j was
exerting a facilitatory, pre-synaptic effect on Ach release from the
splanchnic nerve. This facilitatory effect of PGE-j on cholinergic
nerves is supported by the work of Brody and Kadowitz (197*0. It is,
however, contradictory to the evidence presented by Miele (1969) and
Hedquist (1973) who demonstrated that PGE-| , PGE2 and PGF2a not
alter the adrenal secretion of catecholamines elicited by splanchnic
nerve stimulation.
Experiments using isolated adrenal glands also provide
contradictory evidence. Work previously carried out in this laboratory
(Ellis, 1983), demonstrated that indomethacin had no effect on basal
release of catecholamines from the isolated dog adrenal gland, but did
reduce the stimulated release in response to nicotine. PGE2 also
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induced a marked increase in catecholamine secretion. Nicotinic
stimulation of the gland has been shown to induce release of PGF2a
from the adrenal medulla (Ramwell, Shaw, Douglas and Poisner, 1966).
This evidence suggests that synthesis of stimulation-induced PGs in
the adrenal medulla results in a facilitatory effect of PGs on
stimulation-evoked catecholamine release.
Damas (197*0 has suggested that indomethacin may exert a direct
stimulatory effect on catecholamine release from the rat adrenal
medulla not associated with its inhibitory effect on PG synthesis.
Feuerstein, Feuerstein and Gutman (1979) reported that PGE^ and PGE2
inhibit the release of catecholamines from the rat adrenal medulla in
vitro, whereas indomethacin enhanced the release. These results are
obviously in direct conflict with those of Ellis (1973). They are
supported work previously presented by Gutman and Boonyaviroj who
demonstrated that the Ca++ dependant outflow of catecholamines from
slices of rat adrenal glands was inhibited by PGE-| and PGE2 (Gutman
and Boonyaviroj, 1975; Boonyaviroj and Gutman, 1975).
In vivo experiments also provide conflicting evidence. Ellis
(1973) demonstrated that indomethacin either reduced both the resting
release of catecholamines and the reflex release in response to
baroreceptor stimulation, or had no effect. This would suggest that
PGs facilitate adrenal release of catecholamines in the dog. This
suggestion is supported by Feuerstein, Jimerson and Koplin (1981) who
demonstrated that PGE2 infusion increased circulating noradrenaline
and adrenaline and improved survival of dogs following haemorrhagic
shock. This is contradictory to the evidence they previously
255
presented, using the isolated gland (see above). PGE-j , PGE2 and PGF2ct
have been reported to have no effect on the basal outflow of
catecholamines or release induced by various secretagogues, from the
cat adrenal medulla (Miele, 1969; Hedquist, 1973)•
The in vivo experiments support a facilitatory effect of PGs on
adrenomedullary release of catecholamines. I consider that in vivo
experimental evidence is more reliable, as in vitro experiments
involve many more unphysiological procedures which could effect the
results obtained. I consider that the discussed evidence suggests-:
1. Resting adrenal release of catecholamines may not be affected
by PGs.
2. Stimulation-induced, neuronally produced PGs may facilitate
Ach from the splanchnic nerves, and hence adrenal catecholamine
release.
3. Physiological stimuli such as baroreceptor stimulation may
induce PG biosynthesis within the adrenal medulla, and this may
facilitate adrenal catecholamine release.
3. PGE2, PGF2a and PGA2 have all been isolated from the renal
medulla (Lee, Crowshaw, Takman, Attrep and Gougoutas, 1967) but PGI2
is the prominant PG synthesised in the renal cortex and it stimulates
renin release from the kidney both in vivo and in vitro (Frolich,
1980). Frolich (1980) also demonstrated that indomethacin decreases
PGI2 secretion and plasma renin activity (PRA) from the kidney.
Arachidonic acid has been shown to be a strong stimulus for renin
release in the rabbit (Larsson and Anggard, 1974) but Frolich suggests
that the actions of PGs on renin release are species specific. For
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example, where g-receptor mediated release is concerned, in man,
release is independant of PG effects, in the rat, PGs facilitate renin
secretion (Campbell, Graham and Jackson, 1979) and in the dog,
although the g-receptor mediated release is independant of PGs (Berl,
Henrich, Erickson and Schrier, 1979), baroreceptor stimulated release
requires a PG step (Estilo and Cottrell, 1982).
PGs are important local modulators of the effects of pressor
hormones (McGiff, Crowshaw, Terragno and Lonigro, 1970) and it has
been demonstrated in sodium depleted rats, that indomethacin may
enhance the pressor responsiveness of All in situations where plasma
All levels are elevated (Smyth and Fung, 1984). Captopril can prevent
this effect of indomethacin. This suggests that PGs inhibit the
pressor activity of All. This could be explained by PGs and All
exerting opposing inhibitory and facilitatory, respectively, effects
on noradrenaline release from sympathetic nerves (previously
discussed).
From the evidence discussed, by increasing PG release, captopril
could have the following effects-:
1. By increasing the PG negative feedback on sympathetic nerves -
reduce sympathetically induced vasoconstriction.
2. By increasing vasodilating PGs - reduce vasoconstriction.
3. By increasing stimulation-induced adrenal PG release -
increase PG facilitation of adrenal catecholamine release in
257
situations of cardiovascular stress eg. haemorrhage.
4. By increasing PGs inhibitory effects on All pressor activity,
and by inhibiting All synthesis - reduce vasoconstriction.
Effects 1,2 and 4 would all contribute to the hypotensive effect
of captopril, but 3 is not compatible with the inhibition, by
captopril, of reflex adrenal catecholamine release that I have
demonstrated during this research project.
The effect of captopril on PG release is of clinical importance
in patients receiving captopril ie. indomethacin has been shown to
decrease the hypotensive effect of captopril (Silberbauer etal, 1982).
It is also important to consider the effect of co-administration of
captopril and PG synthesis inhibitors on the reflex release of
catecholamines induced by cardiovascular stresses such as haemorrhage,
hypoglycaemia, exertion etc. Captopril and, apparently, indomethacin
both inhibit such reflex releases of catecholamines, and so patients
receiving both may lack this vital physiological compensatory
mechanism.
The aims of this series of experiments were to answer the
following questions-:
1. Does prior administration of indomethacin increase the
inhibitory effects of captopril on adrenal catecholamine release,
before and after baroreceptor stimulation, in the anaesthetised dog ?
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2. Does prior administration of indomethacin increase the
inhibitory effects of captopril on the catecholamine release evoked
by splanchnic nerve stimulation, from the denervated adrenal gland ?
3. Does prior administration of indomethacin reduce the
hypotensive action of captopril ?
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Part 5 - Results
1. The effect of indomethacin, followed by captopril administration
on adrenal catecholamine release before and after baroreceptor
stimulation.
The effect of indomethacin (5mgkg-1), followed by captopril
administration, on adrenal catecholamine release before and after six
minute baroreceptor stimulation, and the change in catecholamine
release induced by baroreceptor stimulation, was studied in dogs 41-
44. The results are shown in table 5.1 and illustrated in figure 5.1.
The results show that indomethacin reduced the resting release of
catecholamines, and significantly inhibited the reflex release induced
by baroreceptor stimulation. Captopril had little additional effect on
resting release, but further reduced the reflex release, which was
effectively abolished 5-6 minutes after the onset of baroreceptor
stimulation.
These results are compatible with the hypothesis that
prostaglandins exert a facilitatory effect on both resting and reflex
adrenal catecholamine release. Indomethacin may potentiate the effect
of captopril on adrenal catecholamine release.
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Table 5.1
The effect of indomethacin, followed by captopril administration, on
catecholamines output before and after baroreceptor stimulation (BRS)
Time
Drug after onset Total catecholamine output (pmolmin- 1 kg-1 )
Treatment of BRS
(mins) Dogll Dog92 Dog13 Dogll Mean ± SE
0 65 117 162 31 93.8 ± 28.8
Control 1-2 115 387 320 90 228.0 ± 73.9
5-6 157 198 202 138 173.8 ± 15.7
0 15,55 213,107 60,59 10,10 73.6 ± 22.1
Indomethacin 1-2 37,80 291 ,288 60,118 70,99 130.1 ± 35.8*
(5mgkg_1) 5-6 27,105 251,279 79,137 71 ,76 128.1 ± 31.9*
0 15 152 52 73-0
Captopril 1 -2 17 191 ' 87 98.3
(25mg) 5-6 27 128 66 73.7
Change in catecholamine output during BRS
Dog 11 Dog92 Dog 13 Dogll Mean ± SE
Control
0
1-2 50 270 158 59 131.3 ± 51.0
5-6 92 81 10 107 80.0 ± 11.1
Indomethacin
0
1-2 8,25 78,181 0,59 60,59 56.8 ± 20.8*
(5mgkg_1) 5-6 18,50 38,172 19,78 61 ,36 51.5 ± 19.6
Captopril
0
1-2 2 39 35 25.3
(25mg) 5-6 12 -21 11 0.7
Statistical significance (indomethacin data compared with control data)-:
* - p > 0.05
** - p > 0.02
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2. The effect of indomethacin, followed by captopril administration,
on adrenal catecholamine release before and after splanchnic nerve
stimulation.
The effect of indomethacin, followed by captopril administration,
on adrenal catecholamine release before and after splanchnic nerve
stimulation, from the denervated adrenal gland, was studied in dogs
45-47. The results are shown in table 5.2 and illustrated in figure
5.2.
The results show that indomethacin increased resting
catecholamine release in dogs 45-47, but reduced the release evoked by
splanchnic nerve stimulation. Captopril reduced the resting release of
catecholamines and further reduced the release evoked by splanchnic
nerve stimulation.
Comment
It is difficult to explain why indomethacin increases the resting
release in these dogs, while decreasing resting release in dogs 41-44.
It is possible that as the adrenal glands in dogs 41-44 were
innervated, that indomethacin inhibited a neural component of resting
catecholamine release. As discussed in the introduction, Ellis (1983)
also reported that indomethacin had varying effects on resting
catecholamine release, while usually inhibiting reflex release. These
results show that indomethacin did reduce the release of
catecholamines evoked by splanchnic nerve stimulation, indicating that
prostaglandins have a facilitatory effect on this release.
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Table 5.2
The effect of indomethacint followed by captopril administration, on
catecholamines output before and after splanchnic nerve stimulation (SNS)
Drug Total catecholamine output (pmolmln-1kg-1)
Treatment Function










































Change in catecholamine output during SNS
Dog15 Dog16 Dogl7 Meani ± SE
Control +s 17,27 318,331 211,267 200.2 ± 59.8
Indomethacin
(5mgkg-1) ♦s -22,-30 332 252,107 127.8 ± 72.1
Captopril
(25mg) ♦s 5,-13 232,208 26,11 78.2 ± 15.3
C - Control »S - During splanchnic nerve stimulation
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3. The effect of indomethacin, followed by captopril administration,
on systemic blood pressure.
Silberbauer etal (1982) have demonstrated that indomethacin can
blunt the acute hypotensive effect of captopril in both normotensive
and hypertensive patients. It was of interest, therefore to study the
effect of indomethacin on the resting systemic blood pressure (SBP) in
the anaesthetised dog. The effect of indomethacin, followed by
captopril administration, on resting SBP was studied in dogs 41-47.
The results are shown in table 5.3.
The results show that indomethacin had no significant effect on
resting SBP. It can be calculated from the results that captopril
induced a fall in resting SBP of 11.1 ± 3.6mmHg (n=14) when
administered after indomethacin. It can be calculated from table 1.10
and table 3.6 that captopril induced a fall in resting SBP of 15.3 ±
3.0mmHg (n=17) and 13.1 ± 2.9 (n=13) respectively, when administered
before any other drug. This indicates that indomethacin does not
significantly blunt the hypotensive effect of captopril in the
anaesthetised dog.
4. The effect of indomethacin, followed by captopril administration,
on adrenal blood flow.
Work previously carried out in this laboratory (Ellis, 1983)
indicated that prostaglandins may play a role in maintaining adrenal
blood flow in the anaesthetised dog.
The effect of indomethacin, followed by captopril administration,
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SBP-ystemicbloodpressure BF-Adrenalbloodflow(mlmln-1) HAEM-Haematocrit(J) VISC-Relativeviscosity Statisticalsignificance(CaptoprllSBPdavIndome ha inSBPda IndomethacinBFdavsControldata IndomethacinHAEMdatvsControlHAEMdata CaptoprllBFdatavsIndome hacinBFdata CaptoprllHAEMdatavsIndomethacinHAEMdat )-: • -p>0.01 *»-p>0.001
on adrenal blood flow was analysed in dogs 41-47. The results are
shown in table 5.3.
The results show that indomethaoin reduced adrenal blood flow in
these dogs. After captopril administration, the blood flow increased.
Comments
These results suggest that prostaglandins may play a role in
maintaining adrenal blood flow. As has been shown in Part 1, the
adrenal blood flow changes seen after captopril may be partly due to
dilution of the blood by dextran, resulting in a reduction of
haematocrit (table 1.13). Table 5.3 also shows the effect of
indomethacin and captopril on adrenal venous blood haematocrit.
Indomethacin alone can be seen to cause a reduction in haematocrit and
no dextran was infused at this time in the experiments. This infers
that the facilitatory effect of prostaglandins on adrenal blood flow
is not related to a reduction in haematocrit (see discussion). Table
5.3 also shows that in these dogs, after indomethacin administration,
captopril induced a further fall in haematocrit, which may be due to
dilution of the blood by dextran.
5. The effect of indomethacin, followed by captopril administration,
on adrenal vascular resistance.
The results have shown that captopril increases adrenal blood
flow and indomethacin decreases adrenal blood flow. It was of
interest to investigate whether this effect could be explained by
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changes in vascular resistance ie: does captopril vasodilate and
lower resistance or indomethacin vasoconstrict and increase
resistance ?
This was investigated by constructing a linear regression graph
for systemic blood pressure vs adrenal blood flow x relative
viscosity. The reasoning behind this is as follows-:
Vasodilation induces a higher blood flow for a given pressure and
lowers vascular resistance. Vasoconstriction has opposing effects.
This is expressed by Poiseuilles law for a steady flow-:
1. R = P/F




R = resistance, F = flow, P = pressure, AP = pressure gradient,
Ra = radius of vessel, L = length of vessel, V = viscosity of blood.
So a change in resistance could be due to a change in the
geometry of the vessel or to a change in the viscosity of the blood.
The length of the vessel will not change, while viscosity and the
radius may. To investigate if a change in resistance is due to a
change in the radius of the vessel, it is necessary to correct for
possible changes in the viscosity, ie-: (over)
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4. R = AP = L
F x V Ra4
A graph of systemic blood pressure vs flow, corrected for changes
in viscosity will indicate changes in resistance which are due to the
geometric component. This enables a comparison of the effects of
captopril and indomethacin in terms of vasodilation and
vasoconstriction.
The data used to plot this graph is shown in table 5.3. Viscosity
was determined from a graph in "The mechanics of the circulation" by
Caro, Pedley, Schroter and Seed, 1978, page 179. This graph plots
haematocrit (?) vs relative viscosity in human blood. The viscosity of
the adrenal blood was determined from the calculated haematocrit shown
in table 5.3. It is emphasised that the relative viscosity values are
therefore approximated values. The linear regression graph with 95?
confidence limits is shown in figure 5.3.
Comment
Figure 5.3 shows that the 95? confidence limits are large for
the control and post captopril data, but does indicate that a degree
of autoregulation exists in the adrenal gland, as has been reported in
the perfused kidney (Dighe, Hall, Smith and Ungar, 1977), ie, flow is
maintained despite reductions in systemic blood pressure. The graph
shows that indomethacin shifts the line to the right, significantly
between 100 and l45mmHg. Subsequent captopril administration shifted
the regression line back towards the left, relative to indomethacin.
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Figure5-3 Linearregressionliforsystemicbl odp e surev .adr nall wxr lativ viscositybeforeandfterindomethacin,sub equ ntcapt pr l,dmi istr tion. 7089100123llo156 Systemicbloodpressure(mmHg)F=Adrenalbloodfl w(mlmin"') V=Relativeviscosity —95%confidencelim ts Control(n=6) ®-®Indomethacin(n=12) Captopril(n=9)
These results suggest that indomethaein induces a vasoconstriction.
Indomethacin induced a significant reduction in haematocrit, but the
results show that the vasoconstriction induced by indomethacin
overcame this effect, which reinforces the evidence suggesting
indomethacin induces a vasoconstriction.
Captopril, administered after indomethacin, partially countered
the effect of indomethacin, but there is no evidence for a significant
vasodilation by captopril. These observations may explain why
indomethacin reduced adrenal blood flow and why flow was increased
following subsequent captopril administration. The results suggests
that indomethacin exerts a vasoconstriction which would contribute to
the reduction in adrenal blood flow observed following indomethacin
administration. The effect of captopril on adrenal blood flow was
probably due to the reduction in haematocrit observed, although the
possibility that captopril exerts a vasodilation cannot be definately
ruled out. As has been mentioned, there is evidence that
prostaglandins may play a role in maintaining adrenal blood flow.
These results suggest that they may exert a tonic vasodilation on
adrenal blood vessels which would contribute to this role.
6. The effect of indomethacin, followed by captopril administration,
on plasma renin activity.
The effect of indomethacin, followed by captopril administration,
on plasma renin activity (PRA) was studied in dogs 41-45. The results
are shown in table 5.4.
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Table 5.1
The effect of indomethacin, followed by captopril administration on
plasma renin activity in dogs 11-15 (Dhi -h5)
Drug Plasma renin activity Mean
Treatment (ngAImlhi—1) ± SE
D41 D12 D13 D44 D15
Control 28.2 7.6 21.5 13.1 8.5 15.8 ± 1.0
Indomethacin 11.8, 17.5, 25.1, 15.7, 6.7, 16.1 ± 2.3
(5mgkg-1) 7.6 28.2 21.2 11.2 12.5
Captopril 11.3 28.2 38.1 11.3 19.3 22.8 ± 1.6*
(25mg)
Statistical significance (Captopril data vs indomethacin data)-:
* - p > 0.01
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The results show that indomethacin had no effect on PRA and the
subsequent captopril administration induced the increase in PRA
normally detected after captopril administration.
7. The effect of flurbiprofen on adrenal catecholamine release,
before and after splanchnic nerve stimulation
In one dog, dog 52, the effect of an alternative cyclo-oxygenase
inhibitor, flurbiprofen, on adrenal catecholamine release was
analysed. The results are shown in table 5.5.
The results show that flurbiprofen reduced the resting output of
catecholamines and the release evoked by splanchnic nerve stimulation.
These were further reduced by captopril.
These results are similar to those obtained for indomethacin and
confirm that the effects of indomethacin were due to its ability to
inhibit cyclo-oxygenase and not to some other effect.
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Part 5 - Summary of results
1. In four anaesthetised dogs, indomethacin (Smgkg-'' ) reduced the
resting adrenal output of catecholamines from the innervated adrenal
gland and reduced the reflex release of catecholamine induced by
baroreceptor stimulation. Subsequent administration of captopril
(25mg) further reduced the reflex release.
2. In three more anaesthetised dogs, indomethacin increased
resting adrenal catecholamine output from the denervated adrenal
gland and reduced the release evoked by splanchnic nerve stimulation.
Subsequent administration of captopril reduced the resting release and
further reduced the release evoked by splanchnic nerve stimulation.
3. Indomethacin did not affect resting systemic blood pressure
and did not blunt the hypotensive action of captopril.
4. Indomethacin reduced adrenal blood flow and this was increased
following captopril administration.
5. Indomethacin induced an increase in vascular resistance and
this vasoconstriction probably accounts for the decrease in adrenal
blood flow induced by indomethacin.
6. Indomethacin did not alter plasma renin activity, and did not
affect the increase in plasma renin activity which occurs after
captopril administration.
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7. In one dog, flurbiprofen (5mgkg-"') had a similar effect
indomethacin on adrenal catecholamine release.
277
Part 5 - Discussion of results
The results show that indomethacin either reduced (innervated
glands) or increased (denervated glands) resting adrenal catecholamine
release and reduced the reflex release of catecholamines induced by
baroreceptor stimulation and the release evoked by splanchnic nerve
stimulation from denervated glands.
Ellis (1983) also observed varying effects of indomethacin on
resting release of catecholamines. He reported that indomethacin had
no effect on the resting release of catecholamines from the isolated
dog adrenal gland but did reduce the stimulated release in response to
nicotine. He also reported that, in the anaesthetised dog,
indomethacin either reduced or had no effect on the resting release.
The results suggest that prostaglandins may facilitate adrenal
release of catecholamines in response to baroreceptor stimulation.
They also suggest that prostaglandins may facilitate splanchnic nerve
activity or splanchnic nerve stimulation-induced adrenal catecholamine
release. The results therefore support the evidence discussed in the
"Introduction and literature review" which were "for" a facilitatory
role of prostaglandins in the reflex release of catecholamines from
the adrenal medulla in response to cardiovascular stress.
The results of the splanchnic nerve stimulation studies are
compatible with the conclusions of Kayaalp and Turker (1968) and Brody
and Kadowitz (1974) (see "Introduction and literature review", that
prostaglandins (particularly PGE2) may exert a facilitatory,
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presynaptic effect on stimulated acetylcholine release from the
splanchnic nerve. This would explain the reduction in splanchnic nerve-
stimulated adrenal catecholamine release from the denervated adrenal
gland, following indomethacin, observed in my experiments. The
results suggest that coadministration of prostaglandin synthesis
inhibitors may potentiate the inhibitory effect of captopril on
reflex adrenal catecholamine release in response to cardiovascular
stress. This could be of clinical importance. It should be
considered that, in patients receiving such a combination, this
important physiological response to cardiovascular stress may be
severely impaired.
So the results suggest that, in the anaesthetised dog,
prostaglandins exert a facilitatory effect on the reflex and
stimulated release of catecholamines in the adrenal gland. Specific
binding sites for PGE2 and PGE-| have been demonstrated in bovine,
ovine and human medullae (Dazord, Morera, Bertrand and Saez, 197^;
Karaplis and Powell, 1981).
Indomethacin did not affect the resting systemic blood pressure
and had no blunting effect on the hypotensive action of captopril.
This indicates that any increase in vasodilating prostaglandin
synthesis did not contribute to its' hypotensive action. Silberbauer
etal (1982) demonstrated that, in healthy volunteers and patients
with essential hypertension, indomethacin significantly blunted the
hypotensive effect of captopril. This indicates that, in man, part
of the hypotensive effect of captopril may be related to its ability
to increase vasodilating prostaglandin secretion. This effect may
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therefore be species related. These results could also indicate,
however, that prostaglandins and All have parallel but opposite
effects on blood pressure, and the effect of indomethacin may be
related to this and not to an effect of captopril on prostaglandin
synthesis.
The effects of flurbiprofen were comparable with those of
indomethacin which indicates that the effects of indomethacin were
related to cyclo-oxygenase inhibition and not to any other effect.
Indomethacin has calcium antagonist properties (Northover, 1977) and
I particularly wished to omit the possibility that the effect of
indomethacin on adrenal catecholamine release was due to calcium
antagonism. I could find no reference to flurbiprofen being a
calcium antagonist.
The presence of prostaglandins in the adrenal vein may be
important, as they may play a role in counteracting the
vasoconstriction associated with catecholamine release, which could be
damaging to the veins as the concentration of catecholamines is high
in the adrenal veins. PGI2 is a potent inhibitor of platelet
aggregation which may occur in the presence of concentrated
catecholamines. Prostaglandins may therefore have a protective effect
in the adrenal veins. Prostaglandins may play a role in maintaining
adrenal blood flow (Ellis, 1983) (see below) and this would contribute
to this putative protective role.
The results show that indomethacin reduced adrenal blood flow,
and this was restored following captopril administration. This effect
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of indomethacin was observed despite the reduction in haematocrit
observed following indomethacin administration. Following captopril
administration the haematocrit was reduced further. As has been
discussed previously, this effect on blood flow after captopril
administration could be partly due to dilution of the blood by the
infusion of dextran. It was possible, however, that captopril may
cause a vasodilation of the adrenal vascular bed which would
contribute to its effect on blood flow. All is a potent
vasoconstrictor, and it is possible that a non-pressor level of
circulating All may exert a degree of tonic vasoconstriction, or
facilitate such a tonic vasoconstriction by the sympathetic nervous
system (see Part 3). Captopril may abolish such an effect and lower
vascular resistance. This would contribute to its effect on adrenal
blood flow.
The results suggest, however, that the reduction in adrenal blood
flow observed afteh indomethacin administration was due to
vasoconstriction, but there was no evidence for a significant effect
of captopril on vascular resistance. This suggests that much of the
increase in blood flow observed following captopril administration was
due to the reduction in haematocrit, probably due to dilution of the
blood by dextran. It is possible that prostaglandins may exert a
degree of vasodilation, which may be related to their
inhibitory effect on noradrenaline release from sympathetic nerve
endings (see "Introduction and literature review").
PGI2 has been shown to reduce adrenal vascular resistance in
maternal and foetal sheep (Phernetton and Rankin, 1979). Houck and
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Lutherer (1981) and Ellis (1983) have also reported a reduction of
canine adrenal blood flow with indomethacin. In addition, in the dog,
PGs Ei , E2, A-] and A2 administered by close arterial infusions that
do not affect systemic blood pressure, increase blood flow in
carotid, renal, femoral, brachial and coronary arteries (Nakano,
1968). Prostaglandins Ai , A2, B-| , E2 and F2a also increase forearm
blood flow in man (Collier, Karim, Robinson and Somers, 1972) and
PGEi increases lower limb blood flow in man (Carlson, Ekelund and
Oro, 1969). Prostaglandins therefore increase blood flow in many
vascular beds.
My results also indicate that a degree of autoregulation exists
in the adrenal gland, the gland maintaining blood flow despite changes
in systemic blood pressure. This observation is supported by the work
of Houck and Lutherer (1981) who demonstrated that, in the dog, the
adrenal gland was able to maintain its blood flow during haemorrhagic
hypotension to 50mmHg even in the presence of indomethacin.
The results show that indomethacin did not alter plasma renin
activity, or prevent the increase in plasma renin activity induced by
captopril. As was discussed in the "Introduction and literature
review", prostaglandins have been shown to stimulate renin release,
and this effect is probably species specific (Frolich, 1980). The
results suggest that in the anaesthetised dog, prostaglandins are not
involved in basal renin secretion or in the control of renin release
by All. In the discussion in Part 1, I suggested that part of the
increase in plasma renin activity observed after captopril may have
been due to its ability to increase prostaglandin synthesis. This may
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be true for other species but there was no evidence that this was true
in these dogs.
It is of interest that PGE2 has been shown to stimulate
corticosteroid synthesis (Flack, Jessup and Ramwell, 1969; Saruta and
Kaplan, 1972; Louis, Challis, Robinson and Thorburn, 1976), and that
PGE2 may be involved in ACTH induced corticosteroid secretion. As my
results in "Part 2" have shown, corticosteroids may facilitate
catecholamine release and this may be involved in the ability of PGE2
to increase adrenal catecholamine release. Ellis (1973). however,
demonstrated that when PGE2 was retrogradely infused into the canine
adrenal gland, therefore bypassing the adrenal cortex, it still
induced a marked increase in catecholamine release. This would suggest
that the effect of PGE2 is not dependant on any effect on
corticosteroid secretion, but this remains a point of interest.
In conclusion, in the anaesthetised dog, prostaglandins may
facilitate the reflex and stimulated release of catecholamines from
the adrenal medulla. There is no evidence that captopril's ability to
increase vasodilating prostaglandin secretion contributes to its
hypotensive effect in the anaesthetised dog. Prostaglandins may play a
role in maintaining adrenal blood flow. Indomethacin reduces adrenal
blood flow, and this is probably related to a vasoconstriction.
Prostaglandins may exert a tonic vasodilation in the adrenal vascular
bed. Prostaglandins do not appear to play a major role in renin
release in the anaesthetised dog.
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Summary of conclusions
The results suggest that the integrity of the renin-AII system is
required for the adrenal gland to respond to baroreceptor stimulation
in the anaesthetised dog and cat. A minimum, non-pressor level of All
may be required for the gland to respond to the reflex stimulus, and
activation of the renin-AII system is not required for the immediate
adrenal response. The effect of All is likely to be a facilitatory one
on adrenal catecholamine release at the level of the adrenal gland and
not through central activation of sympathetic drive, although this
possibility cannot be ruled out.
In addition to a direct effect on adrenomedullary catecholamine
release, All may exert an indirect effect through stimulation of
adrenocorticosteroids, which may then facilitate adrenal catecholamine
release. In situations of cardiovascular stress, both the renin-AII
system and the pituitary adrenocortical axis may cooperate to
increase adrenal catecholamine release until homeostasis is restored.
The facilitatory effect of All on adrenal catecholamine
release does not depend on central activation of sympathetic drive. As
with sympathetic nerves and other sympathetic ganglia, All may
facilitate splanchnic nerve activity.
Naloxone increases resting adrenal catecholamine release and the
release evoked by both baroreceptor stimulation and splanchnic nerve
stimulation, from both innervated and denervated glands, respectively.
These effects are opposite to those of captopril. Endogenous opioid
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peptides, stored in the chromaffin cells of the adrenal medulla and in
splanchnic nerve terminals and released with catecholamines, may exert
a tonic inhibitory effect on resting adrenal catecholamine release.
Endogenous opiates, released from the adrenal medulla with
catecholamines following baroreceptor stimulation or splanchnic nerve
stimulation may exert a negative feedback on catecholamine release.
The catecholamines stored in splanchnic nerve terminals and released
with noradrenaline, may decrease nicotinic stimulation of the adrenal
medulla. All and endogenous opioid peptides therefore exert opposing
effects on adrenal catecholamine release and this may provide a "fine
tuning" of adrenal catecholamine release.
Captopril may increase adrenal and splanchnic nerve endogenous
opioid peptide levels which may contribute to its inhibitory effect on
adrenal catecholamine release, but this remains purely speculative.
Captopril exerts a considerable inhibitory effect on both adrenal
catecholamine release and systemic blood pressure in the low PRA
state. This shows that an elevated All level is not a requirement for
the effectiveness of captopril. This is consistent with the
hypothesis that it is a minimum circulating level of All which is
important for the response of the adrenal gland to reflex stimuli and
splanchnic nerve activity.
Prostaglandins may facilitate the reflex and stimulated release
of catecholamines from the adrenal medulla. There is no evidence that
captoprils ability to increase vasodilating prostaglandin secretion
contributes to its hypotensive effect in the anaesthetised dog.
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Prostaglandins may play a role in maintaining adrenal blood flow.
Indomethacin reduces adrenal blood flow, and this is probably related
to a vasoconstriction. Prostaglandins may exert a tonic vasodilation
in the adrenal vascular bed. Prostaglandins do not appear to play a
major role in renin release in the anaesthetised dog.
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Appendix 1
Individual dog and cat data tables
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Key
(All dogs were foxhounds)
Sex - M = Male
- F = Female
S = Sample number
Drug = Drug administered (i.v.), listed in order of administration.
T
+BRS = Time after onset of baroreceptor administration (minutes)
CPP = Carotid perfusion pressure (mmHg)
SBP = Systemic blood pressure (mmHg)
CA = Adrenal catecholamine output (pmolmin-1kg-1)
A = Adrenaline
NA/Na = Noradrenaline
BF = Adrenal blood flow (mlmin-"' )
PRA = Plasma renin activity in arterial blood (ngAIml-^hr-1)
All = Angiotensin II
PC02,
p02 = Partial gas pressures (mmHg)
ACTH = Adrenocorticotrophic hormone
(+xmin) = Time after ACTH administration
PPS = Pulses per second
C = Control sample prior to splanchnic nerve stimulation
+ S = During splanchnic nerve stimulation (10 volts, 2 ms and
10 PPS unless stated otherwise
Cortisol
conc. = Concentration of Cortisol (;igml-1 plasma)
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Cortico.
conc. = Concentration of corticosterone (pgml-''plasma)
(All catecholamine samples lost) refers to samples lost due to
breakdown in the assay system.
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1 0 130 85 20 8.7 4.1 31
2 1-2 90 115 44 3.3 5.0 18
3 5-6 90 115 52 4.0 4.7 30
4 9-10 90 115 62 6.5 4.9 34
5 0 130 85 28 6.0 4.1
6 1-2 90 105 38 5.5 4.4
7 5-6 90 105 42 4.0 4.8
8 9-10 90 105 62 4.5 4.6
Captopril (25mg)
9 0 130 55 14 4.5 5.8 64
10 1-2 90 65 16 4.5 6.2 76
11 5-6 90 65 18 8.0 6.9 74
12 9-10 90 65 22 4.5 5.5 86
13 0 130 65 0 6.2 30
14 1-2 90 80 0 6.5 34
15 5-6 90 80 0 6.0 37
16 9-10 90 80 0 5.7 30
All (5ngmin_1)
17 0 130 65 14 2.5 4.1
18 1-2 90 80 26 6.0 4.8
19 5-6 90 80 20 6.0 4.7
20 9-10 90 80 28 4.6 4.7
Blood pH and blood gas
pH = 7.43 ± 0.03
pC02 = 27.3 ± 1.70
p02 = 100.0 ± 9.4
measurements (n=6)
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DOG 2 15kg, F
DRUG
s T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 130 60 16 3.4 0.8 48
2 1-2 90 120 84 6.6 2.8 35
3 5-6 90 120 54 3.6 1 .6 58
4 9-10 90 100 70 4.6 1 .1 54
5 0 130 50 22 9.5 0.5 54
6 1-2 90 80 100 5.4 1 .7 16
7 5-6 90 80 72 3.6 0.8 54
8 9-10 90 90 130 9.5 2.0 38
Captopril (25mg)
9 0 130 50 10 6.0 1 .9 144
10 1-2 90 80 24 3.3 2.2 51
11 5-6 90 80 38 4.2 1 .9 42
12 9-10 90 80 30 7.2 1 .5 16
13 0 130 50 10 5.0 1 .0
14 1-2 90 80 24 3.4 1 .5
15 5-6 90 40 8 4.5 0.6
16 9-10 90 40 16 4.3 0.7
All (Sngmln-1)
17 0 130 45 18 4.3 1 .9
18 1-2 90 70 40 3.2 1 .8
19 5-6 90 50 36 4.3 3.0
20 9-10 90 50 40 4.0 2.4
21 0 130 40 1 .0
22 1-2 90 90 0.7
23 5-6 90 50 0.6
24 9-10 90 50 1 .6
Cycloheximide (50mgkg_l)
25 0 130 40 14 3.0 2.1
26 1-2 90 50 14 5.3 2.0
27 5-6 90 50 16 3.6 1.4
28 9-10 90 50 16 3.1 1 .0
Blood pH and blood gas
pH = 7.32 ± 0.01
pC02 = 36.4 ± 1.37
p02 = 256.2 ± 3.61
measurements (n=6)
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DOG 3 19kg, F
DRUG
s T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 120 85 30 3-3 3.7 56
2 1-2 80 130 99 4.7 4.9 32
3 5-6 80 130 103 5.1 4.8 58
4 9-10 80 100 147 5.2 3.8 58
5 0 120 70 53 2.0 3.2
6 1-2 80 110 147 2.9 5.2
7 5-6 80 110 114 3.3 3.8
8 9-10 80 90 155 4.6 3.0
Captopril (25mg)
9 0 120 60 18 3.6 4.0 272
10 1-2 80 75 77 7.0 7.0 82
11 5-6 80 75 58 9.4 2.3 288
12 9-10 80 60 65 5.7 2.7 192
13 0 120 50 12 9.3 2.8
14 1-2 80 70 52 6.7 3.2
15 5-6 80 70 73 9.5 3.0
16 9-10 80 60 3.7 2.4
All (5ngmin_l)
17 0 120 60 15 2.3 1 .2
18 1-2 80 90 53 3.0 6.0
19 5-6 80 90 96 3.8 4.5
20 9-10 80 85 36 3.0 4.4
21 0 120 60 58 3.0 3.0
22 1-2 80 85 160 3.2 4.0
23 5-6 80 85 120 3.5 3.5
24 9-10 80 60 120 3.0 2.6
Cycloheximide (50mgkg_l)
25 0 120 70 1 5.4
26 1-2 80 110 3 6.5
27 5-6 80 110 2 5.3
28 9-10 80 100 0 4.0
Blood pH and blood gas
pH = 7.43 ± 0.02
pC02 = 32.9 ± 0.90
p02 = 150.0 ± 16.7
measurements (n=9) -:
292
DOG 4 20.5kg, M
DRUG
s T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 120 70 8 2.0 2.3 13
2 1-2 80 130 16 2.0 4.8 34
3 5-6 80 130 24 2.1 3.5 33
4 9-10 80 110 24 2.2 2.9 17
Captopril (25mg)
5 0 120 60 12 5.7 3.5 44
6 1-2 80 90 8 5.0 5.8 43
7 5-6 80 90 8 6.5 4.5 63
8 9-10 80 70 10 3.2 4.0 43
9 0 120 65 2.9 34
10 1-2 80 110 6.0 35
11 5-6 80 110 4.2 26
12 9-10 80 70 2.8 30
All (5ngmin"')
13 0 120 70 12 1 .0 2.0
14 1-2 80 120 14 1 .6 3.8
15 5-6 80 120 18 3.8 2.8
16 9-10 80 100 22 3.0 2.3
17 0 120 55 1 .5
18 1-2 80 110 1 .0
19 5-6 80 110 0.8
20 9-10 80 100 0.7
Cycloheximide (50mgkg_l)
21 0 120 50 18 3-3 1 .2
22 1-2 80 110 8 7.2
23 5-6 80 110 0 3.5
24 9-10 80 110 0 2.2
Blood pH and blood gas
pH = 7.35 ± 0.02
pC02 = 45.1 ± 0.90
p02 = 223.9 ± 1.71
measurements (n=9)
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DOG 5 26kg, M
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 140 85 35 2.2 2.9 33
2 1-2 100 170 66 2.7 3-7 12
3 5-6 100 170 65 2.3 3-8 17
4 9-10 100 170 78 2.6 3-8 17
5 0 140 70 2.9 39
6 1-2 100 110 3.6 29
7 5-6 100 110 3-5 31
8 9-10 100 110 3.0 17
Captopril (25mg)
9 0 125 40 34 3-0 2.7 38
10 1-2 85 65 38 3.5 3-2 45
11 5-6 85 65 58 2.9 3.1 41
12 9-10 85 65 58 2.9 2.9 29
13 0 125 55
14 1-2 85 120
15 5-6 85 120
16 9-10 85 120
All (Sngmin-"1 )
17 0 125 45 34 3.0 1.9
18 1-2 85 60 35 1.7 2.5
19 5-6 85 60 90 2.6 2.3
20 9-10 85 60 97 2.1 2.2
21 0 125 35 1.5
22 1-2 85 70 2.1
23 5-6 85 70 2.6
24 9-10 85 70 2.9
Cycloheximide (50mgkg-1)
25 0 125 45 11 4.5 3.6
26 1-2 85 75 16 4.5 6.0
27 5-6 85 75 11 4.3 2.2
28 9-10 85 75 7 2.9
Blood pH and blood gas measurements (n=7) -:
pH = 7.43 ± 0.01
pC02 = 36.6 ± 0.80
p02 = 185.0 ± 24.1
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DOG 6. 14kg, F
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 110 60 26 2.6 2.5 37
2 1-2 70 140 54 3.1 5.3 11
3 5-6 70 140 66 2.2 4.9 10
4 9-10 70 140 92 4.5 4.1 17
Captopril (25mg)
5 0 110 70 32 2.2 4.2 50
6 1-2 70 145 38 3.1 7.2 56
7 5-6 70 145 24 1 .5 6.0 69
8 9-10 70 145 26 2.0 4.8 52
9 0 110 24 2.2 4.1 43
10 1-2 70 38 2.1 6.0 58
11 5-6 70 36 1 .5 2.0 29
12 9-10 70 40 2.2 2.0 32
Blood pH and blood gas
pH = 7.41 ± 0.05
pC02 = 31.0 ± 3.40
p02 = 314.6 ± 11.0
measurements (n=8)
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DOG 7. 28kg, F
DRUG
T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 110 100 15 8.2 3.8 4
2 1-2 70 195 35 6.8 6.1 4
3 5-6 70 195 28 5.0 5.5 4
4 9-10 70 195 19 4.5 5.5 6
5 0 110 110 14 6.0 4.0 6
6 1-2 70 200 24 7.0 6.5 14
7 5-6 70 200 13 5.0 5.7 13
8 9-10 70 200 29 5.0 5.7 9
Captopril (25mg)
9 0 110 90 10 2.3 6.0 33
10 1-2 70 170 19 4.0 8.0 32
11 5-6 70 170 15 5.1 7.4 42
12 9-10 70 170 13 4.0 6.8 34
13 0 110 90 14 2.8 4.8
14 1 -2 70 170 14 4.0 7.2
15 5-6 70 170 14 5.0 6.1
16 9-10 70 170 16 2.5 5.5
ACTH UOOpg)
17 0 110 90 3.9
18 1-2 70 175 2.6
19 5-6 70 175 2.2
20 9-10 70 175 2.1
21 0 110 95 4.4
22 1-2 70 170 3.5
23 5-6 70 170 2.8
24 9-10 70 150 2.6
Blood pH and blood gas
pH = 7-37 ± 0.01
pC02 = 36.7 ± 1.66
p02 = 203.9 + 5.1
measurements (n=9)
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DOG 8. 22kg, M
DRUG
T CPP SBP CA Ratio BF
+BRS A : NA
Control
1 0 140 90 78 5.2 2.1
2 1-2 100 150 217 3.1 3.8
3 5-6 100 150 203 4.0 6.2
4 9-10 100 95 169 2.4 3.0
5 0 140 80 1 .9
6 1-2 100 120 3.0
7 5-6 100 120 3.4
8 9-10 100 100 3.1
Captopril (25mg)
9 0 120 75 67 2.9 1 .5
10 1-2 80 125 58 2.9 4.2
11 5-6 80 125 98 3.2 3.2
12 9-10 80 125 63 4.6 2.5
13 0 120 70 48 2.9 3.0
14 1-2 80 120 3.5
15 5-6 80 120 2.8
16 9-10 80 120 4.3
ACTH (100jig)
17 + 10 min. 0 120 114 2.7 4.0
18 0 120 60 34 3.8 3.4
19 1-2 80 90 77 3.8 3.9
20 5-6 80 90 62 3.3 3.4
21 9-10 80 90 77 2.9 3.4
22 0 120 80 34 3.8 4.0
23 1-2 80 135 48 2.9 4.0
24 5-6 80 135 67 2.9 4.4
25 9-10 80 135 48 1 .8 4.0
26 + 50 min. 0 120 55 4.0 3.5
Blood pH and blood gas
pH = 7.32 ± 0.02
pC02 = ^3.7 ± 0.60
p02 = 242.1 ± 14.5
measurements (n=7)
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DOG 9. 16kg, F
DRUG
T CPP SBP CA Ratio BF
+BRS A : NA
Control
1 0 110 90 61 3.6 3.3
2 1-2 70 140 153 4.2 4.9
3 5-6 70 140 137 3.1 2.9
4 9-10 70 110 89 3.3 3.0
Captopril (25mg)
5 0 110 70 24 4.9 2.9
6 1-2 70 100 40 2.7 8.8
7 5-6 70 100 28 2.0 5.3
8 9-10 70 100 29 2.5 5.8
9 0 110 70 21 4.6 2.7
10 1-2 70 120 7.1
11 5-6 70 120 55 2.9 5.2
12 9-10 70 900 57 3.5 5.6
ACTH (100)ig)
13 +10 min. 0 110 41 3.5 4.0
14 0 110 70 44 3.2 3.8
15 1-2 70 120 67 4.4 9.0
16 5-6 70 120 85 3.6 5.3
17 9-10 70 110 70 3.1 6.1
18 +30 min. 0 110 57 2.6 5.0
19 0 110 70 47 5.1 4.7
20 1-2 70 110 50 3.3 7.4
21 5-6 70 110 67 2.1 6.7
22 9-10 70 110 61 2.4 6.8
Blood pH and blood gas measurements (n=7)
pH = 7.39 ± 0.02
pC02 = 35.6 ± 1.00
p02 = 203.9 ± 30.6
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DOG 10. 22kg, F
DRUG
s T CPP SBP CA Ratio BF
+BRS A : NA
Control
1 0 140 75 24 8.3 2.5
2 1-2 100 120 373 9.4 3.5
3 5-6 100 120 687 4.6 3.8
4 9-10 100 120 93 8.4 3.0
5 0 140 75 23 4.1 1 .7
6 1-2 100 120 82 7.5 2.2
7 5-6 100 120 82 6.5 1 .8
8 9-10 100 120 1 .6
Cycloheximide (50mgkg_l)
9 0 140 70 46 5.9 1 .6
10 1-2 100 110 80 4.1 4.0
11 5-6 100 110 68 4.6 3-2
12 9-10 100 110 66 9.8 2.5
13 0 140 70 1.0
14 1-2 100 110 16 5.0 3-9
15 5-6 100 110 50 3.8 4.2
16 9-10 100 110 4.0
Blood pH and blood gas
pH = 7.39 ± 0.01
pC02 = 36.4 ± 2.20
p02 = 208.6 ± 19.5
measurements (n=7)
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DOG 11. 23kg, F
DRUG
S T CPP SBP CA Ratio BF
+BRS A : NA
Control
1 0 140 60 23 3.3 3-3
2 1-2 100 100 4.9
3 5-6 100 100 26 4.4 2.9
4 9-10 100 100 31 3.8 3-0
Captopril (25mg)
5 0 130 50 49 2.1 2.9
6 1-2 90 90 31 1.9 8.8
7 5-6 90 90 22 2.4 5.3
8 9-10 90 80 27 1.8 4.0
9 0 130 50 68 3.5 2.7
10 1-2 90 80 7.1
11 5-6 90 80 39 6.3 5.2
12 9-10 90 60 74 4.0 5.6
ACTH OOOjJg)
13 0 130 55 51 3.3 3-8
14 1-2 90 70 72 2.8 9.0
15 5-6 90 70 37 2.0 5.3
16 9-10 90 70 64 2.7 6.1
17 0 130 55 30 3.7 4.7
18 1-2 90 80 57 5.5 7.4
19 5-6 90 80 6.7
20 9-10 90 65 39 3.4 6.8
Blood pH and blood gas
pH = 7.46 ± 0.02
pC02 = 34.6 ± 2.00
p02 = 190.8 ± 25.3
measurements (n=5) -:
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DOG 12. 20.5kg, M
DRUG
s T CPP SBP CA Ratio BF
+ BRS A : NA
Control
1 0 140 110 57 5.3 4.9
2 1 -2 100 160 122 7.1 6.5
3 5-6 100 160 107 7.9 5.5
4 9-10 100 115 103 7.6 5.0
Captopril (25mg)
5 0 140 95 48 5.9 5.6
6 1-2 100 110 73 6.3 6.0
7 5-6 100 110 63 5.3 5.2
8 9-10 100 110 96 6.4 5.5
9 0 140 95 4.5
ACTH (100ug)
10 + 10 min 0 140 4.5
11 + 20 min 0 140 4.3
12 + 30 min 0 140 80 46 5.6 4.3
13 1 -2 100 110 78 2.7 5.0
14 5-6 100 110 88 3.4 4.5
15 9-10 100 110 68 3.5 8.0
16 + 40 min 0 140 3.5
17 0 140 70 38 3.8 7.1
18 1-2 100 95 61 1 .9 4.7
19 5-6 100 95 66 2.9 8.3
20 9-10 100 95 65 2.8 8.3
21 + 50 min 0 140 8.3
Blood pH and blood gas measurements (n=5)
pH = 7.19 ± 0.005
pC02 - ^2.2 ± 3.80
p02 = 218.0 ± 34.3
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DOG 13. 25kg, M
DRUG
s Cortisol Cortico BF
conc. conc.
Control
1 4.63 2.94 6.2
2 4.56 2.16 6.4
Captapril (25mg)
3 3-38 1 .96 8.8
4 2.84 2.14 7.6
All (Sngmin-1)
5 6.39 3.^4 4.0
6 6.73 4.06 3.2
Blood pH and blood gas measurements (n=6)
pH = 7.25 ± 0.02
pC02 = 50.6 ± 2.05
p02 = 130.7 ± 29.3
(All catecholamine samples lost)
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DOG 14 (+19). 18kg, F
DRUG
s Test PPS SBP CA Ratio BF Cortisol Cortico.
A : Na conc. conc.
Control
1 C 90 152 4.6 1 .6
2 + S 2.5 105 122 4.1 0.8
3 2.1 8.63 4.59
4 C 90 216 3.5 2.4
5 + S 5.0 110 494 3.8 2.9
6 2.0 10.4 5.31
7 C 100 225 3.3 2.1
8 + S 10.0 110 451 3.3 2.2
9 2.7 9.99 4.31
10 C 70 304 3.3 2.3
11 + S 20.0 80 477 3.3 2.8
Captopril (25mg)
12 6.1 5.89 2.10
13 C 45 196 3-1 2.9
14 + S 2.5 50 83 2.8 1 .3
15 3-9 8.27 2.87
16 C 60 216 2.2 6.2
17 + S 5.0 65 144 2.9 5.5
18 C 85 99 2.8 3.8
19 + S 10.0 85 82 2.9 3.2
20 C 100 91 2.6 3.4
21 + S 20.0 100 101 2.6 3.7
All (5ngmin_l)
22 2.9 10.7 2.66
23 C 90 3.5
24 + S 2.5 90 4.0
25 4.5 6.12 1 .83
26 C 75 5.0
27 + S 5.0 75 5.2
28 c 100 5.1
29 + s 10.0 100 5.0
30 c 90 101 1 .2 5.1
31 + s 20.0 90 182 1 .2 5.7
Blood pH and blood gas measurements (n=9)
pH = 7.42 ± 0.02
pC02 = 37.8 ± 1.60
p02 = 243.8 ± 24.1
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DOG 15 (+20). 26kg, M
DRUG
S Test PPS SBP CA Ratio BF Cortisol Cortico.
A : Na conc. conc.
Control
1 C 75 212 4.7 3.5
2 + S 2.5 85 250 4.8 3.5
3 1 .7 5.39 2.44
4 C 60 353 4.9 2.8
5 + S 5.0 60 392 5.0 2.7
6 2.5 4.74 2.36
7 C 60 439 4.9 2.5
8 + S 10.0 60 523 4.8 2.5
9 C 60 514 4.7 2.6
10 + S 20.0 60 530 4.6 2.8
Captopril (25mg)
11 3.3 2.92 1 .09
12 C 55 239 4.1 2.9
13 + S 2.5 55 240 4.1 3.7
14 2.8 2.28 0.84
15 C 55 510 4.7 3.5
16 + S 5.0 55 446 4.0 2.9
17 C 60 369 3.9 3.3
18 + S 10.0 60 350 3.8 3-1
19 C 45 440 3.7 3.0
20 + S 20.0 45 407 3.7 2.7
Blood pH and blood gas
pH = 7.30 ± 0.01
pC02 = 42.9 ± 1.00
p02 = 151.1 ± 15.7
measurements (n=8)
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DOG 16. 22kg, M
DRUG
s Test PPS SBP CA Ratio BF Cortico.
A : Na cone.
Control
1 C 110 5.8
2 + S 2.5 110 4.7
3 5.0 2.71
4 C 105 7.8
5 + S 5.0 110 7.9
6 6.9 1.75
7 C 105 7.6
8 + S 10.0 120 7.2
9 C 110 7.5
10 + S 20.0 130 7.5
Captopril (25mg)
11 5.4 1 .77
12 C 100 6.6
13 + S 2.5 100 5.2
14 4.4 2.29
15 C 100 5.0
16 + S 5.0 105 4.7
17 C 90 3.4
18 + S 10.0 100 3.3
19 C 85 4.8
20 + S 20.0 100 5.2
All (5ngmin-■)
21 2.3 3.13
22 c 85 3.3
23 + s 2.5 85 3.5
24 3.5 1 .74
25 c 85 4.1
26 + s 5.0 85 4.0
27 c 85 5.1
28 + s 10.0 90 5.5
29 c 80 4.9
30 + s 20.0 85 5.9
Blood pH and blood gas measurements (n=8)
pH = 7.41 ± 0.01
pC02 = 40.6 ± 1.30
p02 = 182.1 ± 9.60
(All catecholamine samples lost)
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DOG 17. 21kg, F
DRUG
s Test PPS SBP CA Ratio BF Cortisol Cortico
A : Na conc. conc.
Control
1 C 105 6.8
2 + S 2.5 140 7.2
3 6.2 2.61 2.74
4 C 105 6.6
5 + S 5.0 140 7.3
6 6.1 2.10 1.72
7 C 110 6.4
8 + S 10.0 140 7.0
9 C 105 6.0
10 + S 20.0 135 7.0
Captopril (25mg)
11 5.0 3.90 2.25
12 C 100 5.5
13 + S 2.5 120 5.8
14 3.1 5.34 1.81
15 C 110 3.5
16 + S 5.0 135 3.4
17 C 115 2.7
18 + S 10.0 1 40 2.7
19 C 115 2.5
20 + S 20.0 140 2.4
All (5ngmin~i)
21 C 100 2.5
22 + S 2.5 105 3.0
23 2.4 5.05 3.08
24 C 110 2.8
25 + S 5.0 115 2.7
26 2.4 8.09 1.79
27 C 100 3.2
28 + S 10.0 110 3.4
29 C 100 3.5
30 + S 20.0 115 3.2
Blood pH and blood gas measurements (n=6)
pH = 7.37 ± 0.02
pC02 = 42.5 ± 2.50
p02 = 191.8 ± 16.7
(All catecholamine samples lost)
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DOG 18. 30kg, F
DRUG
s Test PPS SBP OA Ratio BF Cortisol Cortico
A : Na conc. oonc.
Control
1 C 135 2.5
2 + S 2.5 135 2.5
3 2.5 3.99 3.67
4 C 120 2.0
5 + S 5.0 120 2.0
6 1 .7 4.71 3.68
7 C 120 2.1
8 + S 10.0 120 1 .9
9 C 100 2.0
10 + S 20.0 100 2.0
Captopril (25mg)
11 3.0 4.73 3.41
12 C 100 3.0
13 + S 2.5 100 3.0
14 2.5 4.94 2.74
15 C 100 2.7
16 + S 5.0 100 2.8
17 C 95 2.9
18 + S 10.0 95 1 .0
19 C 85 1 .6
20 + S 20.0 85 2.4
All (5ngmin->)
21 C 90 2.5
22 + S 2.5 90 2.7
23 2.5 2.40 1.26
24 C 70 2.6
25 + S 5.0 70 2.8
26 2.5 3.11 1.10
27 C 65 2.9
28 + S 10.0 65 2.7
29 C 35 1 .0
30 + S 20.0 35 0.6
Blood pH and blood gas measurements (n=8)
pH = 7.39 ± 0.02
pC02 = 38.5 ± 0.80
p02 = 129.4 ± 35.5
(All catecholamine samples lost)
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DOG 19 (+14). 18kg, F
DRUG
s Test PPS SBP CA Ratio BF Cortisol Cortico.
A : Na conc. conc.
Control
1 C 90 152 4.6 1 .6
2 + S 2.5 105 122 4.1 0.8
3 2.1 8.63 4.59
4 C 90 216 3.5 2.4
5 + S 5.0 110 494 3.8 2.9
6 2.0 10.4 5.31
7 C 100 225 3.3 2.1
8 + S 10.0 110 451 3.3 2.2
9 2.7 9.99 4.31
10 C 70 304 3.3 2.3
11 + S 20.0 80 477 3.3 2.8
Captopril (25mg)
12 6.1 5.89 2.10
13 C 45 196 3.1 2.9
14 + S 2.5 50 83 2.8 1 .3
15 3.9 8.27 2.87
16 C 60 216 2.2 6.2
17 + s 5.0 65 144 2.9 5.5
18 c 85 99 2.8 3.8
19 + s 10.0 85 82 2.9 3.2
20 c 100 91 2.6 3.4
21 + s 20.0 100 101 2.6 3.7
All (5ngmin_1)
22 2.9 10.7 2.66
23 c 90 3.5
24 + s 2.5 90 4.0
25 4.5 6.12 1.83
26 c 75 5.0
27 + s 5.0 75 5.2
28 c 100 5.1
29 + s 10.0 100 5.0
30 c 90 101 1 .2 5.1
31 + s 20.0 90 182 1 .2 5.7
Blood pH and blood gas measurements (n=9)
pH = 7.42 ± 0.02
pC02 = 37.8 ±1.60
p02 = 243.8 ± 24.1
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DOG 20 ( + 15) . 26kg, M
DRUG
S Test PPS SBP OA Ratio BF Cortisol Cortico.
A : Na conc. conc.
Control
1 C 75 212 4.7 3.5
2 + S 2.5 85 250 4.8 3-5
3 1 .7 5.39 2.44
4 C 60 353 4.9 2.8
5 + S 5.0 60 392 5.0 2.7
6 2.5 4.74 2.36
7 C 60 439 4.9 2.5
8 + S 10.0 60 523 4.8 2.5
9 C 60 514 4.7 2.6
10 + s 20.0 60 530 4.6 2.8
Captopril (25mg)
11 3.3 2.92 1 .09
12 C 55 239 4.1 2.9
13 + S 2.5 55 240 4.1 3.7
14 2.8 2.28 0.84
15 C 55 510 4.7 3.5
16 + S 5.0 55 446 4.0 2.9
17 C 60 369 3.9 3.3
18 + S 10.0 60 350 3.8 3.1
19 C 45 440 3.7 3.0
20 + S 20.0 45 407 3.7 2.7
Blood pH and blood gas
pH = 7-30 ± 0.01
pC02 = 42.9 ± 1.00
p02 = 151 .1 ± 15.7
measurements (n=8)
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DOG 21. 28kg, M
DRUG
S Test PPS SBP CA Ratio BF
A : Na
Control
1 C 105 11 2.7 3.5
2 + S 2.5 110 24 3.8 3.6
3 C 110 6 5.0 3.0
4 + S 5.0 130 54 4.4 4.0
5 C 110 5.2
6 + S 10.0 130 6.2
7 C 110 17 3-3 2.7
8 + S 20.0 120 20 2.8 3-4
Captopril (25mg)
9 C 100 28 3.0 4.0
10 + S 2.5 105 19 3.8 4.0
11 C 100 12 5.0 2.5
12 + S 5.0 110 50 4.6 3-3
13 C 100 16 4.3 2.2
14 + S 10.0 120 13 3.9 3-4
15 C 110 29 4.8 2.2
16 + S 20.0 120 22 2.6 3.4
All (5ngmin-')
17 C 28 3-7 2.0
18 + S 2.5 26 4.2 1 .9
19 C 115 24 5.0 2.0
20 + S 5.0 120 47 4.9 2.2
21 C 100 31 4.2 2.5
22 + S 10.0 120 11 3.9 2.8
23 C 110 48 5.0 2.7
24 + S 20.0 120 186 2.8 3-5
Blood pH and blood gas measurements (n=6)
pH = 7.38 ± 0.02
pC02 = 39.0 ± 1.10
p02 = 165.8 ± 15.0
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DOG 22. 22kg, M
DRUG
S Test PPS SBP CA Ratio BF
A : Na
Control
1 C 80 124 4.4 2.3
2 + S 2.5 85 93 5.2 1 .7
3 C 70 91 4.7 1 .2
4 + S 5.0 85 148 4.1 2.7
5 C 40 168 3.9 0.8
6 + S 10.0 80 275 3.5 3.5
7 C 50 168 3.9 1 .5
8 + S 20.0 65 208 3.5 2.3
Captopril (25mg)
9 C 60 83 5.4 4.6
10 + S 2.5 65 52 3-3 5.3
11 C 55 98 3.1 4.5
12 + S 5.0 60 100 3.2 4.2
13 C 40 113 3.0 2.8
14 + S 10.0 40 147 3.1 2.5
15 C 40 69 3.3 1 .3
16 + S 20.0 40 88 3.4 1 .4
All (Sngmin-1)
17 C 40 139 3.1 2.7
18 + S 2.5 40 118 2.7 2.4
19 C 40 177 2.7 3-0
20 + S 5.0 40 250 2.5 3.0
21 C 25 262 2.9 1 .4
22 + S 10.0 25 330 3.1 1 .2
23 C 35 285 3.0 2.0
24 + S 20.0 35 308 3.0 2.2
Blood pH and blood gas measurements (n=8)
pH = 7.33 ± 0.03
pC02 = ^3-3 ± 2.60
p02 = 202.8 ± 15.7
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DOG 23. 25kg, F
DRUG
S Test PPS SBP CA Ratio BF
A : Na
Control
1 C 110 103 2.8 7.3
2 + S 2.5 130 65 3.7 7.1
3 C 110 120 3.6 6.6
4 + S 5.0 125 159 3.7 6.5
5 C 110 116 3.9 5.8
6 + s 10.0 135 261 4.0 5.8
7 c 105 182 4.0 4.2
8 + s 20.0 125 344 3.4 4.2
Captopril (25mg)
9 C 75 4.8
10 + S 2.5 80 4.0
11 C 85 186 3.7 4.9
12 + S 5.0 100 115 4.3 2.7
13 C 90 174 3.8 4.7
14 + S O•O 110 261 3.8 6.6
15 C 95 158 3.9 3.6
16 + s 20.0 110 214 3.9 3.5
All (5ngmin_l)
17 C 85 378 4.4 2.1
18 + S 2.5 85 467 4.0 2.8
Blood pH and blood gas measurements (n=5)
pH = 7.32 ± 0.03
pC02 = 4H.0 ± 1.80
p02 = 237.5 ± 13.3
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DOG 24. 25kg, M
DRUG
S Test PPS SBP CA Ratio BF
A : Na
Control
1 C 105 314 7.3 5.5
2 + S 2.5 105 42 6.5 5.2
3 C 90 11 5.3 4.5
4 + S 5.0 100 75 5.6 5.1
5 C 85 29 5.6 5.5
6 + S 10.0 100 244 5.6 5.1
7 C 90 21 6.2 5.4
8 + S 20.0 100 253 2.9 4.7
Captopril (25mg)
9 C 85 17 5.4 4.2
10 + S 2.5 90 33 6.8 4.4
11 C 90 30 7.4 3.8
12 + S 5.0 100 92 5.2 4.3
13 C 80 23 7.7 3.8
14 + S 10.0 105 107 3.9 4.0
15 C 90 33 6.6 4.0
16 + S 20.0 95 185 3.4 4.0
All (5ngmin-')
17 C 90 78 10.0 2.8
18 + S 2.5 100 86 7.2 3.3
19 C 85 71 8.7 2.5
20 + S 5.0 100 91 7.2 3.0
21 c 75 145 7.9 2.9
22 + s 10.0 105 220 5.6 2.4
23 c 75 248 7.2 2.9
24 + s 20.0 95 299 4.4 2.5
Blood pH and blood gas
pH = 7.37 ± 0.01
pC02 = 37.4 ± 0.70
p02 = 151.0 ± 7.90
measurements (n=5)
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DOG 25. 19kg, M
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 125 88 3.6 6.0
2 + S 155 163 4.4 5.0
3 C 130 64 3.9 6.7
4 + S 160 151 4.1 5.5
Captopril (25mg)
5 C 110 64 4.2 7.6
6 + S 155 116 4.2 6.5
7 C 125 74 4.2
8 + S 155 93 5.0
Blood pH and blood gas
pH = 7.34 ± 0.02
pC02 - 41.6 ± 2.00
p02 = 214.8 ± 22.3
measurements (n=5)
314
DOG 26. 18kg, F
DRUG
s Test SBP CA Ratio BF
A : Na
Control
1 C 120 58 5.3 2.4
2 + S 135 72 6.9 2.2
3 C 115 60 5.9 2.5
4 + S 120 73 6.7 2.5
Captopril (25mg)
5 C 85 45 7.7 2.7
6 + S 95 45 7.2 2.1
7 C 100 41 5.3 3-5
8 + S 100 39 6.4 3.6
All (lOngmin-1)
9 C 115 64 5.3 3.8
10 + S 115 206 6.8 4.3
All (30ngmin_l)
11 C 110 66 6.7 4.1
12 + S 115 251 6.4 4.0
All OOOngmin-1)
13 C 115 104 5.8 3.8
14 + S 115 271 4.7 3.9
Blood pH and blood gas measurements (n=6)
pH = 7.40 ± 0.04
pC02 = 31.7 ± 1 .30
p02 = 237.8 ± 15.1
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DOG 27. 20kg, M
DRUG
s Test SBP CA Ratio BF
A : Na
Control
1 C 90 47 1 .6 5.4
2 + S 90 96 3.8 1 .9
3 C 5.0
4 + S 4.5
Captopril (25mg)
5 C 70 6.0
6 + S 70 6.5
7 C 5.5
8 + S 5.5
All dOngmin-')
9 C 70 302 3.1 5.5
10 + S 70 489 3.9 5.3
All (30ngmin-1)
11 C 65 306 4.3 3.2
12 + S 65 358 5.0 3.2
All (lOOngmin-1)
13 C 55 472 4.0 2.7
14 + S 55 750 4.2 2.7
Blood pH and blood gas measurements (n=3)
pH = 7.33 ± 0.02
pC02 = 35.7 ± 1.50
p02 = 238.3 ± 22.8
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DOG 28. 26kg, M
DRUG
s Test SBP CA Ratio BF
A : Na
Control
1 C 105 23 3-3 7.0
2 + S 115 106 2.6 6.2
3 C 105 6.2
4 + S 115 5.7
Captopril (25mg)
5 C 95 51 4.0 8.7
6 + S 105 85 2.8 10.2
7 C 75 96 2.1 8.2
8 + S 85 167 2.4 11 .0
All OOngmin-1)
9 C 75 137 2.6 9.5
10 + S 90 169 3.0 9.9
All GOngmin-1)
11 C 90 79 3.4 8.5
12 + S 100 137 2.5 8.8
All (1OOngmin-')
13 C 100 87 3.2 7.7
14 + S 115 147 4.5 8.2
Blood pH and blood gas measurements (n=6)
pH = 7.30 ± 0.02
pC02 = 41.5 ± 3.20
p02 = 247.5 ± 15.9
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DOG 29. 19kg, F
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 115 52 2.9 4.7
2 + S 125 92 5.7 4.5
3 C 105 58 5.4 3-5
4 + S 120 197 8.1 3.7
Saralasin (1Ougminkg-i)
5 C 85 30 3.8 2.9
6 + S 95 49 4.7 1 .9
7 C 75 39 4.1 2.2
8 + S 90 67 4.0 3.1
Saralasin infusion off
9 C 110 54 5.5 2.4
10 + S 125 86 8.2 3-0
11 C 110 56 3.2 2.2 Cortisol
12 + S 130 164 5.0 2.5 cono.
Control
13 100 52 5.1 2.3 1.49
14 100 58 2.7 1.6 2.29
ACTH (100ug)
15 +10 min 100 118 2.7 1.3 3-36
16 +20 min 90 178 4.7 1.2 3.70
17 +30 min 90 223 3.5 1.2 3.60
Blood pH and blood gas
pH = 7.23 ± 0.03
pC02 = 47.8 ± 6.60
p02 = 320.0 + 46.7
measurements (n=4)
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DOG 30. 25kg, F
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 115 67 3.2 3.1
2 + S 120 91 4.7 3-6
3 C 105 282 3.8 3.1
4 + S 105 290 3.9 3-6
Saralasin dOugminkg-1)
5 C 90 262 3.7 3.0
6 + S 90 133 3.8 3.5
Saralasin infusion off
7 C 95 213 3.1 4.1
8 + S 95 279 3.1 4.5
9 C 95 619 3.1 4.4
10 + S 95 759 2.9 4.0
Blood pH and blood gas
pH - 7.29 ± 0.02
pC02 - 43.0 ± 1.00
p02 - 217.3 ± 35.7
measurements (n-6)
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DOG 31. 22kg, M
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 105 272 4.0 4.6
2 + S 105 320 3-7 4.3
3 C 105 226 4.5 4.0
4 + S 105 409 2.8 3.7
Saralasin (1Ougminkg-1)
5 C 80 202 3-5 2.9
6 + S 80 260 3-4 2.9
7 C 90 239 3.9 3.3
8 + S 90 236 3.7 3.0
Saralasin infusion off
9 C 115 282 3.4 2.6
10 + S 115 323 3.0 2.7
11 C 105 458 2.9 2.4
12 + S 105 479 3-0 2.3
Blood pH and blood gas measurements (n=4)
pH = 7.30 ± 0.02
pC02 = 39.8 ± 2.50
p02 = 172.5 ± 26.2
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DOG 32. 17kg, F
Diet = Salt loaded
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 100 85 187 3.4 3.0 24.3
2 1-2 60 150 245 3-7 5.4
3 5-6 60 150 240 3-9 3.6
4 0 100 70 171 3-8 2.4 20.3
5 1-2 60 135 303 3.4 4.9
6 5-6 60 135 3.2
Captopril (25mg)
7 0 100 65 90 4.5 4.9 12.6
8 1-2 60 100 100 4.5 5.5
9 5-6 60 100 90 4.4 4.7
10 0 100 60 76 4.6 4.1
11 1-2 60 110 160 6.2 5.0
12 5-6 60 110 105 2.1 4.7
Naloxone (0.3mgmin-1)
13 0 100 120 157 3.7 4.9
14 1-2 60 170 241 3-3 6.1
15 5-6 60 170 355 3.6 5.3
16 0 100 120
17 1-2 60 170
18 5-6 60 170
Blood pH and blood gas
pH = 7.37 ± 0.01
pC02 = 39.4 ± 1.20
p02 = 192.0 ± 8.2
measurements (n=6) -:
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DOG 33- 21kg, M
Diet = Salt depleted
DRUG
s T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 110 140 17 4.5 3-5 20.6
2 1-2 70 200 34 6.0 5.5
3 5-6 70 200 49 4.3 4.7
4 0 110 95 10.8
5 1-2 70 165
6 5-6 70 165
Naloxone (0.3mgmin-1)
7 0 110 90 137 10.1 4.3
8 1-2 70 130 278 8.2 5.4
9 5-6 70 130 231 6.4 3.9
Naloxone infusion off
10 0 110 45 59 6.6 1 .4
11 1-2 70 85 253 7.6 3.6
12 5-6 70 85 135 8.2 3.2
Captopril (25mg)
13 0 110 45 82 6.1 3.4 21 .1
14 1-2 70 96 8.6 3.5
15 5-6 70 143 4.3 5.0
16 0 110 24.6
Naloxone (0.3mgmin
17 0 110 35 74 9.8 2.1
18 1-2 70 50 151 12.5 3.8
19 5-6 70 50 135 10.2 3.3
Naloxone infusion off
20 0 110 55 75 6.0 3.7
21 1-2 70 65 125 9.3 5.0
22 5-6 70 65 84 9.0 3.3
Blood pH and blood gas measurements (n=6)
pH = 7.31 ± 0.01
pC02 = 40.5 ± 2.70
p02 = 180.0 ±11.8
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DOG 34. 17kg, F
Diet = Salt loaded
DRUG
s T CPP SBP CA Ratio BF PRA
+ BRS A : NA
Control
1 0 110 65 8 3-3 2.1 14.3
2 1-2 70 100 34 3.7 3.0
3 5-6 70 100 39 3.8 2.7
4 0 110 60 68 3-8 2.6 10.0
5 1-2 70 120 144 4.9 4.4
6 5-6 70 120
Naloxone (0.3mgmin-1)
7 0 110 100 393 5.01 4.0
8 1-2 70 150 499 4.5 5.4
9 5-6 70 150 494 5.4 4.7
Naloxone infusion off
10 0 110 75 334 4.4 2.8
11 1-2 70 120 462 4.3 6.6
12 5-6 70 120 493 5.6 3.4
Captopril (25mg)
13 0 110 70 202 4.3 5.9 39.4
1 4 1-2 70 90 276 6.5 6.6
15 5-6 70 90 290 4.9 6.2
16 0 110 20.0
Naloxone (O.Smgmin-1)
17 0 110 70 114 5.4 3.6
18 1-2 70 115 310 3.8 4.6
19 5-6 70 115 131 4.7 3.0
Naloxone infusion off
20 0 110 90 261 4.9 4.7
21 1-2 70 115 323 2.1 5.6
22 5-6 70 115 281 6.5 2.3
Blood pH and blood gas measurements (n=6)
pH = 7.41 ± 0.01
PCO2 = 36.0 ± 1.60
p02 = 174.2 ± 11.1
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DOG 35. 22kg, M
DRUG
s T CPP SBP CA Ratio BF
+BRS A : NA
Control
1 0 110 20 6.7 2.5
2 1-2 70 54 3.5 4.4
3 5-6 70 25 6.5 3.2
4 0 110 34 5.1 2.2
5 1-2 70 140 6.7 3.5
6 5-6 70 101 6.1 2.5
Naloxone (0.3mgmin--<)
7 0 110 77 5.9 2.3
8 1-2 70 370 7.7 3.4
9 5-6 70 146 6.4 2.6
Naloxone infusion off + Captopril (25mg)
10 0 110 89 8.0 3-2
11 1-2 70 196 10.8 5.0
12 5-6 70 132 8.5 4.0
Naloxone (0.3mgmin_ ")
13 0 110 64 2.9 3.4
14 1-2 70 122 5.2 4.1
15 5-6 70 70 6.3 3.6
Naloxone infusion off
16 0 110 107 6.4 3.4
17 1-2 70 132 7.2 3.5
18 5-6 70 127 4.3 3.3
Blood pH and blood gas
pH = 7.33 ± 0.03
pC02 = 39.3 ± 2.50
p02 = 241.3 ± 16.3
measurements (n=5)
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DOG 36. 23kg, M
DRUG




2 + S 135
3 C 115 2 3.0 0.2
4 + S 135 7 3.3 0.4
Naloxone (0.3mgmin-"')
5 C 140 6 10.5 0.9
6 + S 160 28 6.3 0.6
7 C 135 10 9.3 0.7
8 + S 165 151 6.1 1 .8
Naloxone infusion off + Captopril (25mg)
9 C 100 34 10.8 0.4
10 + S 120 32 9.2 0.5
11 C 100 43 9.6 0.5
12 + S 120 21 7.4 0.5
Blood pH and blood gas
pH = 7.42 ± 0.05
pC02 = 34.0 ± 2.00
p02 = 157.5 ± 4.80
measurements (n=4)
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DOG 37. 22kg, M
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 115 45 3-3 6.6
2 + S 120 96 4.9 5.6
3 C 115 26 3.3 7.4
4 + S 125 120 4.8 8.4
Naloxone (0.3mgmin-1)
5 C 120 187 4.8 7.4
6 + S 135 314 4.5 5.6
7 C 100 406 4.1 6.8
8 + S 120 584 3.9 8.0
Naloxone infusion off + Captopril (25mg)
9 C 75 49 3.0 6.6
10 + S 85 70 3.9 6.6
11 C 70 61 1.5 5.6
12 + S 80 67 2.2 6.0
Naloxone (0.3mgmin_l)
13 C 70 72 2.1 4.3
14 + S 80 113 3.2 4.5
15 C 70
16 + S 80
Blood pH and blood gas measurements (n=8)
pH = 7.31 ± 0.03
pC02 = 43.3 ± 3.10
p02 = 159.1 ± 23.8
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DOG 38. 24kg, M
Diet = Salt depleted
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 125 90 5 3.5 2.4 20.6
2 1-2 85 135 33 3-5 4.0
3 5-6 85 135 16 3-6 4.2
4 0 125 80 10.8
5 1-2 85 140
6 5-6 85 140
Captopril (25mg)
7 0 125 85 4 2.5 2.1
8 1-2 85 120 20 3-5 3-1
9 5-6 85 120 14 3-0 2.8
10 0 125 75 24.6
11 1-2 85 140
12 5-6 85 140
Blood pH and blood gas measurements (n=7) -:
pH = 7.36 ± 0.02
pC02 = 36.3 ± 1.50
p02 = 371.2 ± 14.7
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DOG 39. 25kg, F
Diet = Salt depleted
DRUG
s T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 110 110 96 7.9 1 .6 41 .5
2 1-2 70 170 234 7.4 5.1
3 5-6 70 170 178 6.9 3-4
4 0 110 95 40.8
5 1-2 70 160
6 5-6 70 160
Captopril (25mg)
7 0 110 60 499 6.7 3-4 45.3
8 1-2 70 110 1081 5.7 4.7
9 5-6 70 110 292 6.0 3.6
10 0 26.3
Blood pH and blood gas measurements (n=5)
pH - 7.24 ± 0.02
pC02 = 46.8 ± 3.90
p02 = 185.0 ± 8.7
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DOG 40. 16kg, F
Diet = Salt loaded
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 115 120 4.7 1.90
2 1-2 75 215 7.8
3 5-6 75 215 7.2
4 0 115 105 4.5 4.00
5 1-2 75 205 4.3
6 5-6 75 205 3.8
Captopril (25mg)
7 0 115 100 8.0 16.0
8 1-2 75 180 6.0
9 5-6 75 180 5.0
10 0 115 90 7.1 11.7
11 1-2 75 180 4.9
12 5-6 75 180 4.5
Blood pH and blood gas measurements (n=5)
pH = 7.40 ± 0.03
pC02 = 36.6 ± 1.60
p02 = 335.0 ± 8.5
(All catecholamine samples lost)
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DOG . 25kg, M
DRUG
T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 120 130 65 4.4 6.1
2 1-2 80 180 115 4.8 7.1
3 5-6 80 180 157 2.7 6.4
Indomethacin (5mgkg_1)
4 0 120 135 45 4.2 3.6
5 1 -2 80 180 37 5.3 4.1
6 5-6 80 180 27 3.6 3.7
7 0 120 135 55 3.1 3.8
8 1-2 80 180 80 4.1 3.9
9 5-6 80 180 105 4.7 3.9
Captopril (25mg) (+ Indomethacin)
10 0 120 115 15 2.2 3.5 14
11 1-2 80 165 17 2.0 4.1
12 5-6 80 165 27 3.0 4.0
Blood pH and blood gas
pH = 7.33 ± 0.03
pC02 = 38.0 ± 1 .90
p02 = 169.5 ± 3.1
measurements (n=4)
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DOG 42. 38kg, M
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 110 120 117 3.7 4.2
2 1-2 70 160 387 2.6 4.4
3 5-6 70 160 198 2.9 4.5
Indomethacin (5mgkg--')
4 0 110 85 213 2.9 1 .9
5 1-2 70 150 291 2.4 3.3
6 5-6 70 150 251 2.6 2.0
7 0 110 70 107 3.0 1 .0
8 1-2 70 125 288 2.1 2.8
9 5-6 70 125 279 2.1 2.0
Captopril (25mg) (+ Indomethacin)
10 0 110 65 152 2.3 3.5 28
11 1-2 70 80 191 2.1 4.0
12 5-6 70 80 128 2.1 3.4
Blood pH and blood gas
pH = 7.34 ± 0.01
pC02 = 38.3 ± 2.10
p02 = 185.0 ± 55.2
measurements (n=5)
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DOG 43. 22kg, M
DRUG
s T CPP SBP CA Ratio BF PRA
+ BRS A : NA
Control
1 0 120 155 162 4.6 5.0 LO•CO
2 1-2 80 220 320 3.6 6.0
3 5-6 80 220 202 3-1 4.9
Indomethacin (5mgkg--")
4 0 120 140 60 6.5 3.2 25.1
5 1-2 80 200 60 4.5 4.1
6 5-6 80 200 79 3.9 4.2
7 0 120 120 59 4.9 2.9 24.2
8 1-2 80 200 118 4.9 4.0
9 5-6 80 200 137 3.3 3.7
Captopril (25mg) (+ Indomethacin)
10 0 120 105 52 2.5 4.6 38.1
11 1-2 80 190 87 5.2 6.5
12 5-6 80 190 668 3-7 6.4
Blood pH and blood gas measurements (n=4)
pH = 7.30 ± 0.04
pC02 = 39.3 ± 2.10
p02 = 286.3 ± 12.5
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DOG 44. 25kg, M
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 120 80 31 3.7 3.0 13
2 1-2 80 125 90 5.8 4.2
3 5-6 80 125 138 3.5 3.8
Indomethacin (5mgkg_l)
4 0 120 70 10 3.7 1 .5 15
5 1-2 80 145 70 3.1 2.4
6 5-6 80 145 71 3.7 2.3
7 0 120 70 40 4.1 1 .2 11
8 1-2 80 135 99 4.9 1 .8
9 5-6 80 135 76 5.0 1 .9
Captopril (25mg) (+ Indomethaein)
10 0 120 70 14
11 1-2 80 115
12 5-6 80 115
Blood pH and blood gas
pH = 7.40 ± 0.03
pC02 = 36.5 ± 1.60
p02 = 235.0 ± 15.0
measurements (n=5)
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DOG 45. 26kg, M
DRUG
S Test SBP CA Ratio BF PRA
A : Na
Control
1 C 125 46 3.8 1 .7 8.5
2 + S 130 63 5.6 2.4
3 C 115 29 3.3 0.9
4 + S 120 56 3.7 1 .3
Indomethacin (5mgkg_i)
5 C 120 69 4.9 1 .7 6.7
6 + S 120 47 4.5 1.1
7 C 125 80 4.3 1 .5 12.5
8 + S 125 50 4.0 0.6
Captopril (25mg) (+ Indomethacin)
9 C 105 48 6.4 2.5 19.3
10 + S 105 53 3.6 2.6
11 C 110 87 3-6 2.1
12 + S 110 74 3.9 2.1
Blood pH and blood gas measurements (n=6)
pH = 7.27 ± 0.03
pC02 = 42.3 ± 3.20
p02 = 271.0 ± 7.8
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DOG 46. 25kg, M
DRUG
S Test SBP CA Ratio BF
A : Na
Control
1 C 85 8 5.2 2.4
2 + S 100 356 2.5 1 .9
3 C 85 92 3.4 2.2
4 + S 100 423 3.2 2.1
Indomethacin (5mgkg- ')
5 C 90 52 3.7 1 .8
6 + S 100 382 2.6 1 .8
7 C 70 0.9
8 + S 85 1 .0
Captopril (25mg) (+ Indomethacin)
9 C 65 40 2.6 1 .8
10 + S 85 272 2.8 2.2
11 C 65 32 2.9 1 .9
12 + S 85 240 3.0 1 .8
Blood pH and blood gas measurements (n=4)
pH = 7.29 ± 0.06
pC02 = 38.8 ± 1.10
p02 = 196.3 ± 12.5
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DOG 47. 13kg, M
DRUG
S Test SBP OA Ratio BF
A : Na
Control
1 C 85 85 7.4 1 .8
2 + S 90 296 4.2 2.1
3 C 85 94 7.3 1 .3
4 + S 100 361 5.0 1 .5
Indomethacin (5mgkg_l)
5 C 75 135 7.0 0.9
6 + S 90 387 6.3 1 .3
7 C 85 159 8.4 0.8
8 + S 92 266 6.1 0.8
Captopril (25mg) (+ Indomethacin)
9 C 90 55 6.3 1 .1
10 + S 90 812 6.9 1.0
11 C 90 51 8.3 0.7
12 + S 90 62 6.4 0.7
Blood pH and blood gas measurements (n=4)
pH = 7.47 ± 0.02
pC02 = 30.5 ± 3.10
p02 = 325.5 ± 46.0
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1 13.1 1 .5
ACTH (100ug)
2 +10 min 13.1 2.2
3 +20 min 14.8 1 .8
4 +30 min 13.8 1 .7
5 +40 min 16.2 1 .6
Blood pH and blood gas
pH = 7.33 ± 0.04
pC02 = 39.2 ± 4.40
p02 = 232.0 ± 6.8
measurements (n=5)
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DOG 49. 22kg, M
DRUG
S CA Ratio BF Cortisol
A : Na conc.
Control
1 86 4.16 4.4
2 46 4.76 2.8
3 32 4.75 3.0
4 45 4.45 3.4
ACTH (100ug)
5 + 10 min 112 4.76 4.3 3-96
6 +20 min 111 4.84 3.9 5.05
7 +30 min 111 4.43 3.8 5.37
8 + 40 min 141 4.70 3.7 6.20
Blood pH and blood gas
pH = 7.39 ± 0.03
pC02 = 40.1 ± 1 .40
p02 = 144.0 ± 14.5
measurements (n=7)
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DOG 50. 27kg, F (see table 2.10)
Blood pH and blood gas measurements (n=5)
pH = 7.38 ± 0.04
pC02 = 44.0 ± 3.50
p02 = 202.0 ± 42.9
DOG 51. 23kg, M
DRUG
s CA Ratio BF Cortisol
A : Na cone.
Control
1 209 6.30














Blood pH and blood gas measurements (n=5)
pH = 7.37 ± 0.01
pC02 = 36.8 ± 1.40
p02 = 183.5 + 15.7
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DOG 52. 22kg, M
DRUG
S Test SBP OA Ratio BF
A : Na
Control
1 C 100 482 4.8 1 .9
2 + S 100 575 4.8 1 .6
3 C 85 158 7.3 0.6
4 + S 85 453 4.4 2.2
Flurbiprofen (5mgkg~ !)
5 C 65 72 6.0 1 .2
6 + S 70 253 4.7 1 .1
7 C 70 30 6.0 0.9
8 + S 70 78 8.3 0.8
Captopril (25mg) (+ Flurbiprofen)
9 C 80 55 3.0 2.5
10 + S 80 68 4.7 2.3
11 C 80 43 4.5 2.1
12 + S 85 88 4.5 2.0
Blood pH and blood gas
pH = 7.39 ± 0.02
pC02 = 34.8 ± 2.50
p02 = 259.0 ± 16.2
measurements (n=6)
340








1 0 140 70 32 2.8 1 .7 56
2 1-2 100 120 82 2.3 2.1 61
3 5-6 100 120 58 2.9 1 .9 16
4 9-10 100 75 72 3.1 1 .4 74
5 0 140 70 78 2.8 2.0 40
6 1-2 100 95 120 2.3 2.0
7 5-6 100 95 134 2.6 1 .5 32
8 9-10 100 95 112 2.5 1 .3
Captopril (25mg)
9 0 140 50 15 3-7 1.3 24
10 1-2 100 1.5 24
11 5-6 100 1.5 40
12 9-10 100 1.4 16
13 0 140 50 75 1 .4 1 .5 32
14 1-2 100 70 91 1 .4 1 .5
15 5-6 100 70 35 1 .2 1 .5 40
16 9-10 100 60 41 1 .4 1 .5 32
All (5ngmin~1)
17 0 140 65 444 1 .8 1 .5
18 1-2 100 100 1 .8
19 5-6 100 100 511 1 .9 1 .4
20 9-10 100 75 498 1 .8 1 .6
21 0 140 70 284 2.2 2.2
22 1-2 100 110 464 1 .2 2.5
23 5-6 100 110 594 1 .1 1 .9
24 9-10 100 75 1.7
Blood pH and blood gas
pH = 7.34 ± 0.03
pC02 = 30.0 ± 2.20
p02 = 234.6 ± 29.7
measurements (n=8)
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CAT 2 3.0kg, F
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 120 55 40 4.5 0.7 17
2 1-2 80 90 136 3.6 0.9 19
3 5-6 80 90 84 4.8 0.7 18
4 9-10 80 90 92 5.3 0.7 19
5 0 120 98 5.8 0.9 24
6 1-2 80 200 6.9 1.2 12
7 5-6 80 26
8 9-10 80
Captopril (25mg)
9 0 120 50 56 2.0 1.7 48
10 1-2 80 60 69 1.8 1.8 16
11 5-6 80 60 70 3-8 1.7 18
12 9-10 80 60 61 3-1 1.5 12
13 0 120 96 3.0 1.5 12
14 1-2 80 113 3.4 1.6 21
15 5-6 80 125 2.4 1.6 8
16 9-10 80 144 1.9 1.6 12
All (5ngmin-')
17 0 120 80 100 6.9 1.6
18 1-2 80 80 166 2.2 1.8
19 5-6 80 80 186 1.7 1.5
20 9-10 80 80 206 1.8 1.5
21 0 120 209 1.9 1.2
22 1-2 80 258 1.4 1.4
23 5-6 80 264 1.4 1.4
24 9-10 80 309 1.1 1.2
Blood pH and blood gas measurements (n=9) -:
pH = 7.40 ± 0.04
pC02 = 25.8 ± 4.10
p02 = 243.0 ± 28.2
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CAT 3 2.7kg, F
DRUG
S T CPP SBP CA Ratio BF PRA
+BRS A : NA
Control
1 0 130 100 44 2.7 0.9 4
2 1-2 90 120 90 2.7 0.9 8
3 5-6 90 120 184 1.2 0.9 24
4 9-10 90 105 116 2.1 0.7 16
5 0 130 70 8
6 1-2 90 110
7 5-6 90 110
8 9-10 90 90 20
Captopril (25mg)
9 0 130 80 46 3.1 0.8 3
10 1-2 90 135 59 3.1 1.3
11 5-6 90 135 59 4.8 1.1 5
12 9-10 90 120 53 4.8 0.8 8
13 0 130 90 57 6.0 0.5
14 1-2 90 130 93 6.7 0.6
15 5-6 90 130 71 6.0 0.5
16 9-10 90 100 44 6.0 0.4
All (5ngmin~1)
17 0 130 100 80 3-9 0.7
18 1-2 90 140 123 1 .4 1 .0
19 5-6 90 140 110 1.4 0.9
20 9-10 90 135 136 1.4 1.0
21 0 130 100 90 2.7 0.8
22 1-2 90 130 123 1.4 1.0
23 5-6 90 130 122 1.8 0.9
24 9-10 90 110 60 2.6 0.5
Blood pH and blood gas measurements (n=8) -:
pH = 7.42 ± 0.03
pC02 = 29.0 ± 2.00
p02 = 249.0 ± 25.1
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Appendix 2
Drugs used and suppliers
3^4
Sodium pentobarbitone (May and Baker)
Heparin (Weddel Pharmaceuticals)
Captopril (Squibb)
Angiotensin I (acetate salt) (Sigma)
Angiotensin II (acetate salt) (Sigma)
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Modulation by the renin—angiotensin system of the baroreceptor reflex
response of the adrenal medulla in the dog
By Margaret R. MacLean and A. Ungar. Department of Pharmacology, University
of Edinburgh, 1 George Square, Edinburgh 8
Feuerstein, Boonaviroj & Gutman (1977) showed that blockade of the renin-
angiotensin system in the cat inhibits the release of catecholamines (CA) from the
adrenal medulla in response to haemorrhage, and concluded that sympathetic
activation of renin release from the kidney mediates the adrenal response to
haemorrhage, by a central action of angiotensin.
We have carried out experiments on six dogs, anaesthetized with pentobarbitone
(30 mg kg-1). Both carotid bifurcations were prepared, and the venous outflow of the
left adrenal gland collected as described by Critchley, Ellis, Henderson & Ungar
(1982). Both cervical vagosympathetic trunks were cut. Baroreceptor tests were
performed by lowering carotid sinus pressure by 40 mmHg for 10 min. CA output
(adrenaline + noradrenaline) was estimated spectrophotofluorometrically in adrenal
venous blood. Plasma renin activity (PRA) was estimated in arterial blood samples.
It is expressed in units of ng angiotensin per ml plasma per hour.
Baroreceptor tests raised CA output from 26-4 + 4-3 pmol min-1 kg-1 by
63-6+ 12-4 pmol min-1 kg-1. PRA, initially 48-7+10-5 units, did not rise during
baroreceptor tests. After injection of the angiotensin converting enzyme inhibitor
captopril (1-1-3 mg kg-1 i.v.), both resting and stimulated release ofCA was reduced.
Baroreceptor tests now raised CA output from 16-6 + 3-3 pmol min-1 kg-1 by
12-6 + 5-5 pmol min-1 kg-1.
Angiotensin II (All) was now infused (50-200 pg min-1 kg-1). This did not affect
arterial pressure, but restored the resting output ofCA to 25-2 ± 7-3 pmol inin-1 kg-1.
Baroreceptor tests during All infusion raised CA output by
32-0 + 9-8 pmol min-1 kg-1. Cycloheximide (50 mg kg-1 i.v.), given after captopril,
lowered the resting output of CA to II-0 + 3-6 pmol min-1 kg-1. Cycloheximide
abolished the adrenal response to baroreceptor tests during All infusion, although
the pressor response to baroreceptor tests was not impaired. In the absence of
captopril, this dose of cycloheximide does not abolish the adrenal response to
baroreceptor tests, but blocks the release of corticosteroids and CA in response to
corticotrophin (Critchley et al. 1982).
We confirm the finding of Feuerstein et al. (1977) that the integrity of the
renin—angiotensin system is necessary for the reflex response of the adrenal medulla.
Our results do not support the interpretation that the release of renin mediates the
response, but suggest rather that a minimum circulating level of All is needed for
the adrenal gland to respond to the reflex stimulus. The action of cycloheximide
suggests that All may act by releasing corticosteroids.
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Modulation by angiotensin of the output of catecholamines from the adrenal
medulla and of its response to splanchnic nerve stimulation in the dog
By Margaret R. MacLean and A. Ungar. Department of Pharmacology, University
of Edinburgh, 1 George Square, Edinburgh 8
We have previously shown that the angiotensin converting enzyme inhibitor
captopril inhibits the reflex release of catecholamines from the adrenal medulla in
response to the lowering of carotid sinus pressure, and that the response can be
restored by the infusion of angiotensin II (All) or of ACTH (MacLean & Ungar,
1984). These results suggested a permissive action of Ail on the adrenal gland, but
did not exclude an action within the central nervous system, as postulated by
JFeuerstein, Boonaviroj & Gutman (1977).
In eleven dogs, anaesthetized with pentobarbitone (30 mg kg"1), the peripheral cut
end of the left splanchnic nerve was stimulated electrically, and the venous outflow
of the left adrenal gland collected for the estimation of catecholamines by HPLC and
of Cortisol by RIA.
Captopril (1 mg kg"1 i.v.) reduced the mean resting output of total catecholamines
(adrenaline + noradrenaline) from 120 + 37 to 104 + 27 pmol min"1 kg"1. The mean
incremental release evoked by splanchnic nerve stimulation at 10 p.p.s. was reduced
from 100 + 21 to 40+ 16 pmol min"1 kg"1 (P < 0-01). A similar reduction in resting
and stimulated output was found during the infusion of the angiotensin antagonist
saralasin (10 fig min"1 kg"1). In five dogs, after captopril, infusion of All (10—
100 ng min"1 kg"1) raised both the resting and the stimulated catecholamines,
without affecting arterial pressure. After the injection of captopril, the mean Cortisol
output of the left adrenal gland rose from 320 + 40 to 480 + 80 ng min"1 kg"1
(P < 0-05).
We conclude that A 11 facilitates the response of the adrenal medulla to sympathetic
stimulation. The rise in Cortisol output after captopril makes it unlikely that the main
action of All on the medulla involves the release of corticosteroids (MacLean &
Ungar, 1984).
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